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Figure 3A 
ATGGTTTTTCCCATAGAAGCCiTTGTAGGACTAGTAACCTT-·-CACA'l'TTCTCTTATAC. 
ATGGTTTTTCCCATAGAAGCCATTGT~GTAAC~CATTTCTCTTATAC 
ATGGTTTTTCCCATA:GAAGCclTTGTAGGACTAGTAACCTT---CACATTTCTCTTATAC 
ATGl,rTTffiTccCATAGM.GCCATTGTAGGACTAGTAACCTT---CACATTTCTCT!lc" 
AT_GGTTTTTCCCATAGAAGCCATTGTAGGACTAGTAACCTT---CACATTTCTCT 'It 
ATGGTTTTTCClfrAGAAGCCATTGTAGGiCTAG$CCTT--~CACATTTCT"CT __ AC 
***-***-***--********-*******~--***-***-*----***********-*-* 
TTCCTATGGACAAAAAAATCT=CAAAAA· C ~CCCTTACCACCGAAAATCCCCGGA 
TTCCTATGIACAAAAAAATCT TTCAAAl<;cc'l'TACCAicGAAAA.TccccGGA 
TTCCTATGGA~TCTCAAAAA i.rlCAAAACCC'.i'TACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAiTCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAMCCCTTACCACCGAAAATCCcfflGGA 
********-*******************-•-~·••-•~~******-*******~**-*** 
GG~TGGCCGGTAATCGGCCATCTTTT!CACTTCAATA,ACGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAATAACGACGGCGACGACCGTCCATTI 
GGATGGCCGGTAATCGGCCATCTTTTJ:ACTTCAATAACGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAA:!CGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTT. 'l'CCACTTCM. . CGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTcl]ACTTciA CGACGGCGACGACCGTCCATTA 
****************·*·*********--*****-**_;**·********************-
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT 
GCTCQAAMCTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCAC',r~TTCGGCTA®T 
GCTCGAAAACTCGGAGACTTA~TGATA.AA;TACGGCCC:CGTTTTCAC',J.'TT'?CGGCT~GGT 
GCTCGAAAACTCGGAGACTTAGCT~TACGGCCCCG'l'TTTCACTTTTCGGCTA::I =~~~~:.=:= *********.****************-*~'*****~••~**************~*****~ 
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Figure 3B 
CTTCCCCTTGTGCTAGTTGTAAGQAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCTTGTGCTAGTTGTAAGCAGTiACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCT_TG-TAGTTGTAAGCA~TTACGAA' ' GCTITAAAAG,fT!TCTCTACAAAT 
CTTCCCCTTG TAGTTGTAAGCAGTTACGAAGCTITAAAAGAIT TTCTCTACAAAT 
CTTCCCCTTGT TAGTTGTAAGCAGTTACGAAGCTATAAAAGATT TTCTCTACAAAT 
***********--***********************-*******-**-************ 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT 
GAflGCCATTTTCTCCAATCGTCCAGCTTTTCTTTAJJGGCGAATACCTTGGCTAc:AITAAT 
GACGCCATTTTITCCAATCGTCCAGCTTTTCTTTACGGCG4TACCTTGGCTACAATAAT 
GACGCCATTTT TCCAATCGTCCAGCTTTTCTTTACGGCGAJITACCTTGGCTACAATAAT 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATAC~TTGGCTA~T 
**-********-***********************-*****-*************:....,.*** 
lciATGCTITT~CAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGT.CA. TT 
l)clATGCTfjTT CAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGTCATT 
GCCATGCTATTT-T ~ACGGACCTTACTGGCGAAAAAA$TTAGTCATT 
GCCATGCTATTTTTGGciAATTACGGA' CCTTACTGGCG~TC' ' '' 'TTAGTETT. 
GCCATGCTATTTTTGGclA,ATTACGGACCTTACTGGCGAAAAAAT~ TTAGT TT 
GCCATGCTATTTTTGGCAAA'XT.ACGG,tCTTAC'I'GGCQMAAAATCGTAAATTAiT TT 
-•-•··••-•·•-*--*-**-******-*****************-*~******-*-*** 
CAGGAAGTTCTCTCTGCTAGTCGTCTCG~TTCAAACAiGT~TT 
CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACAIGTGAGATT•' 
CAGGAAGTTCTC~GCTAGTCGTCTCG1W\AAT$AICACGTGAGAT' 
CAGGAAGTTCTCTclGt:TAGTCGTCTCGAAAAATTCAAACACGTGAGAT 
CAGGAAG'!'.TCTCTct;cTAGTCGTCTCGAAAAA,ftCAAACAC~TGAGATTIGCIAGAATT 
CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACACGTGAGATTCGCCAGAATT 
************'*--*****'**************·*-**-**:..***'*****-.;. ___ :.. •••• 
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Figure 3C 
CAAACGAGCATTAAGAATTTATACACTCGAAT$TGGAAATTCGAGTACGATAAATCTA 
CAAACGAGCATTAAGAATTTATACAC~CGAAT.TGGAAATTCGAGTACGATAAATCTA 
*
GCATTAAGAATTTATACACTCGMTTGATGGAAATTCGAGTACGATAAA'l'CTA 
GCATTAAGAA'l'TTATAiACTCGAATTGATGGAAA'l'TCGAGTACGATAAATEA 
GCATTAAGAATTTATztACTCGAATTGATGG.AAATTCGAGTACGATAAAT TA 
CAAACGAGCATTAAGAATTTATACACTCGAATTGATGGAAA.TTCGAGTACGATAAAT TA. 
**--*******************-*********-**********************•-·~ 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAA'l'GATCGCTGGGAAAAAT 
.GATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAATGATCGCTGGGAAAAAT 
ACI 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGGIAA,AAAT 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGAT~GCTGGIAA,AAAT 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGA.AiATGATCGCTGGGAAAAAT 
*--*~*******i*********i******************-***********-****** 
TATGAATCCGGTAAAGGAGATGAACAAQTGGAIAGATT~AAGAAIGCGTTTAAGGATT.TT 
TATGAATCCGGTAAAGGAGATGAACAAG'l'GG.AIAGATTTAA~CGTTTAAGGATTTT 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAA,GCGTTTAAGGATT';I'T 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATT.TT 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT 
*~********~*********************-**~********-•*****~******** 
ATGITTTTATCAATGG.AlrTTGTft'TATGGGATGCATTTCCAATTCCATTATTTAAATGG 
ATGITT 
ATGATTTTATCAATG~~TTTGTGTTATGGGATGCATTTCCAAT~CCATTATT~~GG 
!;:~~!;~~=;!;!;:;:;:Sc!::~!~~~=:~~:~t!~::::: 
***-******-il:**·**;,i:*-*****;_*************~*;:******·*~************ 
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Figure 3D 
GTGGATTTTCAAG<4CA'4rTAAGGctA,TGAAAA<3GAclTTT~TATAGATTCTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGA~ATAGATTGTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT 
**************-***-*******~***********-~****-*************** 
TTTCAGAA.ITGGTTAGAGGAACATATT~TAAAA.GAGAAAAAAT---GGAGGTTGGTGCA 
.TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT---G~GGTT9jTGCA 
TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT;_--GGAGGTTltrGCA 
TTTCAGAATTGGTTAGAGGAACATATT~GAAAAAATIIJGGAGGTTGGTicA, 
********-********************-**************---****~*~--*-** 
GAAGGGAATGAACAAGATTTCATTGATGTGGTG~TTTCAAAAITGAGTAAIGAATATCTT 
GAAGGGAATGAACAAGATTTCATTGAT~TGG~GCTTTCAAMATGAGTAATGAATATCTT 
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT 
GAAGGGAATGAACAAGATTTl,AT(IGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT 
********************-**-******~***********~*******-********* 
GiTGAAGGTTACTCTCGTGATACTGTCATTAAAG~CAGTITTTAGTTTGGTCTTGGAT 
GGTGAAGGTTACTCTCG~GATACTGTCATTAAAGCAAtlGT.GTTTAGTTTGGTSTTGGA.T 
~TGAAGGTTACTCTCGTGATACTGTCATTAAt;CMCIG,TGTTTAGTTTGGTCTTGGAT 
GGIGAAGGTTACTCTCGt;ATACTGTCA~IAAAGCAACAG.TTAGTTTGGTCTT<;;GAT 
*--**************-***********-**-*****-**~****************** 
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGiCAi'TATTGATAAACAATCAA 
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTA';rTGATAAACAATCAA 
.GCAGCAGACACA.GTTGCTCTTCAcATAAATTGGGGAAT~'l'TATTGAT~CAATCAA 
GCAGCAGACACAGTTGCTCTT~CATAAATTst;GAAT(.;GCATTATTGATAAACAATCAA 
********************************•******-************.******* 
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Figure 3E 
AATGCCTTGAlfflGAAAGCACAAGAAGAGATAGA,CACAAAAGTTGGTAAGGATAGATGGGTA 
.AAiGCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGAIAGATGGGTA 
AA!GCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAA~TGGGTA 
AATGCCTTGAI.GAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGATAGATGGGTA . ~ -· .. 
**-******~-***************************************-********* 
GAAGAGAGTGATATTMGGATTTIGTATACCTCCAAGCTATTGTT~GTGTTACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAA.GCTATTGTTAAAGAAGTGTTACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGT~ACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAA~C~ATTGTTAAAGAAGTGTTACGA 
***********************-************************-*-********* 
TTATATCCACCAGGACCTTTGTTAGTACCAc4GAAAATGT~ATTGTGTTGTTAGT 
;;!~!;6~~~::~~;;;:;;!:~~~~~=:::::::~~:~::::~~!:~ 
TTATATCCACCIGGACCTTTGTTAGTACCACAC~AAAATGTAGAAGATTGTGTTGTTAGT 
******~****-***********~********-*********-*-**'*~********** 
G~TCACATTC~TAAAGIGA-cTAGA'.!'TATTCGCAAACGTCATGAAACTGCAicGIGAT 
GGATATCACATTCCTAAAGGGA<:IAGATTATTCGCAAACGTCATGAAACTGCAACGTGAT 
GG,ATATCACATTCCTAAAGGGA~GATTA'l'TCGCAAACGTCAT<;AAACTGCAACGTGAT 
GGATATCACATTCCTAAAGGIACTAG-AiTATTCGGAAAIG.TGAAACTICAACGTGAT 
*******************--···-•··•-•*********-**-********·**-**-*** 
CCTAAACTCTf;TCAAATC:::CTGATAAGTTCGATCCAG)\GAGATTCATCGC" 
CCTAAACTCTGGTcl!ATCCT~TAjlT~CGATCCAGAGAGATTCATIGC~ 
CCTAAACTCTGGTc;IA:_ TC:CTGA~~TCGATCGAGA_ . _· .GAGAtTCAT GCTAIT.GATAT.T 
CCT~CTCTGGTCi\AATCCTG~Tll.AGTTclA,TCG.At'.;ASAGAT'I'CATC_GC1jG'l'GATA'l''l' 
*·******·***:..:.*-**,--*********--***-****************.:..***.;._***"***"* 
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Figure 3F 
GACTTt;GTGGTCiflACTATGAGT!TATCCcfrTTGGTTCTGGAAGACGATCT~GTCCG 
GACTTTCG.TGGTCAGTACTA$GTATATCCCGTTTGGTT.CTGGAAGACGATCT.TGTCcl 
GACTTTCGTGGTCAGTACTATi,AGTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCCI 
GACTTTcj:rGGTCAGfflA.CTATGAGTATATCCCGTTTGGTTCTGGAAGACGiTCTTGTCCG 
*****-*~******-~*1~**-***-******-*****************-********-
GGGATGACT',l'ATGCATTGCAAGTGGAACACCTAACAATGGCACATTT~TCCAGGGTTTC 
GGGATGACTTAT~TTGCAAGTGGAACACITAACAA'.j:'.GGCACATTTGATCCAIGGTTTC 
GGGAT.GACTTATGCATTGCAAGTGGAACAciTAACAATGGCACATTTGATCCAIGGTTTC 
GGGATGACTTATGCATTGCAAGTGGAACACCTAACAATGGCACATTTGATCCAGGGTTTC 
******************************-****************-*****-****** 
AATTA~CTCCAAATGACGA§ICCTTGGATATGAAGGAAGGTGCAGGCATAA~A 
AATTACAGAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATA 
AATT,ACAGAAC_TCCAAATGACGAGCCCTTGG.TGAA~GGTGCAGGCATAACTATA 
AATTACAGAACTcCAAITG.Af.;AGCccTT<.mATATGAAf;MGGTGCAGGCATAACTATA 
*******-********·-*•*-**-*******-*****-*****************-*** 
AACCTAAGATCTTTCATCTTGGTTGATCATTGTTTAATACTCCTAGATGGGTATTCATTT 
Al\,.CCTAAGATCTTTCATCTTGGTTGATCATTGljTAAT~CTCCTAiATGGir~TTCATTT 
AACCTAAGATCTTTCATCTTGGTT-GATCATTG'rjrAATACTCCT.AIATGGiTATTCATTT 
AAfflc:TAAGA.TTCATCTTGGTTGATCATTGTT:rAA'l.'ACTCCTAGATGG(;TATT~TIT 
**-***-****-*******************-"'**-*********·**~****-*****-**-* 
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Figure 3G 
ACCTTTTTTCAATTAATTGIIJGTACGAGlfTTTTTTAATTTGGT.TTT~TAAIAA.TAA 
ACCTTTTITCAATTAATTGTCAGTACGAGTTTTTITAATTTGGTACATTTGTAATAATAA 
ACCTTT.CAATTAATTGTCAGTACGAGTTTTTITAATTTGGTACATTTGTAATAATAA 
ACCTTTTTTCAATTAITTGTct;TACGfl'rTTTTTTAATTTGGTAlfrTTGTAATAATAA 
*******~*******-***---*****---****-**********--*******-***** 
GT~GAATGA'1'.TGTGCTAATATATAAA'4TTTGCAGAAGATAATTGACTGAT_TGTCCC 
GT.AAA. GAATIA,TTGTGCTAATATATAAAGGTTTGIAGAAGATAATTGACTGATTGTCCC 
GTAAAGAA~TTGTGCTAATATATAAA$GTTT<3IAGAAGA$TTGACTGATTGTCCC 
GTAAAGAAIGATT~TGCT~ATATAAiGGT--Gc++TAATTGAllfl 
********--*****************-*-*--*-*-**-**-*****----******* 
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Figure 4 
MVFPIEAfjvGLVTFT~WTKKSQl{~Kl?Ll?l?KI PGGWPVIGHLFFUi.GPPRPLA 60 
MVFPIEAIVGLV'l'F'l'll'Ll!'FFLWTKKSQKPSK.l?LPl?KIPG<::."WPVIGHLFHFl:tDDGOORPI..A oO 
tiffiPIEAIVGLVTFTFLFFFLWTKKSQKPSKl?LPPKIPGGWPVIGITT:,FHFtIDPGDDRPLA 60 
MVFPpIVGLVTFTFLJifflFLWTKKSQKPSKl?Ll?PKIPGGWPVIGHtE'jlijnDGDDIU'LA 60 
*: *:••:••·••****::********* *****************•~•~:•••***** 
RKLGDIJWKYGPVFTFRLGLPLVLVV_SsYEAtrocFS'l'N.OAIFSNRPAFfS~~~. 120 
RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120 
RKLGl)IJWKYGI?VF'l'FRI,GLPLvtVVSSYEAVKDCFS'l'NDAl'.FSNRPAFLl'GDYLGYNNA 120 
ltl{LGOLADKYGPVFTFRLGLPLVLyVSSY~CFSTNDAIFSNRfAFLY~jNA· 120 
****************************•**:********************:****:*: 
MLFLANYGPYWRKNru(l,VIQEVLSASRLEK~~IQISIKNLYTRIIG~SSTINLT 
MLFLANYGPYWRmRIU,VIQBVLSASRLEKFKHVP.FARlQASIKNLYTRIOGNSS~IITT.T 
MLFLANYGPYWRfil-UUtt.VIQEVLSASRLEKF:KHVRFAlUQASII<NLYTRIDGNSSTIN:LT 
mriA.NYGiYWRKN~IQ~SASlU,EKFKHVRFARIQjs:rKNLYTRIDGNssTINLT 
******•* ********:*•***********•:***:***:****•****:•**'••··· 
180 
180 
180 
180 
DWLEELNFGLIWMIAGKNYESGKGDEQVERFKiAFKD.FMfflLS~F\TLWDAFPil?LF.KWV. 2 4 0 
OWLEELNFGLIVKMIAGKNYESGKGDEQVERFKUFKD)l'MILSMEFVLWDAEF!l?LFKWV 240 
DWLEELNFGLI\r~IAGKNYESGKGDEQVERFKAAFKDFM!LSMEFVLWDAFPIPLFK"h"'V 240 
DWLEELNFGLIVI<MIAGKNYESGKGDEQVERFI".KAFKDFM!LSMfilMWOAF~IPLFKWV 240 
*****************i*********•*~***:**'***:********•~~ ••• i •• ~. 
DFQGH~TFJIDIDSVFQNWLEEH!NKREK-MEV~GNEQI:)FIDvvtSFiSFY:tl 
DFQGHVl'U\MKRTFN>IOSVFQNWLl!lEBINKREK-Mli:VNAEGNEQDFlDVVLSlU15NEYLG 
DFQGIN:KAMKRTnwIOSVFQNWLEEHlmREK-MEVNAEGNEQPFIDWLSKMSNEYLG 
DFQGBVKAMKRTFl<D!DSVFQMEEflI~V·GNSQDFIDvvtSKMSNEYLG 
*****:**********************:**** ***,:**************:*:***· 
EGYSRDTVIKATVFSLVI,DAADTVALHINWGMffiI,LlNNQ~Q~E!DTKVGKDRWVE 
EGYSRDTVIKATVFSLVLDAFIDTVALBINWGMALLINNQKJ\,LTKAQEEID,rKVGKDRWVE 
EGYSRDTVIKATVFSLVLDAADTVAl,H!NWGMALI.INNQKALTKAQEEIPTKV'GKDRWVE 
EGYSRDTVIKATVFSLVLOMDTVALBINiGVALLlNN~QE.EIDTlWmIDRWVE 
******************••········· ·······••:~* ***~*******~***** 
ESPIKOLVYLQAlvqtn.RLYl?l?GPLLVPHENVjo~SGYHIFKiTRLFANVMKLQRDl? 
ESDila)LVYLQAIVKEVLRLYPl?GPLLV.l?HENVEDCVVSGYHIPKG'l'RLk'ANym.LQRDl? 
ESDIKDLVYLQAIVKEVLRLYl?PGPLLVPHENVEOCVV'SGYHiPKGTRLFANVMKLQRDP 
ESDIKDLVYLQAIVl<EVLRLYPPGPLLVI?HENVEDCVVSGYHIPKGTRLF~.NVMKLQRDl? 
* * ***** **** * ***: * * ***•**** ******* ! • * **·*"** **** • * ..... * **---* **** 
299 
;?99 
299 
300 
359 
359 
359 
360 
419 
419 
419 
420 
KLjs!iPPiFPPERF!~rDFRGIJYfilrPFGSGRRSCPGMTYALQVEHL'l'MAHLIQGFN 4 7 9 
KLWS!ll?OTFDl?ERFIATDIDFRGQYYKYI"Pli'GSGRRSCPGMT:!ALQVEHLTMAHLIQGFN 479 
IU,WSDl?DTFDPERF!ATPIDFRGQYYKYIPFGSGAASCl?GMTYALQVEHLTMAHLIQGFN 479 
KLWSWDMPERFI.!Df'IGQ~~Il?FGSGRRSCPGMTYALQVEHLt'MAHLIQGFN 480 
** *:*•.•:••··~·-••**:*::*::*---******************••~········· 
YiTPNDEfr,DMKEGAqI1IRKVNl?VELIIfflPRLAPELY 517 
YRTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517 
YRTPNDEFLDMKEGAGITI:RKVNPVELIIAJ?RLAPELY 517 
YRTPi:>EPLDMKEGAGITIRKVNP¥IfflFRLAFELY 518 
*:**·*•.*•***************;:*•:•******* 
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Figure 7 
CTGTCATTAAAGCAACGGTGTTTGTAAGTTCATCTGTCATTTTTCATTTATTCACTTTT 
ATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTATGTGT 
ACAGGTTCGAGCCTCAGGTGCAACCACTAATGCTTGTATTAGATTATGTTGTCTGCAT 
CATACCCCTAATTGGA GTGTGGCTCTTCCCGAACCCTGCAATGCTGGATGCTGGATGC 
TTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGATGATTTMTAA 
AAATATAGAATGGTAAACAGAAAAAGATGAGATTATTTTTGGGGCTATATGGATTCGC 
CCGGGCTTTGGGAGGJMAACGGTATCTACCAGTTGAGACTTTACTCCAGAACTTTAT 
CTCGAGAGCTCTGAA TAAAAATGAAATAGTATTTACC.4CTCCAAAATCTTTGATGGTAA 
AAA GATGA GATATAACCTCTTATAA TTGATTGAACCACGTTGATAGAATAAAACTTCTT 
TACTCCCA TTCAGCATAAGAAAAATGAAACC4AACGGAA TTCTTCTCTTTTTTAGGGGG 
AAATTCCTTAA TTGCTTGTTGAATATAGATTCATGTCGTTATTCTATTTTTAATMTGAT 
GAAAATCAATATAGTCAAAGTTAATACTTATGTCATTTGGTTTGCGGACAAGTTATATT 
GGAACTATATAATACGTCTATTATAGMTAGTGATTATTTAGAGGATATACATTTTTTT 
TGGATAAATATTTGATTTATTGGATTAAAAATAGAATATACAGGTAAGGTCTAAAACGT 
GTGTTTGCTTTTACACTAAA TAAACTTGACCTCGTACAA TTCTAAGAAAATATTTGAAA 
TAAATGAATTATTTTATTGTTAATCAATTAA/44.AAA TCATAGTATAGATGAGATGTGTG 
CATACTTGGCAATAACTATACI:4ACTAAAACAAGGTATGTGAATAATTGATATTCCTTT 
TTTAATTATTCTTTTTTCCAGAGTTTGGTCTTGGATGCAGCAGACACAGTTGCTCTTCA 
CATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCCTTGACGAAAGCAC 
AAG 
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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
2 
"Formation of Tobacco-specific Nitrosamines in Flue-cured 
Tobacco," CORESTA Meeting, Agro-Phyto Groups, 
Suzhou, China). Retrofitting these curing barns with heat-
exchangers virtually eliminated the mixing of combustion 
5 gases with the curing air and dramatically reduced the 
formation of TSNAs in tobaccos cured in this manner 
(Boyette and Hannn (2001) Rec. Adv. Tab. Sci. 27:17-22.). 
In contrast, in the air-cured Burley tobaccos, TSNA forma-
tion proceeds primarily through reaction of tobacco alka-
This application is a continuation application of U.S. 
patent application Ser. No. 14/878,083 filed Oct. 8, 2015 
(allowed), which is a continuation of U.S. patent application 
Ser. No. 12/971,801 filed Dec. 17, 2010 (now U.S. Pat. No. 
9,187,759), which is a continuation of U.S. application Ser. 
No. 11/580,765, filed Oct. 13, 2006 (now U.S. Pat. No. 
7,884,263), which is a continuation-in-part of International 
Application No. PCT/US2005/005665, filed Feb. 23, 2005, 15 
the contents of each of which are herein incorporated by 
reference in their entirety. 
10 loids with nitrite, a process catalyzed by leaf-borne microbes 
(Bush et al. (200l)Rec. Adv. Tab. Sci. 27:23-46). Thus far, 
attempts to reduce TNSAs through modification of curing 
conditions while maintaining acceptable quality standards 
have not proven to be successful for the air-cured tobaccos. 
In Burley tobaccos, a positive correlation has been found 
between the nornicotine content of the leaf and the amount 
of NNN that accumulates in the cured product (Bush et al. 
(2001) Rec. Adv. Tab. Sci. 27:23-46; Shi et al. (2000) Tab. 
Chem. Res. Conj 54:Abstract 27). However, keeping nor-REFERENCE TO A SEQUENCE LISTING 
SUBMITTED AS A TEXT FILE VIA EFS WEB 
The Sequence Listing written in file 509587SEQLIST.txt 
is 60 kb, was created on Jan. 30, 2018, and is hereby 
incorporated by reference. 
FIELD OF THE INVENTION 
The invention relates to compositions and methods for 
reducing the level of nornicotine and its metabolite, N'-ni-
trosonornicotine, in a plant that is a member of the genus 
Nicotiana, particularly compositions and methods for inhib-
iting expression or function of a cytochrome P450 polypep-
tide involved in the metabolic conversion of nicotine to 
nornicotine. 
BACKGROUND OF THE INVENTION 
20 nicotine levels at a minimum has been difficult because of 
the conversion phenomenon that results in a continual 
introduction of high nornicotine-producing plants within 
commercially grown Burley populations. Minimizing the 
number of Burley plants that accumulate high levels of 
25 nornicotine has traditionally been the responsibility of plant 
breeders and seed producers. Though the percentage of 
converter plants that are ultimately grown in farmers' fields 
can be reduced through the roguing of converter plants 
during the propagation of seed stocks, this process is costly, 
30 time-consuming, and imperfect. 
Previous studies have shown that once a plant has con-
verted, the high nornicotine trait is inherited as a single 
dominant gene (Griffith et al. (1955) Science 121:343-344; 
Burk and Jeffrey (1958) Tab. Sci. 2:139-141; Mann et al. 
35 (1964) Crop Sci. 4:349-353). The nature of this gene, 
however, is currently unknown. In the most simple of 
scenarios, the conversion locus may represent a nonfunc-
tional nicotine N-demethylase gene that regains its function 
in converter plants, possibly through the mobilization of a 
The predominant alkaloid found in commercial tobacco 
varieties is nicotine, typically accounting for 90-95% of the 
total alkaloid pool. The remaining alkaloid fraction is com-
prised primarily of three additional pyridine alkaloids: nor-
nicotine, anabasine, and anatabine. Nornicotine is generated 
directly from nicotine through the activity of the enzyme 
nicotine N-demethylase (FIG. 1). Nornicotine usually rep-
resents less than 5% of the total pyridine alkaloid pool, but 45 
through a process termed "conversion," tobacco plants that 
initially produce very low amounts of nornicotine give rise 
40 mutation-inducing transposable element. Alternatively, the 
converter locus may encode a protein that initiates a cascade 
of events that ultimately enables the plant to metabolize 
nicotine to nornicotine, which would mean that multiple 
genes may be involved. 
Regardless of whether there are one or many genes 
associated with the conversion process, it is clear that the 
gene(s) encoding polypeptides having nicotine demethylase 
activity play a pivotal role in this process. Although the 
inability to purify active nicotine N-demethylase from crude 
to progeny that metabolically "convert" a large percentage 
of leaf nicotine to nornicotine. In tobacco plants that have 
genetically converted (termed "converters"), the great 
majority of nornicotine production occurs during the senes-
cence and curing of the mature leaf (Wernsman and Matz-
inger (1968) Tab. Sci. 12:226-228). Burley tobaccos are 
particularly prone to genetic conversion, with rates as high 
as 20% per generation observed in some cultivars. 
During the curing and processing of the tobacco leaf, a 
portion of the nornicotine is metabolized to the compound 
N'-nitrosonornicotine (NNN; FIG. 1), a tobacco-specific 
nitrosamine (TSNA) that has been shown to be carcinogenic 
in laboratory animals (Hecht and Hoffmann (1990) Cancer 
Surveys 8:273-294; Hoffmann et al. (1994) J. Toxicol. Envi-
ron. Health 41:1-52; Hecht (1998) Chem. Res. Toxicol. 
11:559-603). In flue-cured tobaccos, TSNAs were found to 
be predominantly formed through the reaction of alkaloids 
with the minute amounts of nitrogen oxides present in 
combustion gases formed by the direct-fired heating systems 
found in traditional curing barns (Peele and Gentry (1999) 
50 extracts has impeded the isolation and identification of this 
enzyme, there is some evidence that a member of the 
cytochrome P450 superfamily of monooxygenases may be 
involved (Hao and Yeoman (1996) Phytochem. 41:477-482; 
Hao and Yeoman (1996) Phytochem. 42:325-329; Chelva-
55 rajan et al. (1993) J. Agric. Food Chem. 41:858-862; Hao 
and Yeoman (1998) J. Plant Physiol. 152:420-426). How-
ever, these studies are not conclusive, as the classic P450 
inhibitors carbon monoxide and tetcylasis have failed to 
lower enzyme activity at rates comparable to other reported 
60 P450-mediated reactions (Chelvarajan et al. (1993) J. Agric. 
Food Chem. 41:858-862). 
Furthermore, the cytochrome P450s are ubiquitous, trans-
membrane proteins that participate in the metabolism of a 
wide range of compounds (reviewed by Schuler (1996) Crit. 
65 Rev. Plant Sci. 15:235-284; Schuler and Werck-Reichhart 
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples of 
biochemical reactions mediated by cytochrome P450s 
US 10,383,299 B2 
3 
include hydroxylations, demethylations, and epoxidations. 
4 
The methods of the invention comprise inhibiting the 
expression or function of a cytochrome P450 polypeptide of 
the present invention. In some embodiments, an expression 
cassette comprising an inhibitory sequence that targets 
expression or function of a cytochrome P450 polypeptide of 
the present invention is introduced into the plant or plant part 
of interest, wherein expression of the inhibitory sequence 
produces a polynucleotide or polypeptide that inhibits 
expression or function of a cytochrome P450 polypeptide of 
In plants, the cytochrome P450 gene families are very large. 
For example, total genome sequence examination has 
revealed 272 predicted cytochrome P450 genes in Arabi-
dopsis and at least 455 unique cytochrome P450 genes in 5 
rice (see, for example, Nelson et al. (2004) Plant Physiol. 
135(2):756-772). Even though cytochrome P450 has been 
implicated as having a role in the metabolic conversion of 
nicotine to nornicotine, identification of key participating 
members of this protein family remains a challenge. 
Aside from serving as a precursor for NNN, recent studies 
suggest that the nornicotine found in tobacco products may 
have additional undesirable health consequences. Dickerson 
and Janda demonstrated that nornicotine causes aberrant 
protein glycation within the cell (Dickerson and Janda 15 
(2002) Proc. Natl. Acad. Sci. USA 99:15084-15088). Con-
centrations of nornicotine-modified proteins were found to 
10 the invention. In one such embodiment, the inhibitory 
sequence comprises a sequence set forth in SEQ ID NO: 1, 
3, 5, 7, 9, 11, 13, 14, 15, or 16, or a complement or fragment 
thereof. 
be much higher in the plasma of smokers compared to 
nonsmokers. Furthermore, this same study showed that 
nornicotine can covalently modify commonly prescribed 20 
steroid drugs such as prednisone. Such modifications have 
the potential of altering both the efficacy and toxicity of 
these drugs. 
The methods of the invention find use in the production of 
Nicotiana plants that have decreased levels of nornicotine 
and its metabolite, the nitrosamine N'-nitrosonornicotine, 
within the leaf and stem tissues. When harvested, the leaf 
and stem tissues of these plants can be utilized to produce 
tobacco products having reduced levels of nornicotine and 
this tobacco-specific nitrosamine, and thus reduced carcino-
genic potential for individuals consuming these products or 
exposed to secondary smoke derived from these products. 
Also provided are transgenic Nicotiana plants having a 
nicotine to nornicotine conversion rate of less than about 
25 2%, where the plants comprise a heterologous nucleic acid 
construct comprising a promoter capable of functioning in a 
plant cell operably linked to a nucleic acid sequence having 
a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
In view of the difficulties associated with conversion and 
the undesirable health effects of nornicotine accumulation, 
improved methods for reducing the nornicotine content in 
tobacco varieties, particularly Burley tobacco, are therefore 
desirable. Such methods would not only help ameliorate the 
potential negative health consequences of the nornicotine 
per se as described above, but should also concomitantly 30 
reduce NNN levels. 
SUMMARY OF THE INVENTION 
a Nicotiana nicotine demethylase polynucleotide and a 
second nucleotide sequence capable of forming a double-
stranded RNA with the first nucleotide sequence, where the 
transgenic Nicotiana plants are transgenic converter lines of 
Nicotiana. In some embodiments, the Nicotiana nicotine 
Compositions and methods for reducing the nornicotine 
content in plants that are members of the genus Nicotiana 
are provided. Compositions include isolated cytochrome 
P450 polynucleotides and polypeptides that are involved in 
the metabolic conversion of nicotine to nornicotine in plants, 
particularly Nicotiana species. The isolated polynucleotides 
comprise the nucleotide sequence set forth in SEQ ID NO: 1, 
35 demethylase polynucleotide is a tobacco nicotine demeth-
ylase polynucleotide. 
The present invention also provides a recombinant nucleic 
acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
40 having a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
3, 5, 7, 9, or 11, a nucleotide sequence encoding a polypep-
tide as set forth in SEQ ID NO:2, 4, 6, 8, 10, or 12, and 
fragments and variants thereof. Isolated polypeptides of the 
invention comprise an amino acid sequence set forth in SEQ 45 
ID NO:2, 4, 6, 8, 10, or 12, an amino acid sequence encoded 
by the nucleotide sequence set forth in SEQ ID NO:1, 3, 5, 
7, 9, or 11, and fragments and variants thereof. 
The polynucleotides of the invention find use in suppress-
ing expression of a cytochrome P450 that is involved in the 50 
metabolic conversion of nicotine to nornicotine in a plant, 
including the cytochrome P450s of the present invention. In 
this manner, compositions further include expression cas-
settes comprising an inhibitory sequence that is capable of 
inhibiting expression or function of a cytochrome P450 55 
polypeptide of the invention, where the inhibitory sequence 
is operably linked to a promoter that is functional in a plant 
cell. In some embodiments, the inhibitory sequence com-
prises the sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 
13, 14, 15, or 16, or a complement or fragment thereof. 60 
Compositions also include transformed plants and plant 
parts that comprise an expression cassette of the present 
invention, optionally stably incorporated into the genome of 
the plant. Further provided are tobacco products, including 
chewing tobacco, snuff, cigarettes, pipe tobacco, and cigars, 65 
having a reduced level of nornicotine, and its related nitro-
samine, N'-nitrosonornicotine. 
a tobacco nicotine demethylase polynucleotide and a second 
nucleotide sequence capable of forming a double-stranded 
RNA with the first nucleotide sequence. 
Also provided are methods of reducing the conversion of 
nicotine to nornicotine in a Nicotiana plant comprising 
transforming a Nicotiana plant with a recombinant nucleic 
acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
having a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
a Nicotiana nicotine demethylase polynucleotide and a 
second nucleotide sequence capable of forming a double-
stranded RNA with the first nucleotide sequence; and regen-
erating a transgenic Nicotiana plant. In some embodiments, 
the Nicotiana nicotine demethylase polynucleotide is a 
tobacco nicotine demethylase polynucleotide. 
The present invention also provides seed obtained from 
the transgenic Nicotiana plant having a nicotine to norni-
cotine conversion rate of less than about 2%, where the seed 
comprises a heterologous nucleic acid construct comprising 
a promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence having a first nucleotide 
sequence comprising a fragment of between about 100 
nucleotides and about 400 nucleotides of a Nicotiana nico-
tine demethylase polynucleotide and a second nucleotide 
sequence capable of forming a double-stranded RNA with 
US 10,383,299 B2 
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the first nucleotide sequence, where the transgenic Nicotiana 
plants are transgenic converter lines of Nicotiana. In some 
embodiments, the Nicotiana nicotine demethylase poly-
nucleotide is a tobacco nicotine demethylase polynucleotide. 
6 
28S ribosomal RNA to show the relative equivalence of 
RNA loading among the lanes. 
The present invention also provides transgenic plant cells 5 
comprising a nucleic acid molecule having a promoter 
functional in a plant cell and a nucleic acid sequence 
encoding a nicotine demethylase having an isoleucine resi-
due at position 274 and a tryptophan residue at position 330. 
FIG. 6 shows a Northern blot analysis of transgenic plants 
possessing sense-orientation constructs of members of the 
3D_C12 gene family. (A) Hybridization of the 3D_Cl2-7 
probe to RNAs isolated from nontreated leaves of indepen-
dent transgenic lines expressing 3D_Cl2-7, 3D_C12, and 
7D_A06 constructs and a vector-only control (control 8). 
Estimated size of hybridizing band is indicated in kilobases 
(kb). (B) Ethidium bromide staining of the portion of the gel 
used in (A) that contains the 28S ribosomal RNA to show the 
The present invention also provides methods of screening 10 
for a nicotine demethylase sequence comprising: obtaining 
a nucleic acid sequence that has greater than about 90% 
sequence identity with SEQ ID NO:5 and identifying a 
codon sequence encoding for a tryptophan residue at posi-
tion 330 of the encoded polypeptide. 
relative equivalence of RNA loading among the lanes. 
FIG. 7 shows a genomic sequence of a fragment of the 
3D_Cl2-10 gene possessing an intron. Intron sequences are 
15 indicated in bold, italicized type. Exon sequences are shown 
in plain type. The sequences corresponding to the PCR 
primers used to amplify the fragment from the tobacco 
genomic DNA are underlined. 
Further provided are methods for screening for a nicotine 
demethylase having an isoleucine at position 274 or a 
tryptophan at position 330 comprising obtaining a nucleic 
acid sequence that has greater than about 90% sequence 
identity with SEQ ID NO:5 and identifying a first codon 20 
sequence encoding for an isoleucine residue at position 274 
FIG. 8 shows a diagram of the RNAi constructs used to 
silence expression of of members of the 3D_CD12 gene 
family. 
or a second codon sequence encoding a tryptophan residue 
at position 330 of the encoded polypeptide. DETAILED DESCRIPTION OF THE 
INVENTION 
BRIEF DESCRIPTION OF THE DRAWINGS 25 
FIG. 1 shows the structures of nicotine, nornicotine, and 
N'-nitrosonornicotine (NNN). 
FIG. 2 shows Northern blot analysis of converter and 
nonconverter RNAs using 7D_A06 as a hybridization probe. 
Lanes 1 and 2 show RNAs isolated from sodium bicarbon-
ate-treated leaves of genotypes DH 98-325-5 (nonconverter) 
and DH 98-325-6 (converter), respectively. Lanes 3 and 4 
show RNAs isolated from ethephon-treated leaves of geno-
types DH 98-326-3 (nonconverter) and DH 98-326-1 (con-
verter), respectively. Estimated size of the hybridizing band 
is indicated in kilobases (kb). 
Background and Definitions 
Before describing the present invention in detail, it is to 
be understood that many modifications and other embodi-
30 ments of the inventions set forth herein will come to mind 
to one skilled in the art to which this invention pertains 
having the benefit of the teachings presented in the forego-
ing descriptions and the associated drawings. Therefore, it is 
to be understood that the invention is not to be limited to the 
35 specific embodiments disclosed and that modifications and 
other embodiments are intended to be included within the 
FIGS. 3A-3G shows a nucleotide sequence alignment of 
members of the 3D_C12 gene family. Asterisks denote 
positions where sequence identity is conserved among all 40 
sequences compared. Positions where differences are found 
are indicated with dashes and the corresponding residues are 
shaded grey. The nucleotide sequences present in the align-
ment include 3D_C12 (SEQ ID NO:1), 3D_Cl2-10 (SEQ 
scope of the appended claims. Rather, these embodiments 
are provided so that this disclosure will satisfy applicable 
legal requirements. 
Although specific terms are employed herein, they are 
used in a generic and descriptive sense only and not for 
purposes of limitation. Like numbers refer to like elements 
throughout. Further, the article "a" and "an" are used herein 
to refer to one or more than one (i.e., to at least one) of the 
grammatical object of the article. By way of example, "an 
element" means one or more element. Throughout the 
ID NO:3); 3D_Cl2-7 (SEQ ID NO:5); 7D_A06 (SEQ ID 45 
NO:7); 3D_Cl2-15 (SEQ ID NO:9); and 131A_A02 (SEQ 
ID NO:11). The 3D_Cl2-15 and 131A_A02 entries are 
partial-length cDNA sequences. The 99 bp region of 
3D_C12 that was used to make the RNAi-based construct is 
underlined. 
FIG. 4 shows an alignment of predicted amino acid 
sequences for full-length members of the 3D_C12 family of 
P450 genes. The amino acid sequences present in the 
aligrnnent include 3D_C12 (SEQ ID NO:2), 3D_Cl2-10 
(SEQ ID NO:4); 3D_Cl2-7 (SEQ ID NO:6); and 7D_A06 
(SEQ ID NO: 8). Asterisks denote positions conserved 
among all four sequences. Residues that differ among the 
members are shaded in grey. 
FIG. 5 shows a Northern blot analysis of transgenic plants 
possessing the 3D_C12/RNAi construct. (A) Hybridization 
of the 3D_Cl2-7 probe to RNAs isolated from ethephon-
treated, cured leaves of transgenic plants displaying low 
nornicotine phenotypes (3D_C12/RNAi-1, 3, and 4) and 
high nornicotine phenotypes (3D_C12/RNAi-6, 7, and vec-
tor-only control plant 11 ). Estimated size of hybridizing 
band is indicated in kilo bases (kb). (B) Ethidium bromide 
staining of the portion of the gel used in (A) that contains the 
specification the word "comprising," or variations such as 
"comprises" or "comprising," will be understood to imply 
the inclusion of a stated element, integer or step, or group of 
50 elements, integers or steps, but not the exclusion of any other 
element, integer or step, or group of elements, integers or 
steps. 
The present invention is drawn to compositions and 
methods for inhibiting the expression or function of 
55 cytochrome P450 polypeptides that are involved in the 
metabolic conversion of nicotine to nornicotine in a plant, 
particularly plants of the Nicotiana genus, including tobacco 
plants of the various commercial varieties. As used herein, 
the terms "inhibit," "inhibition," and "inhibiting" are defined 
60 as any method known in the art or described herein that 
decreases the expression or function of a gene product of 
interest (i.e., the target gene product). "Inhibition" can be in 
the context of a comparison between two plants, for 
example, a genetically altered plant versus a wild-type plant. 
65 Alternatively, inhibition of expression or function of a target 
gene product can be in the context of a comparison between 
plant cells, organelles, organs, tissues, or plant parts within 
US 10,383,299 B2 
7 8 
sequences including, but not limited to, single-stranded 
forms, double-stranded forms, hairpins, stem-and-loop 
structures, and the like. 
The term "variant" as used herein is intended to mean a 
the same plant or between different plants, and includes 
comparisons between developmental or temporal stages 
within the same plant or plant part or between plants or plant 
parts. "Inhibition" includes any relative decrement of func-
tion or production of a gene product of interest, up to and 
including complete elimination of function or production of 
that gene product. The term "inhibition" encompasses any 
method or composition that down-regulates translation and/ 
or transcription of the target gene product or functional 
activity of the target gene product. 
5 substantially similar sequence, and the term "native" poly-
nucleotide or polypeptide is intended to mean a naturally 
occurring nucleotide sequence or amino acid sequence, 
respectively. By "fragment" is intended a portion of a 
polynucleotide or a portion of an amino acid sequence and 
10 hence protein encoded thereby. 
As used herein, the term "plant part" includes plant cells, 
plant protoplasts, plant cell tissue cultures from which a 
whole plant can be regenerated, plant calli, plant clumps, 
and plant cells that are intact in plants or parts of plants such 
The term "inhibitory sequence" encompasses any poly-
nucleotide or polypeptide sequence capable of inhibiting the 
expression or function of a cytochrome P450 polypeptide 
involved in the metabolic conversion of nicotine to norni-
cotine in a plant, such as full-length polynucleotide or 
polypeptide sequences, truncated polynucleotide or poly-
peptide sequences, fragments of polynucleotide or polypep-
tide sequences, variants of polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense- 20 
oriented nucleotide sequences, the complement of a sense-
15 as embryos, pollen, anthers, ovules, seeds, leaves, flowers, 
stems, branches, fruit, roots, root tips, and the like. Progeny, 
variants, and mutants of regenerated plants are also included 
within the scope of the invention, provided that these 
or antisense-oriented nucleotide sequence, inverted regions 
of nucleotide sequences, hairpins of nucleotide sequences, 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. 25 
The term "polynucleotide sequence" includes sequences of 
RNA, DNA, chemically modified nucleic acids, nucleic acid 
analogs, combinations thereof, and the like. 
Inhibitory sequences are designated herein by the name of 
the target gene product. Thus, a "cytochrome P450 inhibi- 30 
tory sequence" refers to an inhibitory sequence that is 
capable of inhibiting the expression of a cytochrome P450 
polypeptide that is involved in the metabolic conversion of 
nicotine to nomicotine in a plant, for example, at the level 
of transcription and/or translation, or which is capable of 35 
inhibiting the function of such a cytochrome P450 polypep-
tide. When the phrase "capable of inhibiting" is used in the 
context of a polynucleotide inhibitory sequence, it is 
intended to mean that the inhibitory sequence itself exerts 
the inhibitory effect; or, where the inhibitory sequence 40 
encodes an inhibitory nucleotide molecule (for example, 
hairpin RNA, miRNA, or double-stranded RNA polynucle-
otides ), or encodes an inhibitory polypeptide (i.e., a poly-
peptide that inhibits expression or function of the target gene 
product), following its transcription (for example, in the case 45 
of an inhibitory sequence encoding a hairpin RNA, miRNA, 
or double-stranded RNA polynucleotide) or its transcription 
and translation (in the case of an inhibitory sequence encod-
ing an inhibitory polypeptide), the transcribed or translated 
product, respectively, exerts the inhibitory effect on the 50 
target gene product (i.e., inhibits expression or function of 
the target gene product). 
By "host cell" is meant a cell that comprises a heterolo-
gous nucleic acid sequence of the invention. Though the 
nucleic acid sequences of the invention, and fragments and 55 
variants thereof, can be introduced into any cell of interest, 
of particular interest are plant cells, more particularly cells 
of a Nicotiana plant species, for example, the tobacco plant 
species and varieties described herein below. 
The use of the term "polynucleotide" is not intended to 60 
limit the present invention to polynucleotides comprising 
DNA. Those of ordinary skill in the art will recognize that 
polynucleotides can comprise ribonucleotides and combina-
tions of ribonucleotides and deoxyribonucleotides. Such 
deoxyribonucleotides and ribonucleotides include both natu- 65 
rally occurring molecules and synthetic analogues. The 
polynucleotides of the invention also encompass all forms of 
comprise the introduced nucleic acid sequences of the 
invention. 
By "phenotypic change" is intended a measurable change 
in one or more cell functions. For example, plants having a 
genetic modification at the genomic locus encoding a 
cytochrome P450 polypeptide of the invention can show 
reduced or eliminated expression or activity of that 
cytochrome P450 polypeptide. 
The term "introducing" is intended to mean presenting to 
the plant the polynucleotide or polypeptide in such a manner 
that the sequence gains access to the interior of a cell of the 
plant. 
The term "operably linked" is intended to mean a func-
tional linkage between two or more elements. For example, 
an operable linkage between a polynucleotide of interest and 
a regulatory sequence (i.e., a promoter) is a functional link 
that allows for expression of the polynucleotide of interest. 
Operably linked elements may be contiguous or non-con-
tiguous. When used to refer to the joining of two protein 
coding regions, by operably linked is intended that the 
coding regions are in the same reading frame. 
The term "heterologous" according to the present inven-
tion when used in reference to a sequence is intended to 
mean a sequence that originates from a foreign species, or, 
if from the same species, is substantially modified from its 
native form in composition and/or genomic locus by delib-
erate human intervention. The term also is applicable to 
nucleic acid constructs, also referred to herein as "poly-
nucleotide constructs" or "nucleotide constructs." In this 
manner, a "heterologous" nucleic acid construct is intended 
to mean a construct that originates from a foreign species, or, 
if from the same species, is substantially modified from its 
native form in composition and/or genomic locus by delib-
erate human intervention. Heterologous nucleic acid con-
structs include, but are not limited to, recombinant nucleo-
tide constructs that have been introduced into a plant or plant 
part thereof, for example, via transformation methods or 
subsequent breeding of a transgenic plant with another plant 
of interest. 
For example, a promoter operably linked to a heterolo-
gous polynucleotide is from a species different from the 
species from which the polynucleotide was derived, or, if 
from the same/analogous species, one or both are substan-
tially modified from their original form and/or genomic 
locus, or the promoter is not the native promoter for the 
operably linked polynucleotide. Furthermore, as used herein 
a chimeric gene comprises a coding sequence operably 
linked to a transcription initiation region that is heterologous 
to the coding sequence. 
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N-demethylation reaction, or an indirect one, i.e., in the form 
of production of a product that leads to the up-regulation of 
the nicotine demethylase activity of the leaf. Regardless of 
the mechanism, any means by which expression and/or 
5 function of the polypeptides encoded by members of this 
cytochrome P450 gene family are targeted for inhibition 
within a Nicotiana plant will be effective in reducing nor-
nicotine levels, and levels of its carcinogenic metabolite, 
The term "expression" as used herein refers to the bio-
synthesis of a gene product, including the transcription 
and/or translation of said gene product. For example, for the 
purposes of the present invention, an expression cassette, as 
described elsewhere herein, capable of expressing a poly-
nucleotide that inhibits the expression of at least one 
cytochrome P450 polypeptide of the invention is an expres-
sion cassette capable of producing an RNA molecule that 
inhibits the transcription and/or translation of at least one 
cytochrome P450 polypeptide. The "expression" or "pro- 10 
duction" of a protein or polypeptide from a DNA molecule 
refers to the transcription and translation of the coding 
sequence to produce the protein or polypeptide, while the 
"expression" or "production" of a protein or polypeptide 
from an RNA molecule refers to the translation of the RNA 
coding sequence to produce the protein or polypeptide. 
Cytochrome 450 Polynucleotides and Polypeptides, and 
Variants and Fragments Thereof 
NNN, within leaves and stems of these plants. 
The cytochrome P450 genes of the invention were iso-
lated from tobacco lines of a Burley variety. The first of 
these cytochrome P450 genes, designated 3D_C12, encodes 
an mRNA transcript corresponding to nucleotides (nt) 
1-1551 of the cDNA sequence set forth in SEQ ID NO:1, 
Compositions of the present invention include isolated 
cytochrome P450 polynucleotides and polypeptides that are 
involved in the metabolic conversion of nicotine to norni-
cotine in plants, including commercial varieties of tobacco 
plants. In particular, compositions of the invention include 
isolated polypeptides comprising the amino acid sequences 
as shown in SEQ ID NOS:2, 4, 6, 8, 10, and 12, and isolated 
polynucleotides comprising the nucleotide sequences as 
shown in SEQ ID NOS: 1, 3, 5, 7, 9, and 11. The polynucle-
otides of the invention find use in inhibiting expression of 
these cytochrome P450 polypeptides or variants thereof that 
are involved in the metabolic conversion of nicotine to 
nomicotine in plants, particularly tobacco plants. 
15 which codes for the full-length 517-residue polypeptide set 
forth in SEQ ID NO:2. The second member of this novel 
cytochrome P450 family, designated 3D_Cl2-10, encodes 
an mRNA transcript corresponding to nt 1-1551 of the 
cDNA sequence set forth in SEQ ID NO:3, which codes for 
20 the full-length 517-residue polypeptide set forth in SEQ ID 
NO:4. The third of these cytochrome P450 genes, designated 
3 D _ C 12-7, encodes an mRNA transcript corresponding to nt 
1-1551 of the cDNA sequence set forth in SEQ ID NO:5, 
which codes for the full-length 517 residue polypeptide set 
25 forth in SEQ ID NO:6. The fourth member of the novel 
cytochrome P450 family, designated 7D_A06, encodes an 
mRNA transcript corresponding to nt 1-1554 of the cDNA 
sequence set forth in SEQ ID NO:7, which codes for the 
full-length 518-residue polypeptide set forth in SEQ ID 
30 NO:8. 
In this manner, the invention further provides expression 
cassettes comprising all or a portion of the polynucleotide 
sequence set forth in SEQ ID NO:1, 3, 5, 7, 9, or 11, a 
complement or fragment thereof, or a sequence having 35 
substantial sequence identity to SEQ ID NO:1, 3, 5, 7, 9, or 
11, or a complement or fragment thereof, operably linked to 
a promoter that is functional in a plant cell for use in 
expressing an inhibitory RNA transcript that interferes with 
expression (i.e., transcription and/or translation) of 40 
cytochrome P450 polypeptides described herein. In some 
embodiments, the expression cassettes comprise the nucleo-
tide sequence as shown in SEQ ID NO:13, 14, 15, or 16, a 
complement or fragment thereof, or a sequence having 
substantial sequence identity to SEQ ID NO:13, 14, 15, or 45 
16, or a complement or fragment thereof. Introduction of 
these expression cassettes into a Nicotiana plant of interest, 
particularly a tobacco plant of varieties commonly known as 
flue or bright varieties, Burley varieties, dark varieties, and 
oriental/Turkish varieties, results in the production of 50 
tobacco plants having reduced amounts of nornicotine and 
the nitrosamine, N'-nitrosonomicotine (NNN). Leaf and 
stem material from these transgenic plants can be used to 
produce a variety of tobacco products having reduced levels 
of nornicotine, and a concomitant reduction in this carcino- 55 
genie nitrosamine metabolite. 
The cytochrome P450 polynucleotides and encoded poly-
peptides of the present invention represent a novel 
cytochrome P450 gene family, designated the 3D_C12 
cytochrome 450 gene family, that is newly identified as 60 
having a role in the metabolic conversion of nicotine to 
nomicotine in tobacco plants. Suppression of the expression 
of their encoded gene products in transgenic tobacco plants 
results in a significant reduction in the accumulation of 
nomicotine in the leaves of these transgenic plants. While 65 
not being bound by theory, the metabolic role of these 
polypeptides may be a direct one, i.e., directly catalyzing the 
Two partial-length P450 gene sequences sharing high 
sequence identity to the full-length members of the 3D_C12 
cytochrome P450 gene family were also isolated from these 
Burley tobacco lines. The first of these, designated 3D_Cl2-
15, encodes an mRNA transcript corresponding to the cDNA 
sequence set forth in SEQ ID NO:9, which encodes the 
partial-length polypeptide set forth in SEQ ID NO:10. The 
second partial-length P450 gene sequence, designated 
131A_A02, encodes an mRNA transcript corresponding to 
the cDNA sequence set forth in SEQ ID NO: 11, which 
encodes the partial-length polypeptide set forth in SEQ ID 
NO:12. 
In one aspect, the cytochrome P450 genes of the present 
invention are involved in the conversion of nicotine to 
nornicotine in a plant. In one aspect, the cytochrome P450 
genes of the present invention have nicotine demethylase 
activity. 
An alignment of the members of the 3D_C12 cytochrome 
P450 gene family is shown in FIGS. 3A-3G. The predicted 
amino acid sequences for the four full-length clones are 
aligned in FIG. 4. These sequences share high sequence 
identity with each other (at least 90% at both the nucleotide 
and amino acid level (see Tables 2 and 3, Example 4 herein 
below). 
The invention encompasses isolated or substantially puri-
fied polynucleotide or protein compositions. An "isolated" 
or "purified" polynucleotide or protein, or biologically 
active portion thereof, is substantially or essentially free 
from components that normally accompany or interact with 
the polynucleotide or protein as found in its naturally 
occurring environment. Thus, an isolated or purified poly-
nucleotide or protein is substantially free of other cellular 
material, or culture medium when produced by recombinant 
techniques, or substantially free of chemical precursors or 
other chemicals when chemically synthesized. Optimally, an 
"isolated" polynucleotide is free of sequences ( optimally 
protein encoding sequences) that naturally flank the poly-
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nucleotide (i.e., sequences located at the 5' and 3' ends of the 
polynucleotide) in the genomic DNA of the organism from 
which the polynucleotide is derived. For example, in various 
embodiments, the isolated polynucleotide can contain less 
than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of 5 
nucleotide sequence that naturally flank the polynucleotide 
in genomic DNA of the cell from which the polynucleotide 
12 
A fragment of a cytochrome P450 polynucleotide of the 
present invention that encodes a biologically active portion 
of a cytochrome P450 polypeptide of the present invention 
will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 
200, 250, 300, 350, 400, 450, or 500 contiguous amino 
acids, or up to the total number of amino acids present in a 
full-length cytochrome P450 polypeptide of the invention 
(e.g., 517 for SEQ ID NOS: 2, 4, and 6; and 518 for SEQ ID 
NO:8), or will encode at least 15, 25, 30, 50, 75, 100, 125, 
is derived. A protein that is substantially free of cellular 
material includes preparations of protein having less than 
about 30%, 20%, 10%, 5%, or 1 % (by dry weight) of 
contaminating protein. When the protein of the invention or 
biologically active portion thereof is recombinantly pro-
duced, optimally culture medium represents less than about 
30%, 20%, 10%, 5%, or 1 % (by dry weight) of chemical 
precursors or non-protein-of-interest chemicals. 
10 150, or up to the total number of amino acids present in a 
partial-length cytochrome P450 polypeptide of the invention 
(e.g., 173 for SEQ ID NO:10; and 222 for SEQ ID NO:12). 
In one aspect, a fragment of a cytochrome P450 polynucle-
otide of the invention encodes a polypeptide that comprises 
Fragments of the disclosed cytochrome P450 polynucle-
otides and polypeptides encoded thereby are also encom-
passed by the present invention. Fragments of a polynucle-
otide may encode protein fragments that retain the biological 
activity of the native protein and hence are involved in the 
metabolic conversion of nicotine to nomicotine in a plant. 
Alternatively, fragments of a polynucleotide that are useful 
15 position 330 of the encoded polypeptide sequence. In 
another aspect, the polynucleotide fragment encodes a frag-
ment of a cytochrome P450 polypeptide, where the poly-
peptide fragment comprises the amino acids from position 
225 through the amino acid at about position 600 of SEQ ID 
20 NO:6. In in one such embodiment, the polynucleotide frag-
ment encodes a fragment of a cytochrome P450 polypeptide, 
where the polypeptide fragment comprises the amino acids 
from about position 239 through the amino acid at about 
position 402 of SEQ ID NO: 6. A biologically active portion as hybridization probes or PCR primers using methods 
described below generally do not encode fragment proteins 
retaining biological activity. Furthermore, fragments of the 
disclosed nucleotide sequences include those that can be 
assembled within recombinant constructs for use in gene 
silencing with any method known in the art, including, but 
not limited to, sense suppression/cosuppression, antisense 
suppression, double-stranded RNA (dsRNA) interference, 
hairpin RNA interference and intron-containing hairpin 
RNA interference, amplicon-mediated interference, 
ribozymes, and small interfering RNA or micro RNA, as 
described herein below. Thus, fragments of a cytochrome 35 
P450 polynucleotide sequence may range from at least about 
25 of a cytochrome P450 polypeptide can be prepared by 
isolating a portion of one of the cytochrome P450 poly-
nucleotides of the present invention, expressing the encoded 
portion of the cytochrome P450 polypeptide ( e.g., by recom-
binant expression in vitro), and assessing the activity of the 
30 encoded portion of the cytochrome P450 polypeptide, i.e., 
the ability to promote conversion of nicotine to nomicotine, 
using assays known in the art and those provided herein 
below. 
20 nucleotides, about 50 nucleotides, about 70 nucleotides, 
about 100 nucleotides, about 150 nucleotides, about 200 
nucleotides, about 250 nucleotides, about 300 nucleotides, 
about 350 nucleotides, about 400 nucleotides, and up to the 40 
full-length polynucleotide encoding the proteins of the 
invention, depending upon the desired outcome. In one 
aspect, the fragments of a cytochrome P450 polynucleotide 
sequence can be a fragment of between about 50 and about 
400 nucleotides, between about 70 and about 350 nucleo- 45 
tides, between about 90 and about 325 nucleotides, between 
about 90 and about 300 nucleotides, between about 90 and 
about 275 nucleotides, between about 100 and about 400 
nucleotides, between about 100 and about 350 nucleotides, 
between about 100 and about 325 nucleotides, between 50 
about 100 and about 300 nucleotides, between about 125 and 
about 300 nucleotides, or between about 125 and about 275 
nucleotides in length. In some embodiments, a fragment of 
a cytochrome P450 polynucleotide is about 50, about 60, 
about 70, about 80, about 90, about 100, about 125, about 55 
150, about 175, about 200, about 225, about 250, about 275, 
about 300, about 325, about 350, about 400 nucleotides in 
length, and other such values between about 70 and about 
400 nucleotides. In one such embodiment, a fragment of a 
cytochrome P450 polynucleotide of the invention is about 60 
90 bp to about 110 bp in length, including 90, 91, 92, 93, 94, 
95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 
108, 109, and 110 bp in length. In another such embodiment, 
a fragment of a cytochrome P450 polynucleotide of the 
invention is about 290 to about 310 bp in length, including 65 
290,291,292,293,294,295,296,297,298,299,300,301, 
302,303,304,305,306,307,308, 309, and 310 bp in length. 
Polynucleotides that are fragments of a cytochrome P450 
nucleotide sequence of the present invention comprise at 
least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 
500, 550, 600, 650, 700, 800, 900, 950, 1000, 1050, 1100, 
1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 
1600, 1650, or 1700 contiguous nucleotides, or up to the 
number of nucleotides present in a full-length cytochrome 
P450 polynucleotide as disclosed herein (e.g., 539 for SEQ 
ID NO:9; 666 for SEQ ID NO: 11; 1733 for SEQ ID NOS: 1, 
3, and 5; and 1727 for SEQ ID NO:7). Polynucleotides that 
are fragments of a cytochrome P450 nucleotide sequence of 
the present invention comprise fragments from about 20 to 
about 1700 contiguous nucleotides, from about 50 to about 
1600 contiguous nucleotides, from about 75 to about 1500 
contiguous nucleotides, from about 100 to about 1400 
nucleotides, from about 150 to about 1300 contiguous 
nucleotides, from about 150 to about 1200 contiguous 
nucleotides, from about 17 5 to about 1100 contiguous 
nucleotides, or from about 200 to about 1000 contiguous 
nucleotides from a cytochrome P450 polynucleotide as 
disclosed herein. 
In one aspect, fragments of a cytochrome P450 polynucle-
otide comprise a polynucleotide sequence containing the 
nucleotides from about position 700 to about position 1250 
of a cytochrome P450 coding sequence. In another aspect, 
fragments of a cytochrome P450 polynucleotide comprise a 
polynucleotide sequence containing the nucleotides from 
about position 715 to about position 1210, or from about 
position 717 to about position 1207 of a cytochrome P450 
coding sequence disclosed herein. 
In other embodiments of the invention, fragments of a 
cytochrome P450 polynucleotide comprise a polynucleotide 
sequence containing the nucleotides from about position 265 
to about position 625 of a cytochrome P450 coding sequence 
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disclosed herein, or a complement thereof. In some of these 
embodiments, the fragments of a cytochrome P450 coding 
sequence disclosed herein comprise the nucleotides corre-
sponding to about position 297 to about position 594 of the 
P450 coding sequence set forth in SEQ ID NO:3 or SEQ ID 
NO:5, or a complement thereof. 
In yet other embodiments of the invention, fragments of 
a cytochrome P450 polynucleotide comprise a polynucle-
otide sequence containing the nucleotides from about posi-
tion 1420 to about position 1580 of a cytochrome P450 
coding sequence disclosed herein, or a complement thereof. 
In some of these embodiments, the fragments of a 
cytochrome P450 coding sequence disclosed herein com-
prise the nucleotides corresponding to about position 1453 
to about position 1551 of the P450 coding sequence set forth 
in SEQ ID NO: 1, or a complement thereof. 
Variants of the disclosed polynucleotides and polypep-
tides encoded thereby are also encompassed by the present 
invention. Such naturally occurring variants include those 
variants that share substantial sequence identity to the dis-
closed cytochrome P450 polynucleotides and polypeptides 
disclosed herein as defined herein below. The compositions 
and methods of the invention can be used to target expres-
sion or function of any naturally occurring cytochrome P450 
that shares substantial sequence identity to the disclosed 
cytochrome P450 polypeptides and which possesses the 
relevant cytochrome P450 activity, i.e., involvement in the 
metabolic conversion of nicotine to nomicotine in plants. 
Such variants may result from, for example, genetic poly-
morphism or from human manipulation as occurs with 
breeding and selection. Biologically active variants of a 
cytochrome P450 protein of the invention, for example, 
variants of the polypeptide set forth in SEQ ID NO:2, 4, 6, 
8, 10, or 12, will have at least about 40%, 45%, 50%, 55%, 
60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
94%, 95%, 96%, 97%, 98%, 99% or more sequence identity 
to the amino acid sequence for the native protein as deter-
mined by sequence alignment programs and parameters 
described elsewhere herein, and are characterized by their 
functional involvement in the metabolic conversion of nico-
tine to nornicotine in plants. A biologically active variant of 
a protein of the invention may differ from that protein by as 
few as 1-15 amino acid residues, as few as 10, as few as 9, 
as few as 8, as few as 7, as few as 6, as few as 5, as few as 
4, as few as 3, as few as 2, or as few as 1 amino acid residue. 
Variants of a particular polynucleotide of the present 
invention include those naturally occurring polynucleotides 
that encode a cytochrome P450 polypeptide that is involved 
in the metabolic conversion of nicotine to nomicotine in 
plants. Such polynucleotide variants can comprise a deletion 
and/or addition of one or more nucleotides at one or more 
sites within the native polynucleotide disclosed herein and/ 
or a substitution of one or more nucleotides at one or more 
sites in the native polynucleotide. Because of the degeneracy 
of the genetic code, conservative variants for polynucle-
otides include those sequences that encode the amino acid 
sequence of one of the cytochrome P450 polypeptides of the 
invention. Naturally occurring variants such as these can be 
identified with the use of well-known molecular biology 
techniques, as, for example, with polymerase chain reaction 
(PCR) and hybridization techniques as outlined below. Vari-
ant polynucleotides also include synthetically derived poly-
nucleotides, such as those generated, for example, by using 
site-directed mutagenesis but which still share substantial 
sequence identity to the naturally occurring sequences dis-
closed herein, and thus can be used in the methods of the 
invention to inhibit the expression or function of a 
14 
cytochrome P450 that is involved in the metabolic conver-
sion of nicotine to nornicotine, including the cytochrome 
P450 polypeptides set forth in SEQ ID NOS:2, 4, 6, and 8, 
and polypeptides comprising the sequence set forth in SEQ 
5 ID NO:10 or 12. Generally, variants of a particular poly-
nucleotide of the invention, for example, the sequence set 
forth in SEQ ID NO:1, 3, 5, 7, 9, or 11, will have at least 
about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 
85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 
10 99% or more sequence identity to that particular polynucle-
otide as determined by sequence alignment programs and 
parameters described elsewhere herein. 
Variants of a particular polynucleotide of the present 
invention (also referred to as the reference polynucleotide) 
15 can also be evaluated by comparison of the percent sequence 
identity between the polypeptide encoded by the reference 
polynucleotide and the polypeptide encoded by a variant 
polynucleotide. For example, isolated polynucleotides 
encoding a polypeptide with a particular percent sequence 
20 identity to the full-length polypeptide of SEQ ID NO:2, 4, 6, 
or 8, or the partial-length polypeptide encoded by SEQ ID 
NO:9 or 11 are disclosed. Such polynucleotides can be used 
in the methods of the present invention to target expression 
of cytochrome P450 polypeptides involved in the metabolic 
25 conversion of nicotine to nornicotine in plants, particularly 
tobacco plants, thereby inhibiting accumulation of nomico-
tine and its metabolite N'-nitrosonornicotine in the stems and 
leaves of the genetically modified plant. Percent sequence 
identity between any two polypeptides can be calculated 
30 using sequence alignment programs and parameters 
described elsewhere herein. Where any given pair of poly-
nucleotides of the invention is evaluated by comparison of 
the percent sequence identity shared by the two polypeptides 
they encode, the percent sequence identity between the two 
35 encoded polypeptides is at least about 40%, 45%, 50%, 
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 
93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence 
identity. In one aspect, a variant polypeptide of the present 
invention includes a polypeptide having a tryptophan at 
40 position 330 or an isoleucine at position 274 of the 
cytochrome P450 polypeptide, or both a tryptophan at 
position 330 and an isoleucine at position 274. 
Furthermore, the polynucleotides of the invention can be 
used to isolate corresponding cytochrome P450 sequences 
45 from other organisms, particularly other plants, more par-
ticularly other members of the Nicotiana genus. PCR, 
hybridization, and other like methods can be used to identify 
such sequences based on their sequence homology to the 
sequences set forth herein. Sequences isolated based on their 
50 sequence identity to the nucleotide sequences set forth 
herein or to variants and fragments thereof are encompassed 
by the present invention. Such sequences include sequences 
that are orthologs of the disclosed sequences. 
According to the present invention, "orthologs" are genes 
55 derived from a common ancestral gene and which are found 
in different species as a result of speciation. Genes found in 
different species are considered orthologs when their nucleo-
tide sequences and/or their encoded protein sequences share 
at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
60 94%, 95%, 96%, 97%, 98%, 99%, or greater sequence 
identity. Functions of orthologs are often highly conserved 
among species. Thus, isolated polynucleotides that encode 
for a cytochrome P450 polypeptide that is involved in the 
nicotine-to-nomicotine metabolic conversion and which 
65 hybridize under stringent conditions to the cytochrome P450 
sequences disclosed herein, or to variants or fragments 
thereof, are encompassed by the present invention. Such 
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sequences can be used in the methods of the present inven-
tion to inhibit expression of cytochrome P450 polypeptides 
that are involved in the metabolic conversion of nicotine to 
nomicotine in plants. 
16 
0.0lxSSC to about lxSSC. The duration of hybridization is 
from about 14 to about 16 hours. 
Using PCR, oligonucleotide primers can be designed for 5 
use in PCR reactions to amplify corresponding DNA 
sequences from cDNA or genomic DNA extracted from any 
plant of interest. Methods for designing PCR primers and 
PCR cloning are generally known in the art and are disclosed 
in Sambrook et al. (1989) Molecular Cloning: A Laboratory 10 
Manual (2d ed., Cold Spring Harbor Laboratory Press, 
Plainview, N.Y.). Innis et al., eds. (1990) PCR Protocols: A 
Guide to Methods and Applications (Academic Press, New 
York); Innis and Gelfand, eds. (1995) PCR Strategies (Aca-
15 
demic Press, New York); and Innis and Gelfand, eds. (1999) 
PCR Methods Manual (Academic Press, New York). Known 
methods of PCR include, but are not limited to, methods 
using paired primers, nested primers, single specific primers, 
degenerate primers, gene-specific primers, vector-specific 
primers, partially mismatched primers, and the like. 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and 
temperature of the final wash solution. For DNA-DNA 
hybrids, the Tm can be approximated from the equation of 
Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284: 
Tm=81.5° C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-
500/L; where M is the molarity of monovalent cations, % 
GC is the percentage of guanosine and cytosine nucleotides 
in the DNA, % form is the percentage of formamide in the 
Hybridization techniques involve the use of all or part of 
a known polynucleotide as a probe that selectively hybrid-
izes to other corresponding polynucleotides present in a 
population of cloned genomic DNA fragments or cDNA 
fragments (i.e., genomic or cDNA libraries) from a chosen 
organism. 
Hybridization may be carried out under stringent condi-
tions. By "stringent conditions" or "stringent hybridization 
conditions" is intended conditions under which a probe will 
hybridize to its target sequence to a detectably greater degree 
than to other sequences (e.g., at least 2-fold over back-
ground). Stringent conditions are sequence-dependent and 
will be different in different circumstances. By controlling 
the stringency of the hybridization and/or washing condi-
tions, target sequences that are 100% complementary to the 
probe can be identified (homologous probing). Alternatively, 
stringency conditions can be adjusted to allow some mis-
matching in sequences so that lower degrees of similarity are 
detected (heterologous probing). Generally, a probe is less 
than about 1000 nucleotides in length, optimally less than 
500 nucleotides in length. 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at 
pH 7.0 to 8.3 and the temperature is at least about 30° C. 
Stringent conditions may also be achieved with the addition 
of destabilizing agents such as formamide. Exemplary low 
stringency conditions include hybridization with a buffer 
solution of 30 to 35% formamide, 1 M NaCl, 1 % SDS 
(sodium dodecyl sulphate) at 37° C., and a wash in lx to 
2xSSC (20xSSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 
to 55° C. Exemplary moderate stringency conditions include 
hybridization in 40 to 45% formamide, 1.0 M NaCl, 1 % 
SDS at 37° C., and a wash in 0.5x to lxSSC at 55 to 60° C. 
Exemplary high stringency conditions include hybridization 
in 50% formamide, 1 M NaCl, 1 % SDS at 37° C., and a wash 
in 0.lxSSC at 60 to 65° C. Optionally, wash buffers may 
comprise about 0.1 % to about 1 % SDS. Duration of hybrid-
ization is generally less than about 24 hours, usually about 
4 to about 12 hours. The duration of the wash time will be 
at least a length of time sufficient to reach equilibrium. 
In a specific embodiment, stringency conditions include 
hybridization in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf 
thymus DNA and 50% formamide at 42° C., and at least one 
post-hybridization wash in a solution comprising from about 
hybridization solution, and L is the length of the hybrid in 
base pairs. The Tm is the temperature (under defined ionic 
strength and pH) at which 50% of a complementary target 
sequence hybridizes to a perfectly matched probe. Tm is 
reduced by about 1 ° C. for each 1 % of mismatching; thus, 
Tm, hybridization, and/or wash conditions can be adjusted to 
hybridize to sequences of the desired identity. For example, 
if sequences with 2:90% identity are sought, the Tm can be 
20 decreased 10° C. Generally, stringent conditions are selected 
to be about 5° C. lower than the thermal melting point (Tm) 
for the specific sequence and its complement at a defined 
ionic strength and pH. However, severely stringent condi-
tions can utilize a hybridization and/or wash at 1, 2, 3, or 4° 
25 C. lower than the thermal melting point (Tm); moderately 
stringent conditions can utilize a hybridization and/or wash 
at 6, 7, 8, 9, or 10° C. lower than the thermal melting point 
(Tm); low stringency conditions can utilize a hybridization 
and/or wash at 11, 12, 13, 14, 15, or 20° C. lower than the 
30 thermal melting point (Tm). Using the equation, hybridiza-
tion and wash compositions, and desired Tm, those of 
ordinary skill will understand that variations in the strin-
gency of hybridization and/or wash solutions are inherently 
described. If the desired degree of mismatching results in a 
35 Tm of less than 45° C. (aqueous solution) or 32° C. (forma-
mide solution), it is optimal to increase the SSC concentra-
tion so that a higher temperature can be used. An extensive 
guide to the hybridization of nucleic acids is found in Tij ssen 
(1993) Laboratory Techniques in Biochemistry and Molecu-
40 lar Biology-Hybridization with Nucleic Acid Probes, Part 1, 
Chapter 2 (Elsevier, New York); and Ausubel et al., eds. 
(1995) Current Protocols in Molecular Biology, Chapter 2 
(Greene Publishing and Wiley-Interscience, New York). See 
Sambrook et al. (1989) Molecular Cloning: A Laboratory 
45 Manual (2d ed., Cold Spring Harbor Laboratory Press, 
Plainview, N.Y.). 
Hybridization probes may be genomic DNA fragments, 
cDNA fragments, RNA fragments, or other oligonucle-
otides, and may be labeled with a detectable group such as 
50 
32P, or any other detectable marker. For example, probes for 
hybridization can be made by labeling synthetic oligonucle-
otides based on the cytochrome P450 polynucleotides 
sequences of the present invention. Methods for preparation 
of probes for hybridization and for construction of cDNA 
55 and genomic libraries are generally known in the art and are 
disclosed in Sambrook et al. (1989) Molecular Cloning: A 
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory 
Press, Plainview, N.Y.). 
For example, the cytochrome P450 polynucleotide 
60 sequences disclosed herein, or one or more portions thereof, 
may be used as probes capable of specifically hybridizing to 
corresponding cytochrome P450 polynucleotides and mes-
senger RNAs. To achieve specific hybridization under a 
variety of conditions, such probes include sequences that are 
65 unique among cytochrome P450 polynucleotide sequences, 
including upstream regions 5' to the coding sequence and 
downstream regions 3' to the coding sequence, and are 
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optimally at least about 10 nucleotides in length, and most 
optimally at least about 20 nucleotides in length. Such 
probes may be used to amplify corresponding cytochrome 
P450 polynucleotides. This technique may be used to isolate 
additional coding sequences from a desired plant or as a 5 
diagnostic assay to determine the presence of coding 
sequences in a plant. Hybridization techniques include 
hybridization screening of plated DNA libraries ( either 
plaques or colonies; see, for example, Sambrook et al. 
(1989) Molecular Cloning: A Laboratory Manual (2d ed., 10 
Cold Spring Harbor Laboratory Press, Plainview, N.Y.). 
As used herein, with respect to the sequence relationships 
between two or more polynucleotides or polypeptides, the 
term "reference sequence" is a defined sequence used as a 
basis for sequence comparison. A reference sequence may be 15 
a subset or the entirety of a specified sequence; for example, 
as a segment of a full-length cDNA or gene sequence, or the 
complete cDNA or gene sequence. 
As used herein, the term "comparison window" makes 
reference to a contiguous and specified segment of a poly- 20 
nucleotide sequence, wherein the polynucleotide sequence 
in the comparison window may comprise additions or dele-
tions (i.e., gaps) compared to the reference sequence (which 
does not comprise additions or deletions) for optimal align-
ment of the two polynucleotides. Generally, the comparison 25 
window is at least 20 contiguous nucleotides in length, and 
optionally can be 30, 40, 50, 100, or longer. Those of skill 
in the art understand that to avoid a high similarity to a 
reference sequence due to inclusion of gaps in the poly-
nucleotide sequence a gap penalty is typically introduced 30 
and is subtracted from the number of matches. 
18 
supra), Clustal W (Higgins et al. (1994) Nucleic Acids Res. 
22: 4673-4680), and GAP (University of Wisconsin Genetic 
Computing Group software package) algorithms using 
default parameters. The present invention also encompasses 
the use of any equivalent program thereof for the analysis 
and comparison of nucleic acid and protein sequences. By 
"equivalent program" is intended any sequence comparison 
program that, for any two sequences in question, generates 
an alignment having identical nucleotide or amino acid 
residue matches and an identical percent sequence identity 
when compared to the corresponding alignment generated 
by BLASTX, Clustal W, or GAP. 
For purposes of the foregoing discussion of variant 
nucleotide and polypeptide sequences encompassed by the 
present invention, the term "sequence identity" or "identity" 
in the context of two polynucleotides or polypeptide 
sequences makes reference to the residues in the two 
sequences that are the same when aligned for maximum 
correspondence over a specified comparison window. When 
percentage of sequence identity is used in reference to 
proteins it is recognized that residue positions which are not 
identical often differ by conservative amino acid substitu-
tions, where amino acid residues are substituted for other 
amino acid residues with similar chemical properties (e.g., 
charge or hydrophobicity) and therefore do not change the 
functional properties of the molecule. When sequences differ 
in conservative substitutions, the percent sequence identity 
may be adjusted upwards to correct for the conservative 
nature of the substitution. Sequences that differ by such 
conservative substitutions are said to have "sequence simi-
larity" or "similarity." Means for making this adjustment are 
well known to those of skill in the art. Typically this involves 
scoring a conservative substitution as a partial rather than a 
Methods of alignment of sequences for comparison are 
well known in the art. Thus, the determination of percent 
sequence identity between any two sequences can be accom-
plished using a mathematical algorithm. Non-limiting 
examples of such mathematical algorithms are the algorithm 
of Myers and Miller (1988) CABIOS 4:11-17; the local 
alignment algorithm of Smith et al. (1981) Adv. Appl. Math. 
2:482; the global alignment algorithm of Needleman and 
Wunsch (1970) J. Mal. Biol. 48:443-453; the search-for-
local alignment method of Pearson and Lipman (1988) Proc. 
Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and 
Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, modi-
fied as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. 
USA 90:5873-5877. 
35 full mismatch, thereby increasing the percentage sequence 
identity. Thus, for example, where an identical amino acid is 
given a score of 1 and a non-conservative substitution is 
given a score of zero, a conservative substitution is given a 
score between zero and 1. The scoring of conservative 
The BLAST programs of Altschul et al. (1990) J. Mal. 
Biol. 215:403 are based on the algorithm of Karlin and 
Altschul (1990) supra. BLAST nucleotide searches can be 
performed with the BLASTN program, score=l00, word-
length=12, to obtain nucleotide sequences homologous to a 
nucleotide sequence encoding a protein of the invention. 
BLAST protein searches can be performed with the 
BLASTX program, score=50, wordlength=3, to obtain 
amino acid sequences homologous to a protein or polypep-
tide of the invention. To obtain gapped alignments for 
comparison purposes, Gapped BLAST (in BLAST 2.0) can 
be utilized as described in Altschul et al. (1997) Nucleic 
Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 
2.0) can be used to perform an iterated search that detects 
distant relationships between molecules. See Altschul et al. 
(1997) supra. When utilizing BLAST, Gapped BLAST, 
PSI-BLAST, the default parameters of the respective pro-
grams ( e.g., BLAS TN for nucleotide sequences, BLAS TX 
for proteins) can be used (See www.ncbi.nlm.nih.gov). 
Alignment may also be performed manually by inspection. 
The sequence identity/similarity values provided herein 
were calculated using the BLASTX (Altschul et al. (1997) 
40 substitutions is calculated, e.g., as implemented in the pro-
gram PC/GENE (Intelligenetics, Mountain View, Calif.). 
The term "percentage of sequence identity" as used herein 
means the value determined by comparing two optimally 
aligned sequences over a comparison window, wherein the 
45 portion of the polynucleotide sequence in the comparison 
window may comprise additions or deletions (i.e., gaps) as 
compared to the reference sequence (which does not com-
prise additions or deletions) for optimal alignment of the two 
sequences. The percentage is calculated by determining the 
50 number of positions at which the identical nucleic acid base 
or amino acid residue occurs in both sequences to yield the 
number of matched positions, dividing the number of 
matched positions by the total number of positions in the 
window of comparison, and multiplying the result by 100 to 
55 yield the percentage of sequence identity. 
When any two polypeptide sequences are optimally 
aligned for comparison, it is recognized that residues appear-
ing opposite of one another within the alignment occupy 
positions within their respective polypeptides that corre-
60 spond to one another. Such positions are referred to herein 
as "corresponding positions" and the residues residing at 
corresponding positions are referred to as "corresponding 
residues" or residues that "correspond" to one another. Thus, 
for example, where a polypeptide of interest is optimally 
65 aligned to a reference polypeptide sequence having, for 
example, 10 residues, the residue within the polypeptide of 
interest appearing opposite residue 5 of the reference 
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sequence is referred to as the "residue at the position 
corresponding to residue 5" of the reference sequence. 
20 
that is at least about 8-fold greater than the conversion rate 
of the nicotine demethylase encoded by SEQ ID NO:3 or 
SEQ ID NO:5. 
In another aspect, the present invention provides a method 
In like manner, when any two polynucleotide sequences 
are optimally aligned for comparison, it is recognized that 
the nucleotides appearing opposite of one another within the 
aligmnent occupy positions within their respective poly-
nucleotide positions that correspond to one another. Such 
positions are referred to herein as "corresponding positions" 
and the nucleotides residing at corresponding positions are 
referred to as "corresponding nucleotides" or nucleotides 
that "correspond" to one another. Thus, for example, where 
5 for screening for a nicotine demethylase having an isoleu-
cine at position 274 or a tryptophan at position 329 of the 
polypeptide. This method comprises obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 
with SEQ ID NO:3 or SEQ ID NO:5; and identifying a first 
10 codon sequence encoding for an isoleucine residue at posi-
tion 274 of the encoded polypeptide or a second codon 
sequence encoding a tryptophan residue at position 330 of 
the encoded polypeptide. As noted above, any suitable a polynucleotide of interest is optimally aligned to a refer-
ence polynucleotide sequence having, for example, 300 
nucleotides, the nucleotide within the polynucleotide of 
15 
interest appearing opposite nucleotide 275 of the reference 
sequence is referred to as the "nucleotide at the position 
corresponding to nucleotide 275" of the reference sequence. 
Where a region of nucleotides is being compared between 
a polynucleotide of interest and a reference polynucleotide, 20 
the nucleotides within these regions are said to "correspond" 
to one another. Thus, for example, where a region of a 
reference polynucleotide sequence, for example, the poly-
nucleotide sequence set forth in SEQ ID NO:5, resides from 
nucleotide position 265 to nucleotide position 625 of the 25 
reference polynucleotide, and this region of nucleotides is 
being compared to the corresponding region of nucleotides 
within an optimally aligned polynucleotide sequence of 
interest, the nucleotides within the corresponding region of 
the polynucleotide of interest are referred to herein as "a 30 
region" of the polynucleotide of interest that "corresponds to 
nucleotide position 265 to nucleotide position 625" of the 
reference sequence, in this case, SEQ ID NO:5. 
Cytochrome P450 polynucleotide and polypeptide 
35 
sequences can be identified using the sequences provided 
herein. Such methods include obtaining a polynucleotide or 
polypeptide sequence at least 80%, 85%, 90%, 95%, 98%, 
99% sequence identity with the polynucleotide sequence of 
SEQ ID NO 1, 3, 5, 7, 9, or 11 or a complement or fragment 40 
thereof, or a polypeptide sequence of SEQ ID NO:2, 4, 6, 7, 
10, or 12. In one embodiment, the identified sequence 
contains or encodes for a tryptophan residue at position 330 
and an isoleucine residue at position 274. 
In this manner, one aspect of the present invention is 45 
directed to a method of screening for a nicotine demethylase 
sequence. This method comprises obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 
with SEQ ID NO:3 or SEQ ID NO:5; and identifying within 
this nucleic acid sequence a codon sequence encoding for a 50 
tryptophan residue at position 330 of the polypeptide 
encoded by the nucleic acid sequence. In some embodi-
ments, this nucleic acid sequence also encodes an isoleucine 
method known to those of skill in the art can be used to 
identify these codons. In one embodiment, either or both of 
the first and second codons are identified by a method 
selected from the group consisting of identifying a single 
nucleotide polymorphism and RT-PCR. In some embodi-
ments of this aspect of the invention, the screening method 
identifies a nicotine demethylase that converts nicotine to 
nornicotine at a rate that is at least about 5-fold greater than 
the conversion rate of the nicotine demethylase encoded by 
SEQ ID NO:3 (polypeptide set forth in SEQ ID NO:4) or 
SEQ ID NO:5 (polypeptide set forth in SEQ ID NO:6). In 
particular embodiments, the nicotine demethylase identified 
with this screening method has a conversion rate that is at 
least about 8-fold greater than the conversion rate of the 
nicotine demethylase encoded by SEQ ID NO:3 or SEQ ID 
NO:5. 
The present invention also provides transgenic plant cells, 
plants, and seed comprising a nucleic acid molecule having 
a promoter functional in a plant cell and a nucleic acid 
sequence encoding a nicotine demethylase having an iso-
leucine residue at position 274 and a tryptophan residue at 
position 330. In some embodiments, the nucleic acid 
sequence encoding this nicotine demethylase is derived from 
a sequence selected from the group consisting of SEQ ID 
NO:3, SEQ ID NO:5, and SEQ ID NO:7. These transgenic 
plant cells, plants, and seed include, but are not limited to, 
Nicotiana plant cells, Nicotiana plants, and seed of Nicoti-
ana plants. In some embodiments, the Nicotiana plant cells, 
Nicotiana plants, and seed of Nicotiana plants are from 
converter Nicotiana plants. 
Expression Cassettes for Use in the Methods of the Inven-
tion 
Compositions of the present invention further include 
expression cassettes comprising inhibitory sequences 
capable of inhibiting expression or function of a cytochrome 
P450 polypeptide involved in the conversion of nicotine to 
nornicotine in a Nicotiana plant or plant part thereof, where 
the inhibitory sequences are operably linked to a promoter 
that is functional in a plant cell. In this manner, expression 
cassettes comprising all or part of the sequence set forth in 
SEQ ID NO:1, 3, 5, 7, 9, or 11, a complement or fragment 
thereof, or sequences sharing substantial sequence identity 
to SEQ ID NO:1, 3, 5, 7, 9, 11, or a complement or fragment 
thereof, operably linked to a promoter that is functional in a 
plant cell are constructed for use in the gene-silencing 
methods of the present invention described herein below. 
Such sequences are referred to herein as "inhibitory 
sequences" or "inhibitory polynucleotide sequences" as they 
are capable of being expressed as an RNA molecule that 
inhibits expression (i.e, transcription and/or translation) of 
the target cytochrome P450 polypeptide, for example, the 
at position 274 of the encoded polypeptide. Any suitable 
method known in the art can be used to identify the codon 55 
sequence encoding the tryptophan or isoleucine residue. In 
one embodiment, the codon sequence is identified by a 
method selected from the group consisting of identifying a 
single nucleotide polymorphism and RT-PCR. In some 
embodiments of this aspect of the invention, the screening 60 
method identifies a nicotine demethylase that converts nico-
tine to nomicotine at a rate that is at least about 5-fold 
greater than the conversion rate of the nicotine demethylase 
encoded by SEQ ID NO:3 (polypeptide set forth in SEQ ID 
NO:4) or SEQ ID NO:5 (polypeptide set forth in SEQ ID 
NO:6). In particular embodiments, the nicotine demethylase 
identified with this screening method has a conversion rate 
65 polypeptide set forth in SEQ ID NO:2, 4, 6, or 8 and variants 
thereof, or a polypeptide comprising the sequence set forth 
in SEQ ID NO:10 or 12 and variants thereof, where the 
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variant polypeptides have substantial sequence identity to 
these disclosed cytochrome P450 polypeptides and are 
involved in the metabolic conversion of nicotine to norni-
cotine in a plant. 
22 
about position 594 of the P450 coding sequence set forth in 
SEQ ID NO:3 or SEQ ID NO:5 and a sequence that is fully 
or partially complementary thereto. In preferred embodi-
ments, such inhibitory sequences are expressed as a hairpin 
RNA as described herein below. 
In yet other embodiments of the invention, the inhibitory 
sequence within an expression cassette of the invention 
comprises a polynucleotide sequence containing the nucleo-
tides from about position 1420 to about position 1580 of a 
cytochrome P450 coding sequence disclosed herein and a 
sequence that is fully or partially complementary thereto. In 
some of these embodiments, the inhibitory sequence com-
prises the nucleotides corresponding to about position 1453 
As noted above, such inhibitory sequences include frag- 5 
ment sequences of the target cytochrome P450 polynucle-
otides. For example, a fragment sequence can include any 
portion of the cytochrome P450 sequence, including coding 
and non-coding sequence (e.g., 5' UTR, intron, and 3' UTR 
sequences), and can include fragments of between about 20 10 
and about 400 nucleotides, between about 50 and about 400 
nucleotides, between about 100 and about 400 nucleotides, 
between about 125 and about 325 nucleotides, between 
about 125 and about 300 nucleotides, or between about 125 
and about 275 nucleotides. 
In this manner, such inhibitory sequences include, but are 
not limited, sequences that comprise a fragment of a 
cytochrome P450 polynucleotide sequence ranging from at 
least about 20 nucleotides, about 50 nucleotides, about 70 
nucleotides, about 100 nucleotides, about 150 nucleotides, 20 
about 200 nucleotides, about 250 nucleotides, about 300 
nucleotides, about 350 nucleotides, and up to the full-length 
polynucleotide encoding the proteins of the invention, 
depending upon the desired outcome. In one aspect, the 
inhibitory sequences comprise a fragment of a cytochrome 25 
P450 polynucleotide sequence that is between about 50 and 
about 400 nucleotides, between about 50 and about 350 
nucleotides, between about 70 and about 350 nucleotides, 
between about 90 and about 325 nucleotides, between about 
15 
to about position 1551 of the P450 coding sequence set forth 
in SEQ ID NO: 1 and a sequence that is fully or partially 
complementary thereto. In preferred embodiments, such 
inhibitory sequences are expressed as a hairpin RNA as 
described herein below. 
90 and about 300 nucleotides, between about 90 and about 30 
275 nucleotides, between about 100 and about 400 nucleo-
tides, between about 100 and about 350 nucleotides, 
between about 100 and about 325 nucleotides, between 
about 100 and about 300 nucleotides, between about 125 and 
about 300 nucleotides, or between about 125 and about 275 35 
nucleotides in length. In some embodiments, the inhibitory 
sequences comprise a fragment of a cytochrome P450 
polynucleotide sequence that is about 50, about 60, about 70, 
about 80, about 90, about 100, about 125, about 150, about 
175, about 200, about 225, about 250, about 275, about 300, 40 
about 325, about 350, about 400 nucleotides in length, and 
other such values between about 50 and about 400 nucleo-
tides. It is recognized that the inhibitory sequence can also 
comprise a sequence that is complementary to all or a part 
of the fragment of the cytochrome P450 polynucleotide 45 
sequence. 
It is recognized that expression cassettes of the present 
invention encompass constructs in which a desired nucleic 
acid sequence is operably linked to a promoter that is 
functional in a plant cell, particularly in the cell of a 
Nicotiana plant. By "promoter" is intended a regulatory 
region of DNA usually comprising a TATA box capable of 
directing RNA polymerase II to initiate RNA synthesis at the 
appropriate transcription initiation site for a particular poly-
nucleotide sequence. A promoter may additionally comprise 
other recognition sequences generally positioned upstream 
or 5' to the TATA box, referred to as upstream promoter 
elements, which influence the transcription initiation rate. It 
is also recognized that expression cassettes of the present 
invention encompass additional domains that modulate the 
level of expression, the developmental timing of expression, 
or tissue type that expression occurs in (e.g., Australian 
Patent No. AU-A-77751/94 and U.S. Pat. Nos. 5,466,785 
and 5,635,618). By "functional" is intended the promoter, 
when operably linked to an inhibitory sequence encoding an 
inhibitory nucleotide molecule (for example, a hairpin RNA, 
double-stranded RNA, miRNA polynucleotide, and the 
like), the promoter is capable of initiating transcription of 
the operably linked inhibitory sequence such that the inhibi-
tory nucleotide molecule is expressed. The promoters can be 
selected based on the desired outcome. The nucleic acids can 
be combined with constitutive, tissue-preferred, or other 
promoters for expression in plants. 
An expression cassette of the present invention may also 
contain at least one additional gene to be cotransformed into 
the plant. Alternatively, the additional gene(s) can be pro-
In one such embodiment, the inhibitory sequences com-
prise a fragment of a cytochrome P450 polynucleotide of the 
invention that is about 90 bp to about 110 bp in length, 
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 
102,103,104,105,106,107,108,109, and ll0bp in length, 
and can also comprise a sequence that is complementary to 
all or a part of the fragment sequence. In another such 
embodiment, a fragment of a cytochrome P450 polynucle-
otide of the invention is about 290 to about 310 bp in length, 
including 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 
300,301,302,303,304,305,306,307,308,309, and310 
bp in length, and can also comprise a sequence that is 
complementary to all or a part of the fragment sequence. 
50 vided on multiple expression cassettes. Such an expression 
cassette is provided with a plurality of restriction sites and/or 
recombination sites for insertion of the cytochrome P450 
inhibitory polynucleotide sequence to be under the transcrip-
tional regulation of the regulatory regions. The expression 
In other embodiments of the invention, the inhibitory 
sequence within an expression cassette of the invention 
comprises a polynucleotide sequence containing the nucleo-
tides from about position 265 to about position 625 of a 
cytochrome P450 coding sequence disclosed herein and 
sequence that is fully or partially complementary thereto. In 
some of these embodiments, the inhibitory sequence com-
prises the nucleotides corresponding to about position 297 to 
55 cassette may additionally contain selectable marker genes. 
In this manner, an expression cassette of the present 
invention includes a transcriptional and translational initia-
tion region (i.e., a promoter) in the 5'-3' direction of tran-
scription, an inhibitory sequence as described elsewhere 
60 herein, and a transcriptional and translational termination 
region (i.e., termination region) functional in a plant cell. 
The regulatory regions (i.e., promoters, transcriptional regu-
latory regions, and translational termination regions) and/or 
the inhibitory sequence of the invention may be native/ 
65 analogous to the host cell or to each other. Alternatively, the 
regulatory regions and/or the inhibitory sequence of the 
invention may be heterologous to the host cell or to each 
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other. While heterologous promoters can be used to express 
the inhibitory sequences of the invention, native promoter 
sequences may also be used. 
24 
3:506-511; Christopherson et al. (1992) Proc. Natl. Acad. 
Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; 
Reznikoff (1992) Mal. Microbial. 6:2419-2422; Barkley et 
The termination region may be native with the transcrip-
tional initiation region, may be native with the operably 5 
linked inhibitory sequence of the invention, may be native 
with the plant host, or may be derived from another source 
(i.e., foreign or heterologous to the promoter, the inhibitory 
sequence of interest, the plant host, or any combination 
thereof). Convenient termination regions are available from 10 
the Ti-plasmid of A. tumefaciens, such as the octopine 
synthase and nopaline synthase termination regions. See 
also Guerineau et al. (1991) Mal. Gen. Genet. 262:141-144; 
Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) 
Genes Dev. 5:141-149; Magen et al. (1990) Plant Cell 15 
2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas 
al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 
48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et 
al. (1988) Cell 52:713-722; Deuschle et al. (1989) Proc. 
Natl. Acad. Aci. USA 86:5400-5404; Fuerst et al. (1989) 
Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. 
(1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, 
University of Heidelberg; Reines et al. (1993) Proc. Natl. 
Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mal. 
Cell. Biol. 10:3343-3356; Zambretti et al. (1992) Proc. Natl. 
Acad. Sci. USA 89:3952-3956; Baim et al. (1991) Proc. Natl. 
Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) 
Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman 
(1989) Topics Mal. Struc. Biol. 10:143-162; Degenkolb et al. 
et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et 
al. (1987) Nucleic Acids Res. 15:9627-9639. 
Expression cassettes of the present invention may addi-
tionally contain 5' leader sequences that can act to enhance 20 
translation. Translation leaders are known in the art and 
(1991) Antimicrob. Agents Chemother. 35:1591-1595; 
Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; 
Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gos-
sen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; 
Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-
include: picornavirus leaders, for example, EMCV leader 
(Encephalomyocarditis 5' noncoding region) (Elroy-Stein et 
al. (1989) Proc. Natl. Acad. Sci. USA 86:6126-6130); poty-
virus leaders, for example, TEV leader (Tobacco Etch Virus) 
(Gallie et al. (1995) Gene 165(2): 233-238), MDMV leader 
(Maize Dwarf Mosaic Virus) (Virology 154:9-20), and 
human immunoglobulin heavy-chain binding protein (BiP) 
(Macejak et al. (1991) Nature 353:90-94); untranslated 
leader from the coat protein mRNA of alfalfa mosaic virus 
(AMY RNA 4) (Jobling et al. (1987) Nature 325:622-625); 
tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in 
Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 
237-256); and maize chlorotic mottle virus leader (MCMV) 
(Lommel et al. (1991) Virology 81:382-385). See also, 
Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other 
methods known to enhance translation can also be utilized. 
In preparing the expression cassette, DNA fragments of 
the invention may be manipulated so as to provide for the 
DNA sequences in the proper orientation and, as appropri-
ate, in the proper reading frame. Adapters or linkers may be 
employed to join the DNA fragments or other manipulations 
may be involved to provide for convenient restriction sites, 
removal of superfluous DNA, removal of restriction sites, or 
the like. For this purpose, in vitro mutagenesis, primer 
repair, restriction, annealing, resubstitutions, e.g., transitions 
and transversions, may be involved. 
919; Hlavka et al. (1985) Handbook of Experimental Phar-
macology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. 
(1988) Nature 334:721-724. Such disclosures are herein 
25 incorporated by reference. The above list of selectable 
marker genes is not meant to be limiting. Any selectable 
marker gene can be used in the present invention. 
A number of promoters can be used in the practice of the 
invention. Of particular interest are constitutive promoters, 
30 inducible promoters, particularly chemical-inducible pro-
moters, and tissue-preferred promoters, particularly leaf-
preferred promoters. 
Chemical-inducible promoters can be used to inhibit the 
expression of a cytochrome P450 that is involved in the 
35 metabolic conversion of nicotine to nomicotine in a plant 
through the application of an exogenous chemical regulator. 
Chemical-inducible promoters are known in the art and 
include, but are not limited to, the tobacco PR-la promoter, 
which is activated by salicylic acid. Other chemical-induc-
40 ible promoters of interest include steroid-responsive pro-
moters (see, for example, the glucocorticoid-inducible pro-
moter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 
88:10421-10425 and McNellis et al. (1998) Plant J. 14(2): 
247-257) and tetracycline-inducible promoters (see, for 
45 example, Gatz et al. (1991) Mal. Gen. Genet. 227:229-237, 
and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incor-
porated by reference. 
Constitutive promoters include, for example, the core 
promoter of the Rsyn7 promoter and other constitutive 
50 promoters disclosed in U.S. Pat. No. 6,072,050; the core 
CaMV 35S promoter (Odell et al. (1985) Nature 313:810-
812); ubiquitin (Christensen et al. (1989) Plant Mal. Biol. 
12:619-632 and Christensen et al. (1992) Plant Mal. Biol. 
18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 
The expression cassettes of the present invention can also 
comprise a selectable marker gene for the selection of 
transformed cells. Selectable marker genes are utilized for 
the selection of transformed cells or tissues. Marker genes 
include genes encoding antibiotic resistance, such as those 
encoding neomycin phosphotransferase II (NEO) and 
hygromycin phosphotransferase (HPT), as well as genes 
conferring resistance to herbicidal compounds, such as glu-
fosinate ammonium, bromoxynil, imidazolinones, and 2,4-
dichlorophenoxyacetate (2,4-D). Additional selectable 
markers include phenotypic markers such as ~-galactosidase 
and fluorescent proteins such as green fluorescent protein 
(GFP) (Rouwendal et al. (1997) Plant Mo. Biol. 33:989-999; 60 
Su et al. (2004) Biotechnol Bioeng 85:610-9 and Fetter et al. 
(2004) Plant Cell 16:215-28), cyan florescent protein (CYP) 
(Bolte et al. (2004) J. Cell Science 117:943-54 and Kato et 
55 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-
2730); ALS promoter (U.S. Pat. No. 5,659,026), and the 
like. Other constitutive promoters include, for example, U.S. 
Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 
5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611. 
Tissue-preferred promoters can be utilized to target 
expression of an inhibitory polynucleotide sequence of the 
present invention within a particular plant tissue. Tissue-
preferred promoters include Yamamoto et al. (1997) Plant J. 
12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. al. (2002) Plant Physiol 129:913-42), and yellow fluorescent 
protein (PhiYFP™ from Evrogen, see, Bolte et al. (2004) J. 
Cell Science 117:943-954). For additional selectable mark-
ers, see generally, Yarranton (1992) Curr. Opin. Biotech. 
65 38(7):792-803; Hansen et al. (1997) Mal. Gen Genet. 254 
(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-
168; Rinehart et al. (1996) Plant Physiol. 112(3): 1331-1341; 
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Van Camp et al. (1996) Plant Physiol. 112(2):525-535; 
Canevascini et al. (1996) Plant Physiol. 112(2):513-524; 
Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; 
Lam (1994) Results Prob!. Cell Differ. 20:181-196; Orozco 
26 
nicotine to nornicotine in the Nicotiana plant or plant part. 
Methods for monitoring the expression level of a protein are 
known in the art, and include, but are not limited to, 
et al. (1993) Plant Mal Biol. 23(6):1129-1138; Matsuoka et 5 
al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and 
Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. 
Northern blot analysis as discussed in the examples herein 
below. Methods for determining the activity of the targeted 
cytochrome P450 polypeptide in converting nicotine to 
nornicotine are described elsewhere herein below, and 
include, but are not limited to, alkaloid analysis using gas 
chromatography, for example the procedures described in 
the examples herein below. 
Of particular interest are leaf-preferred promoters that 
provide for expression predominately in leaf tissues. See, for 
example, Yamamoto et al. (1997) Plant J. 12(2):255-265; 10 
Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et In other embodiments of the invention, the activity of one 
or more cytochrome P450 polypeptides is reduced or elimi-
nated by transforming a plant or plant part with an expres-
sion cassette comprising a polynucleotide encoding a poly-
peptide that inhibits the activity of one or more cytochrome 
P450 polypeptides of the present invention. The activity of 
al. (1994) Plant Cell Physiol. 35(5):773-778; Gator et al. 
(1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mal. 
Biol. 23(6): 1129-1138; Baszczynski et al. (1988) Nucl. Acid 
Res. 16:4732; Mitra et al. (1994) Plant Molecular Biology 15 
26:35-93; Kayaya et al. (1995) Molecular and General 
Genetics 248:668-674; and Matsuoka et al. (1993) Proc. 
Natl. Acad. Sci. USA 90(20):9586-9590. Senecence-regu-
lated promoters are also of use, such as SAM22 (Crowell et 
a cytochrome P450 polypeptide in converting nicotine to 
nornicotine in a Nicotiana plant or plant part is inhibited 
according to the present invention if this conversion activity 
is statistically lower than conversion activity of the same 
cytochrome P450 polypeptide in a Nicotiana plant or plant 
al. (1992) Plant Mal. Biol. 18:459-466); SAG 12 (Lohman et 20 
al. (1994) Physiol. Plant. 92:322-328; Wingler et al. (1998) 
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino 
(1997) Plant Physiol. 113:313-319; SAG15 (Gan (1995) 
"Molecular Characterization and Genetic Manipulation of 
Plant Senescence," Ph.D. Thesis, University of Wisconsin, 25 
Madison); SENl (Oh et al. (1996) Plant Mal. Biol. 30:739-
754; promoter of a senescence-specific gene for expression 
ofIPT (Gan andAmasino 91995) Science 270:1986-1988); 
and the like (see, for example, Or: et al. (1999) Plant Cell 
11:1073-1080 and McCabe et al. (2001) Plant Physiol. 30 
127:505-516). 
part that has not been genetically modified to inhibit the 
conversion activity of that cytochrome P450 polypeptide 
and which has been cultured and harvested using the same 
protocols. In particular embodiments, activity of a 
cytochrome P450 polypeptide in converting nicotine to 
nornicotine in a modified Nicotiana plant or plant part 
according to the invention is inhibited if the activity is less 
than 95%, less than 90%, less than 80%, less than 70%, less 
than 60%, less than 50%, less than 40%, less than 30%, less 
than 20%, less than 10%, less than 5%, less than 4%, less 
Methods for Inhibiting Expression or Function of a 
Cytochrome P450 Involved in the Conversion of Nicotine to 
Nornicotine 
Methods of reducing the concentration, content, and/or 
activity of a cytochrome P450 polypeptide of the present 
invention in a Nicotiana plant or plant part, particularly the 
leaf tissue, are provided. Many methods may be used, alone 
or in combination, to reduce or eliminate the activity of a 
cytochrome P450 polypeptide of the present invention. In 
addition, combinations of methods may be employed to 
reduce or eliminate the activity of two or more different 
cytochrome P450 polypeptides. 
In accordance with the present invention, the expression 
of a cytochrome P450 polypeptide of the present invention 
is inhibited if the protein level of the cytochrome P450 
polypeptide is statistically lower than the protein level of the 
same cytochrome P450 polypeptide in a plant that has not 
been genetically modified or mutagenized to inhibit the 
expression of that cytochrome P450 polypeptide, and where 
these plants have been cultured and harvested using the 
same protocols. In particular embodiments of the invention, 
the protein level of the cytochrome P450 polypeptide in a 
modified plant according to the invention is less than 95%, 
less than 90%, less than 80%, less than 70%, less than 60%, 
less than 50%, less than 40%, less than 30%, less than 20%, 
less than 10%, less than 5%, less than 4%, less than 3%, less 
than 2%, or less than 1 % of the protein level of the same 
cytochrome P450 polypeptide in a plant that is not a mutant 
or that has not been genetically modified to inhibit the 
expression of that cytochrome P450 polypeptide and which 
has been cultured and harvested using the same protocols. 
The expression level of the cytochrome P450 polypeptide 
may be measured directly, for example, by assaying for the 
level of the cytochrome P450 transcript or cytochrome P450 
polypeptide expressed in the Nicotiana plant or plant part, or 
indirectly, for example, by measuring the conversion of 
than 3%, less than 2%, or less than 1 % of the conversion 
activity of the same cytochrome P450 polypeptide in a 
Nicotiana plant that that has not been genetically modified 
35 to inhibit the expression of that cytochrome P450 polypep-
tide and which has been cultured and harvested using the 
same protocols. The activity of a cytochrome P450 poly-
peptide in converting nicotine to nornicotine in a Nicotiana 
plant or plant part is eliminated according to the invention 
40 when it is not detectable by the assay methods described 
elsewhere herein. Methods of determining the activity of a 
cytochrome P450 polypeptide in converting nicotine to 
nornicotine in a Nicotiana plant or plant part are described 
elsewhere herein, and include the alkaloid analyses using 
45 gas chromatography disclosed in the examples herein below. 
In specific embodiments, a cytochrome P450 inhibitory 
polynucleotide sequence described herein is introduced into 
a Nicotiana plant or plant part. Subsequently, a Nicotiana 
plant or plant part having the introduced inhibitory poly-
50 nucleotide sequence of the invention is selected using meth-
ods known to those of skill in the art such as, but not limited 
to, Southern blot analysis, DNA sequencing, PCR analysis, 
or phenotypic analysis. A plant or plant part altered or 
modified by the foregoing embodiments is grown under 
55 plant forming conditions for a time sufficient to modulate the 
concentration and/or activity of polypeptides of the present 
invention in the plant. Plant forming conditions are well 
known in the art and discussed briefly elsewhere herein. 
In some embodiments, a transformed tobacco plant con-
60 taining a cytochrome P450 inhibitory polynucleotide 
sequence described herein has a reduced level of conversion 
of nicotine to nornicotine. In particular embodiments, con-
version of nicotine to nornicotine in a transformed tobacco 
plant or plant part according to the invention is less than 
65 95%, less than 90%, less than 80% less than 70%, less than 
60%, less than 50%, less than 40%, less than 30%, less than 
20% less than 10%, less than 5%, less than 4%, less than 3%, 
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less than 2%, or less than 1 % of the conversion in a tobacco 
plant that that has not been genetically modified to inhibit 
the expression of that cytochrome P450 polypeptide and 
which has been cultured and harvested using the same 
protocols. In some embodiments, the transformed tobacco 
plant is a converter tobacco plant. In some embodiments, the 
transformed tobacco plant has a conversion rate lower than 
the rate observed in commercial nonconverter tobacco 
plants. 
It is also recognized that the level and/or activity of the 
polypeptide may be modulated by employing a polynucle-
otide that is not capable of directing, in a transformed plant, 
the expression of a protein or an RNA. For example, the 
polynucleotides of the invention may be used to design 
polynucleotide constructs that can be employed in methods 
for altering or mutating a genomic nucleotide sequence in an 
organism. Such polynucleotide constructs include, but are 
not limited to, RNA:DNA vectors, RNA:DNA mutational 
vectors, RNA:DNA repair vectors, mixed-duplex oligo-
nucleotides, self-complementary RNA:DNA oligonucle-
otides, and recombinogenic oligonucleobases. Such nucleo-
tide constructs and methods of use are known in the art. See, 
U.S. Pat. Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 
5,795,972; and 5,871,984; all of which are herein incorpo-
rated by reference. See also, WO 98/49350, WO 99/07865, 
WO 99/25821, and Beetham et al. (1999) Proc. Natl. Acad. 
Sci. USA 96:8774-8778; herein incorporated by reference. 
It is therefore recognized that methods of the present 
invention do not depend on the incorporation of the entire 
cytochrome P450 inhibitory polynucleotide into the 
genome, only that the Nicotiana plant or plant part thereof 
is altered as a result of the introduction of this inhibitory 
polynucleotide into a cell. In one embodiment of the inven-
tion, the genome may be altered following the introduction 
28 
plant or plant part that is descended from a Nicotiana plant 
or plant part so altered and which comprises the alteration. 
A control plant or plant part provides a reference point for 
measuring changes in phenotype of the subject plant or plant 
5 part. 
The measurement of changes in phenotype can be mea-
sured at any time in a plant or plant part, including during 
plant development, senescence, or after curing. In other 
embodiments, the measurement of changes in phenotype can 
10 be measured in plants grown under any conditions, includ-
ing from plants grown in a growth chamber, greenhouse, or 
in a field. In one embodiment, changes in phenotype can be 
measured by determining the nicotine to nornicotine con-
version rate. In a preferred embodiment, conversion can be 
15 measured by dividing the percentage of nornicotine (as a 
percentage of the total tissue weight) by the sum of the 
percentage nicotine and nornicotine (as percentages of the 
total tissue weight) and multiplying by 100. 
According to the present invention, a control plant or 
20 plant part may comprise a wild-type Nicotiana plant or plant 
part, i.e., of the same genotype as the starting material for the 
genetic alteration that resulted in the subject plant or plant 
part. A control plant or plant part may also comprise a 
Nicotiana plant or plant part of the same genotype as the 
25 starting material but that has been transformed with a null 
construct (i.e., with a construct that has no known effect on 
the trait of interest, such as a construct comprising a select-
able marker gene). Alternatively, a control plant or plant part 
may comprise a Nicotiana plant or plant part that is a 
30 non-transformed segregant among progeny of a subject plant 
or plant part, or a Nicotiana plant or plant part genetically 
identical to the subject plant or plant part but that is not 
exposed to conditions or stimuli that would induce suppres-
sion of the cytochrome P450 gene of interest. Finally, a 
35 control plant or plant part may comprise the subject plant or 
plant part itself under conditions in which the cytochrome 
P450 inhibitory sequence is not expressed. In all such cases, 
the subject plant or plant part and the control plant or plant 
of the cytochrome P450 inhibitory polynucleotide into a 
cell. For example, the inhibitory polynucleotide, or any part 
thereof, may incorporate into the genome of the plant. 
Alterations to the genome include, but are not limited to, 
additions, deletions, and substitutions of nucleotides into the 
genome. While the methods of the present invention do not 40 
depend on additions, deletions, and substitutions of any 
particular number of nucleotides, it is recognized that such 
additions, deletions, or substitutions comprise at least one 
nucleotide. 
part are cultured and harvested using the same protocols. 
As described elsewhere herein, methods are provided to 
reduce or eliminate the activity and/or concentration of a 
cytochrome P450 polypeptide of the present invention by 
introducing into a Nicotiana plant or plant part a cytochrome 
P450 inhibitory polynucleotide sequence that is capable of 
It is further recognized that reducing the level and/or 
activity of a cytochrome P450 sequence of the present 
invention can be performed to elicit the effects of the 
sequence only during certain developmental stages and to 
switch the effect off in other stages where expression is no 
longer desirable. Control of cytochrome P450 expression 
can be obtained via the use of inducible or tissue-preferred 
promoters. Alternatively, the gene could be inverted or 
deleted using site-specific recombinases, transposons or 
recombination systems, which would also turn on or off 
expression of the cytochrome P450 sequence. 
According to the present invention, changes in levels, 
ratios, activity, or distribution of cytochrome P450 polypep-
tides of the present invention, or changes in Nicotiana plant 
or plant part phenotype, particularly reduced accumulation 
of nornicotine and its carcinogenic metabolite, NNN, could 
be measured by comparing a subject plant or plant part to a 
control plant or plant part, where the subject plant or plant 
part and the control plant or plant part have been cultured 
and/or harvested using the same protocols. As used herein, 
a subject plant or plant part is one in which genetic altera-
tion, such as transformation, has been affected as to the 
cytochrome P450 polypeptide of interest, or is a Nicotiana 
45 inhibiting expression or function of a cytochrome P450 
polypeptide that is involved in the metabolic conversion of 
nicotine to nornicotine. In some embodiments, the inhibitory 
sequence is introduced by transformation of the plant or 
plant part, such as a plant cell, with an expression cassette 
50 that expresses a polynucleotide that inhibits the expression 
of the cytochrome P450 polypeptide. The polynucleotide 
may inhibit the expression of a cytochrome P450 polypep-
tide directly, by preventing translation of the cytochrome 
P450 polypeptide messenger RNA, or indirectly, by encod-
55 ing a polypeptide that inhibits the transcription or translation 
of an cytochrome P450 polypeptide gene encoding a 
cytochrome P450 polypeptide. Methods for inhibiting or 
eliminating the expression of a gene product in a plant are 
well known in the art, and any such method may be used in 
60 the present invention to inhibit the expression of cytochrome 
P450 polypeptides. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention may be reduced or 
eliminated by disrupting the gene encoding the cytochrome 
65 P450 polypeptide. The invention encompasses mutagenized 
plants that carry mutations in cytochrome P450 genes, 
where the mutations reduce expression of the cytochrome 
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P450 gene or inhibit the activity of an encoded cytochrome 
P450 polypeptide of the present invention. 
30 
In some embodiments of the present invention, a Nicoti-
ana plant or plant part is transformed with an expression 
cassette that is capable of expressing a polynucleotide that 5 
inhibits the expression of a cytochrome P450 sequence. 
Such methods may include the use of sense suppression/ 
cosuppression, antisense suppression, double-stranded RNA 
or part of a messenger RNA encoding the cytochrome P450 
polypeptide. Over expression of the antisense RNA mol-
ecule can result in reduced expression of the native gene. 
Accordingly, multiple plant lines transformed with the anti-
sense suppression expression cassette are screened to iden-
tify those that show the greatest inhibition of cytochrome 
P450 polypeptide expression. 
The polynucleotide for use in antisense suppression may 
correspond to all or part of the complement of the sequence 
encoding the cytochrome P450 polypeptide, all or part of the 
complement of the 5' and/or 3' untranslated region of the 
( dsRNA) interference, hairpin RNA interference and intron-
containing hairpin RNA interference, amplicon-mediated 10 
interference, ribozymes, and small interfering RNA or micro 
RNA. cytochrome P450 polypeptide transcript, or all or part of the 
complement of both the coding sequence and the untrans-
lated regions of a transcript encoding the cytochrome P450 
For cosuppression, an expression cassette is designed to 
express an RNA molecule corresponding to all or part of a 
messenger RNA encoding a cytochrome P450 polypeptide 
of interest (for example, a cytochrome P450 polypeptide 
comprising the sequence set forth in SEQ ID NO:2, 4, 6, 8, 
10, or 12 or a sequence having substantial sequence identity 
to SEQ ID NO:2, 4, 6, 8, 10, or 12) in the "sense" 
orientation. Over expression of the RNA molecule can result 
in reduced expression of the native gene. Multiple plant lines 
transformed with the cosuppression expression cassette are 
then screened to identify those that show the greatest inhi-
bition of cytochrome P450 polypeptide expression. 
The polynucleotide used for cosuppression may corre-
spond to all or part of the sequence encoding a cytochrome 
P450 polypeptide or the present invention, all or part of the 
5' and/or 3' untranslated region of a cytochrome P450 
polypeptide transcript, or all or part of both the coding 
sequence and the untranslated regions of a transcript encod-
ing a cytochrome P450 polypeptide. In some embodiments 
where the polynucleotide comprises all or part of the coding 
region for a cytochrome P450 polypeptide of the present 
invention, the expression cassette is designed to eliminate 
the start codon of the polynucleotide so that no protein 
product will be transcribed. 
Cosuppression may be used to inhibit the expression of 
plant genes to produce plants having undetectable protein 
levels for the proteins encoded by these genes or may also 
be used to inhibit the expression of multiple proteins in the 
same plant (e.g., Brain et al. (2002) Plant Cell 14:1417-
1432; U.S. Pat. No. 5,942,657). Methods for using cosup-
pression to inhibit the expression of endogenous genes in 
plants are described in Flavell et al. (1994) Proc. Natl. Acad. 
Sci. USA 91:3490-3496; Jorgensen et al. (1996) Plant Mal. 
Biol. 31:957-973; Johansen and Carrington (2001) Plant 
Physiol. 126:930-938; Brain et al. (2002) Plant Cell 
14:1417-1432; Stoutjesdijk et al (2002) Plant Physiol. 129: 
1723-1731; Yu et al. (2003) Phytochemistry 63:753-763; and 
U.S. Pat. Nos. 5,034,323, 5,283,184, and 5,942,657; each of 
which is herein incorporated by reference. The efficiency of 
cosuppression may be increased by including a poly-dT 
region in the expression cassette at a position 3' to the sense 
sequence and 5' of the polyadenylation signal. See, U.S. 
Patent Publication No. 20020048814, herein incorporated 
by reference. Typically, such a nucleotide sequence has 
substantial sequence identity to the sequence of the tran-
script of the endogenous gene, optimally greater than about 
65% sequence identity, more optimally greater than about 
85% sequence identity, most optimally greater than about 
95% sequence identity (e.g., U.S. Pat. Nos. 5,283,184 and 
5,034,323; herein incorporated by reference). 
In some embodiments of the invention, inhibition of the 
expression of the cytochrome P450 polypeptide of the 
present invention may be obtained by antisense suppression. 
For antisense suppression, the expression cassette is 
designed to express an RNA molecule complementary to all 
15 polypeptide. In addition, the antisense polynucleotide may 
be fully complementary (i.e., 100% identical to the comple-
ment of the target sequence) or partially complementary 
(i.e., less than 100% identical to the complement of the 
target sequence) to the target sequence. Antisense suppres-
20 sion may be used to inhibit the expression of multiple 
proteins in the same plant (e.g., U.S. Pat. No. 5,942,657). 
Furthermore, portions of the antisense nucleotides may be 
used to disrupt the expression of the target gene. Generally, 
sequences of at least 50 nucleotides, 100 nucleotides, 200 
25 nucleotides, 300, 400, 450, 500, 550, or greater may be used. 
Methods for using antisense suppression to inhibit the 
expression of endogenous genes in plants are described, for 
example, in Liu et al (2002) Plant Physiol. 129:1732-1743 
and U.S. Pat. Nos. 5,759,829 and 5,942,657, each of which 
30 is herein incorporated by reference. Efficiency of antisense 
suppression may be increased by including a poly-dT region 
in the expression cassette at a position 3' to the antisense 
sequence and 5' of the polyadenylation signal. See, U.S. 
Patent Publication No. 20020048814, herein incorporated 
35 by reference. 
For dsRNA interference, a sense RNA molecule like that 
described above for cosuppression and an antisense RNA 
molecule that is fully or partially complementary to the 
sense RNA molecule are expressed in the same cell, result-
40 ing in inhibition of the expression of the corresponding 
endogenous messenger RNA. 
Expression of the sense and antisense molecules can be 
accomplished by designing the expression cassette to com-
prise both a sense sequence and an antisense sequence for 
45 the target cytochrome P450 sequence. Alternatively, sepa-
rate expression cassettes may be used for the sense and 
antisense sequences. Multiple plant lines transformed with 
the dsRNA interference expression cassette or expression 
cassettes are then screened to identify plant lines that show 
50 the greatest inhibition of expression of the targeted 
cytochrome P450 polypeptide. Methods for using dsRNA 
interference to inhibit the expression of endogenous plant 
genes are described in Waterhouse et al. (1998) Proc. Natl. 
Acad. Sci. USA 95:13959-13964, Liu et al. (2002) Plant 
55 Physiol. 129:1732-1743, and WO 99/49029, WO 99/53050, 
WO 99/61631, and WO 00/49035; each of which is herein 
incorporated by reference. 
Amplicon expression cassettes comprise a plant virus-
derived sequence that contains all or part of the target gene 
60 but generally not all of the genes of the native virus. The 
viral sequences present in the transcription product of the 
expression cassette allow the transcription product to direct 
its own replication. The transcripts produced by the ampli-
con may be either sense or antisense relative to the target 
65 sequence (i.e., the messenger RNA for a cytochrome P450 
polypeptide that is involved in the metabolic conversion of 
nicotine to nornicotine). Methods of using amplicons to 
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inhibit the expression of endogenous plant genes are 
described, for example, in Angell and Baulcombe (1997) 
EMBO J. 16:3675-3684, Angell and Baulcombe (1999) 
Plant J. 20:357-362, and U.S. Pat. No. 6,646,805, each of 
which is herein incorporated by reference. 
In additional embodiments of the present invention, the 
polynucleotide expressed by the expression cassette of the 
invention is catalytic RNA or has ribozyme activity specific 
for the messenger RNA of a cytochrome P450 polypeptide 
described herein. Thus, the polynucleotide causes the deg-
radation of the endogenous messenger RNA, resulting in 
reduced expression of the cytochrome P450 polypeptide. 
This method is described, for example, in U.S. Pat. No. 
4,987,071, herein incorporated by reference. 
In further embodiments of the invention, inhibition of the 
expression of one or more cytochrome P450 polypeptides 
may be obtained by RNA interference (RN Ai) by expression 
of a gene encoding a micro RNA (miRNA). miRNAs are 
regulatory agents consisting of about 22 ribonucleotides. 
miRNA are highly efficient at inhibiting the expression of 
endogenous genes. See, for example Javier et al. (2003) 
Nature 425: 257-263, herein incorporated by reference. 
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interference to inhibit or silence the expression of genes are 
described, for example, in Chuang and Meyerowitz (2000) 
Proc. Natl. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et al. 
(2002) Plant Physiol. 129:1723-1731; Waterhouse and 
5 Helliwell (2003) Nat. Rev. Genet. 4:29-38; Pandolfini et al. 
BMC Biotechnology 3:7, and U.S. Patent Publication No. 
20030175965; each of which is herein incorporated by 
reference. A transient assay for the efficiency of hpRNA 
constructs to silence gene expression in vivo has been 
10 described by Panstruga et al. (2003) Mal. Biol. Rep. 30:135-
140, herein incorporated by reference. 
For ihpRNA, the interfering molecules have the same 
general structure as for hpRNA, but the RNA molecule 
additionally comprises an intron that is capable of being 
15 spliced in the cell in which the ihpRNAis expressed. The use 
of an intron minimizes the size of the loop in the hairpin 
RNA molecule following splicing, and this increases the 
efficiency of interference. See, for example, Smith et al. 
(2000) Nature 407:319-320. In fact, Smith et al. show 100% 
20 suppression of endogenous gene expression using ihpRNA-
mediated interference. Methods for using ihpRNA interfer-
ence to inhibit the expression of endogenous plant genes are 
described, for example, in Smith et al. (2000) Nature 407: 
319-320; Wesley et al. (2001) Plant J. 27:581-590; Wang 
For miRNA interference, the expression cassette is 
designed to express an RNA molecule that is modeled on an 
endogenous miRNA gene. The miRNA gene encodes an 
RNA that forms a hairpin structure containing a 22-nucleo-
tide sequence that is complementary to another endogenous 
gene (target sequence). For suppression of cytochrome P450 
polypeptide expression, the 22-nucleotide sequence is 
selected from a cytochrome P450 polypeptide transcript 30 
sequence and contains 22 nucleotides encoding this 
cytochrome P450 polypeptide sequence in sense orientation 
and 21 nucleotides of a corresponding antisense sequence 
that is complementary to the sense sequence. miRNA mol-
ecules are highly efficient at inhibiting the expression of 
endogenous genes, and the RNA interference they induce is 
inherited by subsequent generations of plants. 
25 and Waterhouse (2001) Curr. Opin. Plant Biol. 5:146-150; 
Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38; 
Helliwell and Waterhouse (2003) Methods 30:289-295, and 
U.S. Patent Publication No. 20030180945, each of which is 
herein incorporated by reference. 
In one such embodiment, RNAi is accomplished by 
expressing an inhibitory sequence that comprises a first 
sequence ofa cytochrome P450 polynucleotide of the inven-
tion that is about 90 bp to about 110 bp in length, including 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 
35 104, 105, 106, 107, 108, 109, and 110 bp in length, and a 
second sequence that is complementary to all or a part of the 
first sequence. In another such embodiment, the inhibitory 
sequence comprises a first sequence of a cytochrome P450 
polynucleotide of the invention that is about 290 to about 
In still other embodiments of the invention, inhibition of 
the expression of one or more cytochrome P450 polypep-
tides by RNAi may be obtained by hairpin RNA (hpRNA) 
interference or intron-containing hairpin RNA (ihpRNA) 
interference. These methods are highly efficient at inhibiting 
the expression of endogenous genes. See, Waterhouse and 
Helliwell (2003) Nat. Rev. Genet. 4:29-38 and the references 
cited therein. 
For hpRNA interference, the expression cassette is 
designed to express an RNA molecule that hybridizes with 
itself to form a hairpin structure that comprises a single-
stranded loop region and a base-paired stem. The base-
paired stem region comprises a sense sequence correspond-
ing to all or part of the endogenous messenger RNA 
encoding the gene product whose expression is to be inhib-
ited, in this case, a cytochrome P450 polypeptide described 
herein, and an antisense sequence that is fully or partially 
complementary to the sense sequence. Alternatively, the 
base-paired stem region may correspond to a portion of a 
promoter sequence controlling expression of the gene 
encoding the cytochrome P450 polypeptide to be inhibited. 
Thus, the base-paired stem region of the molecule generally 
determines the specificity of the RNA interference. hpRNA 
molecules are highly efficient at inhibiting the expression of 
endogenous genes, and the RNA interference they induce is 
inherited by subsequent generations of plants. See, for 
example, Chuang and Meyerowitz (2000) Proc. Natl. Acad. 
Sci. USA 97:4985-4990; Stoutjesdijk et al. (2002) Plant 
Physiol. 129:1723-1731; and Waterhouse and Helliwell 
(2003) Nat. Rev. Genet. 4:29-38. Methods for using hpRNA 
40 310 bp in length, including 290, 291, 292, 293, 294, 295, 
296,297,298,299,300,301,302,303,304,305,306,307, 
308, 309, and 310 bp in length, and a second sequence that 
is complementary to all or a part of the fragment sequence. 
In other embodiments of the invention, RNAi is accom-
45 plished by expressing an inhibitory sequence that comprises 
a first polynucleotide sequence containing the nucleotides 
from about position 265 to about position 625 of a 
cytochrome P450 coding sequence disclosed herein and a 
second sequence that is fully or partially complementary 
50 thereto. In some of these embodiments, the inhibitory 
sequence comprises as the first polynucleotide sequence the 
nucleotides corresponding to about position 297 to about 
position 594 of the P450 coding sequence set forth in SEQ 
ID NO:3 or SEQ ID NO:5 and the second sequence is the 
55 complement (i.e., antisense sequence) of this first sequence. 
The inhibitory sequence can optionally comprise an intron 
sequence linked between the first and second sequences. 
Any intron known to those of skill in the art can be used in 
this manner. In some embodiments, the intron is from the 
60 soybean omega-6 fatty acid desaturase (FAD) (see GenBank 
Accession No. DQ672337, and Example 7 herein below). In 
one such embodiment, the intron comprises about 151 
nucleotides that comprise nucleotides 100-247 of the soy-
bean omega-6 fatty acid desaturase polynucleotide shown in 
65 Genbank Accession No. DQ672337. Examples of other 
intrans include, but are not limited to, the intron nucleotide 
sequences of alcohol dehydrogenase (adhl) genes. Expres-
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sion of this inhibitory sequence produces an intron-contain-
ing hairpin RNA that strongly interferes with expression of 
the cytochrome P450 polypeptides disclosed herein. In this 
manner, Nicotiana plants that are normally converters of 
nicotine to nornicotine that are transformed with an expres- 5 
sion cassette comprising such an inhibitory sequence advan-
tageously have a nicotine to nornicotine conversion rate that, 
surprisingly, is even lower than that observed for Nicotiana 
plants that are nonconverters of nicotine to nornicotine. 
In yet other embodiments of the invention, RNAi is 10 
accomplished by expressing an inhibitory sequence that 
comprises a first polynucleotide sequence containing the 
nucleotides from about position 1420 to about position 1580 
of a cytochrome P450 coding sequence disclosed herein and 
a sequence that is fully or partially complementary thereto. 15 
In some of these embodiments, the inhibitory sequence 
comprises as the first polynucleotide sequence the nucleo-
tides corresponding to about position 1453 to about position 
1551 of the P450 coding sequence set forth in SEQ ID NO: 1 
and the second sequence is the complement (i.e., antisense 20 
sequence) of this first sequence. The inhibitory sequence can 
optionally comprise an intron sequence linked between the 
first and second sequences. Any intron known to those of 
skill in the art can be used in this manner, as noted herein 
above. Expression of this inhibitory sequence produces a 25 
hairpin RNA (or intron-containing hairpin RNA when the 
intron is present) that also interferes with expression of the 
cytochrome P450 polypeptides disclosed herein. 
The expression cassette for hpRNA interference may also 
be designed such that the sense sequence and the antisense 30 
sequence do not correspond to an endogenous RNA. In this 
embodiment, the sense and antisense sequence flank a loop 
sequence that comprises a nucleotide sequence correspond-
ing to all or part of the endogenous messenger RNA of the 
target gene. Thus, it is the loop region that determines the 35 
specificity of the RNA interference. See, for example, WO 
02/00904, herein incorporated by reference. 
Transcriptional gene silencing (TGS) may be accom-
plished through use of hpRNA constructs wherein the 
inverted repeat of the hairpin shares sequence identity with 40 
the promoter region of a gene to be silenced. Processing of 
the hpRNA into short RNAs that can interact with the 
homologous promoter region may trigger degradation or 
methylation to result in silencing (Aufsatz et al. (2002) Proc. 
Natl. Acad. Sci. 99 (Suppl. 4): 16499-16506; Mette et al. 45 
(2000) EMBO J. 19(19):5194-5201). 
In further embodiments, a polynucleotide may be utilized 
that encodes a zinc finger protein that binds to a gene 
encoding a cytochrome P450 polypeptide, resulting in 
reduced expression of the gene. In particular embodiments, 50 
the zinc finger protein binds to a regulatory region of a 
cytochrome P450 polypeptide gene. In other embodiments, 
the zinc finger protein binds to a messenger RNA encoding 
a cytochrome P450 polypeptide and prevents its translation. 
Methods of selecting sites for targeting by zinc finger 55 
proteins have been described, for example, in U.S. Pat. No. 
6,453,242, and methods for using zinc finger proteins to 
inhibit the expression of genes in plants are described, for 
example, in U.S. Patent Publication No. 20030037355; each 
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expression of antibodies in plant parts and the inhibition of 
molecular pathways by expression and binding of antibodies 
to proteins in plant parts are well known in the art. See, for 
example, Conrad and Sonnewald (2003) Nature Biotech. 
21:35-36, incorporated herein by reference. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention is reduced or eliminated 
by disrupting the gene encoding the cytochrome P450 
polypeptide. The gene encoding the cytochrome P450 poly-
peptide may be disrupted by any method known in the art, 
for example, by transposon tagging or by mutagenizing 
plants using random or targeted mutagenesis and selecting 
for plants that have reduced cytochrome P450 activity. 
Transposon tagging may be used to reduce or eliminate 
the activity of one or more cytochrome P450 polypeptides of 
the present invention. Transposon tagging comprises insert-
ing a transposon within an endogenous cytochrome P450 
gene to reduce or eliminate expression of the cytochrome 
P450 polypeptide. 
In this embodiment, the expression of one or more 
cytochrome P450 polypeptides is reduced or eliminated by 
inserting a transposon within a regulatory region or coding 
region of the gene encoding the cytochrome P450 polypep-
tide. A transposon that is within an exon, intron, 5' or 3' 
untranslated sequence, a promoter, or any other regulatory 
sequence of a cytochrome P450 polypeptide gene may be 
used to reduce or eliminate the expression and/or activity of 
the encoded cytochrome P450 polypeptide. 
Methods for the transposon tagging of specific genes in 
plants are well known in the art. See, for example, Maes et 
al. (1999) Trends Plant Sci. 4:90-96; Dharmapuri and Santi 
(1999) FEMS Microbial. Lett. 179:53-59; Meissner et al. 
(2000) Plant J. 22:265-274; Phogat et al. (2000) J. Biosci. 
25:57-63; Walbot (2000) Curr. Opin. Plant Biol. 2:103-107; 
Gai et al. (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice 
et al. (1999) Genetics 153:1919-1928). 
Additional methods for decreasing or eliminating the 
expression of endogenous genes in plants are also known in 
the art and can be similarly applied to the instant invention. 
These methods include other forms of mutagenesis, such as 
ethyl methanesulfonate-induced mutagenesis, deletion 
mutagenesis, and fast neutron deletion mutagenesis used in 
a reverse genetics sense (with PCR) to identify plant lines in 
which the endogenous gene has been deleted. For examples 
of these methods see Ohshima et al. (1998) Virology 243: 
472-481; Okuhara et al. (1994) Genetics 137:867-874; and 
Quesada et al. (2000) Genetics 154:421-436; each of which 
is herein incorporated by reference. In addition, a fast and 
automatable method for screening for chemically induced 
mutations, TILLING (Targeting Induced Local Lesions In 
Genomes), using denaturing HPLC or selective endonu-
clease digestion of selected PCR products is also applicable 
to the instant invention. See McCallum et al. (2000) Nat. 
Biotechnol. 18:455-457, herein incorporated by reference. 
Mutations that impact gene expression or that interfere 
with the function of the encoded cytochrome P450 protein 
can be determined using methods that are well known in the 
art. Insertional mutations in gene exons usually result in 
null-mutants. Mutations in conserved residues can be par-
of which is herein incorporated by reference. 60 ticularly effective in inhibiting the metabolic function of the 
encoded protein. Conserved residues of plant cytochrome 
P450 polypeptides suitable for mutagenesis with the goal to 
eliminate activity of a cytochrome P450 polypeptide in 
In other embodiments of the invention, the polynucleotide 
encodes an antibody that binds to at least one cytochrome 
P450 polypeptide, and reduces the activity of a cytochrome 
P450 polypeptide of the present invention. In another 
embodiment, the binding of the antibody results in increased 65 
turnover of the antibody-cytochrome P450 polypeptide 
complex by cellular quality control mechanisms. The 
converting nicotine to nornicotine in a Nicotiana plant or 
plant part have been described (See, for example, FIGS. 3 
and 4). Such mutants can be isolated according to well-
known procedures. 
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In another embodiment of this invention, dominant 
mutants can be used to trigger RNA silencing due to gene 
inversion and recombination of a duplicated gene locus. See, 
for example, Kusaba et al. (2003) Plant Cell 15:1455-1467. 
While a number of sequences are recognized in the 
practice of the invention, in particular SEQ ID NO:3 and 
SEQ ID NO:5 find particular use. While not bound by any 
particular mechanisms of action, it is believed that these 
sequences encode a nicotine demethylase that catalyzes the 
oxidative N-demethylation of nicotine to nornicotine. Thus, 
methods to specifically inhibit these coding sequences and 
not other P450 sequences may be beneficial to the recom-
binant plant. That is, strategies that would lead to inhibition 
of gene function of this individual locus may prove to be 
superior to those that inhibit the entire gene family. The 
P450 enzymes are involved in many mechanisms in the 
plant, the inhibition of which may prove deleterious or 
detrimental to the growth and development of the plant or 
may negatively impact factors such as the disease defense 
capabilities of the plant. Likewise, because the Nicotiana 
plant P450 enzymes have been implicated in plant metabo-
lites such as phenylpropanoid, alkaloids, terpenoids, lipids, 
cyanogenic glycosides, glucosinolates, and a host of other 
chemical entities, disruption of p450 activity may alter 
components involved in tobacco flavor, texture, or other 
properties that would impact the commercial usefulness of 
the plant. Therefore, the use of the methods discussed above 
to inhibit expression in a manner that specifically targets the 
coding sequence of SEQ ID NO:3 or SEQ ID NO:5 may be 
preferred, including targeted mutational strategies, such as 
chimeraplasty. See, for example, Stewart et al. (2000) Bio-
techniques 29( 4): 838-843; Graham et al. (2002) Biochim 
Biophys Acta 1587 (1 ): 1-6, herein incorporated by reference. 
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unique genetic locus). For certain applications it would be 
useful to have a means of diagnostically differentiating this 
specific member of the 3D_C12 gene family from the rest of 
the closely related sequences within this family. For 
5 example, it is possible that within the naturally existing 
tobacco germplasm (or in mutagenized populations), acces-
sions may exist in which this gene is naturally dysfunctional 
and may therefore may be valuable as a permanently non-
converter resource. A method to specifically assay for such 
10 genotypes (e.g. deletion mutants, rearrangements, and the 
like) could serve as a powerful tool. To obtain such a tool, 
the sequence alignment shown in FIGS. 3A-3G was used to 
design PCR primers in regions possessing polymorphisms 
among the members. One primer combination (5' primer 
15 shown in SEQ ID NO:25 and 3' primer shown in SEQ ID 
NO:26) using sequences specific to 3D_Cl2-10 yields two 
particularly useful results: (1) all PCR products amplified 
from tobacco genomic DNA gave that same unique product 
(as determined by DNA sequence analysis); and (2) the 
20 presence of a 992 bp intron was revealed that is located 
between the primer sequences (FIG. 7; intron shown in SEQ 
ID NO:24). 
When any cDNA corresponding to a member of the 
3D_C12 family is used as a hybridization probe in a South-
25 em blotting assay of tobacco genomic DNA, a complex 
pattern is observed. This is expected, given that there are 
multiple, closely related members of this gene family. 
Because the intron regions of genes are typically less 
conserved than exons, it is predicted that the use of an 
30 intron-specific probe would reduce this complexity and 
better enable one to distinguish the gene(s) corresponding to 
the 3D_Cl2-7/3D_C12-10 gene from the other members of 
the family. Indeed, the probe corresponding to the sequence 
shown in FIG. 7 resulted in a Southern blotting pattern with The protein encoded by the cDNAdesignated 3D_Cl2-10 
(SEQ ID NO:4) differs from 3D_Cl2-7 (SEQ ID NO:6) at 
only two amino acid residues immediately following the 
start methionine. The codons corresponding to these amino 
acids were contained within the PCR primer used to gener-
ate the 3D_Cl2-7 cDNA. Thus, the original mRNA template 
from which 3D_Cl2-7 was amplified may be the same as 
that corresponding to the 3D_Cl2-10 gene, with the PCR 
primer sequences mediating the changes observed in the 
second and third amino acid sequence. Regardless, the 
encoded protein products would function identically. The 
location of the two amino acids that differ between the 45 
35 greatly reduced complexity. The use of a 3D_Cl2-10 intron-
specific probe, and/or the PCR primers used to generate the 
fragment shown in FIG. 7, therefore provide powerful tools 
in assays to determine whether any naturally occuring, or 
mutagenized, tobacco plants possess deletions or rearrange-
40 ments that may render the gene inactive. Such a plant can 
then be used in breeding programs to create tobacco lines 
that are incapable of converting. 
Transformed Plants, Plant Parts, and Products Having 
Reduced Nornicotine and NNN Content 
The cytochrome P450 polynucleotides of the invention, 
predicted proteins is in the N-terminal signal sequence that 
merely serves to anchor the protein to the endoplasmic 
reticulum membrane and therefore would not be expected to 
influence the catalytic properties of the enzyme. 
In another embodiment of the invention, the compositions 
of the invention find use in screening methods to identify 
nonconverter plants for use in breeding programs. In this 
manner, the nucleotide sequences of the invention can be 
used to screen native germplasms for nonconverter plants 
having a stable mutation in one or more p450 genes iden-
tified herein. These nonconverter plants identified by the 
methods of the invention can be used to develop breeding 
lines. 
In addition to the nucleotide sequences encoding P450 
coding sequences, compositions of the invention include an 
intron sequence in the 3D_Cl2-10 sequence that can be used 
in screening methods. While not bound by any mechanism 
of action, the 3D_Cl2-7/3D_C12-10 gene(s) may represent 
the only member(s) of the 3D_C12 family involved in the 
metabolic conversion of nicotine to nornicotine (and as 
stated previously there is a good likelihood that the 
3D_Cl2-7 and 3D_Cl2-10 cDNAs originated from a single 
and variants and fragments thereof, can be used in the 
methods of the present invention to inhibit expression or 
function of cytochrome P450s that are involved in the 
metabolic conversion of nicotine to nornicotine in a plant. In 
50 this manner, inhibitory sequences that target expression or 
function of a cytochrome P450 polypeptide disclosed herein 
are introduced into a plant or plant cell of interest. In some 
embodiments the expression cassettes described herein are 
introduced into a plant of interest, for example, a Nicotiana 
55 plant as noted herein below, using any suitable transforma-
tion methods known in the art including those described 
herein. 
The methods of the invention do not depend on a par-
ticular method for introducing a sequence into a plant or 
60 plant part, only that the desired sequence gains access to the 
interior of at least one cell of the plant or plant part. Methods 
for introducing polynucleotide sequences into plants are 
known in the art and include, but are not limited to, stable 
transformation methods, transient transformation methods, 
65 and virus-mediated methods. 
Transformation protocols as well as protocols for intro-
ducing heterologous polynucleotide sequences into plants 
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vary depending on the type of plant or plant cell targeted for 
transformation. Suitable methods of introducing polynucle-
otides into plant cells of the present invention include 
microinjection (Crossway et al. (1986) Biotechniques 4:320-
334), electroporation (Shillito et al. (1987) Meth. Enzymol. 
153:313-336; Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 
83:5602-5606), Agrobacterium-mediated transformation 
(U.S. Pat. Nos. 5,104,310, 5,149,645, 5,177,010, 5,231,019, 
5,463,174, 5,464,763, 5,469,976, 4,762,785, 5,004,863, 
5,159,135, 5,563,055, and 5,981,840), direct gene transfer 
(Paszkowski et al. (1984) EMBO J. 3:2717-2722), and 
ballistic particle acceleration (see, for example, U.S. Pat. 
Nos. 4,945,050, 5,141,131, 5,886,244, 5,879,918, and 
5,932,782; Tomes et al. (1995) in Plant Cell, Tissue, and 
Organ Culture: Fundamental Methods, ed. Gamborg and 
Phillips (Springer-Verlag, Berlin); McCabe et al. (1988) 
Biotechnology 6:923-926). Also see Weissinger et al. (1988) 
Ann. Rev. Genet. 22:421-477; Christou et al. (1988) Plant 
Physiol. 87:671-674 (soybean); McCabe et al. (1988) Biol 
Technology 6:923-926 (soybean); Finer and McMullen 
(1991) In Vitro Cell Dev. Biol. 27P: 175-182 (soybean); 
Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soy-
bean); De Wet et al. (1985) in The Experimental Manipu-
lation of Ovule Tissues, ed. Chapman et al. (Longman, N.Y.), 
pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell 
Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. 
Genet. 84:560-566 (whisker-mediated transformation); 
D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electropo-
ration); all of which are herein incorporated by reference. 
Any plant tissue that can be subsequently propagated 
using clonal methods, whether by organogenesis or embryo-
genesis, may be transformed with a recombinant construct 
comprising a cytochrome P450 inhibitory sequence, for 
example, an expression cassette of the present invention. By 
"organogenesis" in intended the process by which shoots 
and roots are developed sequentially from meristematic 
centers. By "embryogenesis" is intended the process by 
which shoots and roots develop together in a concerted 
fashion (not sequentially), whether from somatic cells or 
gametes. Exemplary tissues that are suitable for various 
transformation protocols described herein include, but are 
not limited to, callus tissue, existing meristematic tissue 
(e.g., apical meristems, axillary buds, and root meristems) 
and induced meristem tissue (e.g., cotyledon meristem and 
hypocotyl meristem), hypocotyls, cotyledons, leaf disks, 
pollen, embryos, and the like. 
As used herein, the term "stable transformation" is 
intended to mean that the nucleotide construct of interest 
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with a virus or viral nucleic acids. Generally, such methods 
involve incorporating an expression cassette of the invention 
within a viral DNA or RNA molecule. It is recognized that 
promoters for use in the expression cassettes of the invention 
5 also encompass promoters utilized for transcription by viral 
RNA polymerases. Methods for introducing polynucleotides 
into plants and expressing a protein encoded therein, involv-
ing viral DNA or RNA molecules, are known in the art. See, 
for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866, 
10 785, 5,589,367, 5,316,931, and Porta et al. (1996) Molecular 
Biotechnology 5:209-221; herein incorporated by reference. 
Transformed cells may be grown into Nicotiana plants in 
accordance with conventional methods. See, for example, 
methods disclosed in Vasil and Hildebrandt (1965) Science 
15 150:889; Negaard and Hoffman (1989) Biotechniques 7(8): 
808-812. These plants may then be grown, and either 
pollinated with the same transformed line or different lines, 
and the resulting progeny having expression of the desired 
phenotypic characteristic identified, i.e., reduced expression 
20 of one or more cytochrome P450s that are involved in the 
metabolic conversion of nicotine to nornicotine, and thus 
reduced content of nornicotine, and a concomitant reduced 
content of its nitrosamine metabolite, NNN, in the plant, 
particularly in the leaf tissues. Two or more generations may 
25 be grown to ensure that expression of the desired phenotypic 
characteristic is stably maintained and inherited and then 
seeds harvested to ensure expression of the desired pheno-
typic characteristic has been achieved. In this manner, the 
present invention provides transformed seed ( also referred to 
30 as "transgenic seed") having a polynucleotide of the inven-
tion, for example, an expression cassette of the invention, 
stably incorporated into their genome. 
The compositions and methods of the invention can be 
used to reduce the nornicotine content, particularly in the 
35 leaves and stems, of any plant of the genus Nicotiana 
including, but not limited to, the following species: acumi-
nata, aifinis, alata, attenuate, bigelovii, clevelandii, excel-
sior, forgetiana, glauca, glutinosa, langsdorifii, longiflora, 
obtusifolia, palmeri, paniculata, plumbaginifolia, qudrival-
40 vis, repanda, rustica, suaveolens, sylvestris, tabacum, 
tomentosa, trigonophylla, and x sanderae. The present 
invention also encompasses the transformation of any vari-
eties of a plant of the genus Nicotiana, including but not 
limited to Nicotiana acuminata multiflora, Nicotiana alata 
45 grandiflora, Nicotiana bigelovii quadrivalvis, Nicotiana 
bigelovii wallacei, Nicotiana obtusifolia obtusifolia, Nico-
tiana obtusifolia plameri, Nicotiana quadrivalvis bigelovii, 
Nicotiana quadrivalvis quadrivalvis, Nicotiana quadrivalvis 
introduced into a plant integrates into the genome of the 
plant and is capable of being inherited by the progeny 50 
thereof. "Transient transformation" is intended to mean that 
wallacei, and Nicotiana trigonophylla palmeri, as well as 
varieties commonly known as flue or bright varieties, Burley 
varieties, dark varieties, and oriental/Turkish varieties. 
a sequence is introduced into the plant and is only tempo-
rally expressed or is only transiently present in the plant. 
In specific embodiments, the inhibitory sequences of the 
invention can be provided to a plant using a variety of 
transient transformation methods. The inhibitory sequences 
of the invention can be transiently transformed into the plant 
using techniques known in the art. Such techniques include 
viral vector systems and the precipitation of the polynucle-
otide in a manner that precludes subsequent release of the 
DNA. Thus, the transcription from the particle-bound DNA 
can occur, but the frequency with which it is released to 
become integrated into the genome is greatly reduced. Such 
methods include the use of particles coated with polyethy-
enlimine (PEI; Sigma #P3143). 
In other embodiments, the inhibitory sequence of the 
invention may be introduced into plants by contacting plants 
The transgenic plants of the genus Nicotiana as described 
herein are suitable for conventional growing and harvesting 
techniques, such as cultivation in manure rich soil or without 
55 manure, bagging the flowers or no bagging, or topping or no 
topping. The harvested leaves and stems may be used in any 
traditional tobacco product including, but not limited to, 
pipe, cigar and cigarette tobacco, and chewing tobacco in 
any form including leaf tobacco, shredded tobacco, or cut 
60 tobacco. 
Thus the present invention provides a Nicotiana plant, 
particularly leaf tissues of these plants, comprising an 
expression cassette of the invention and a reduced amount of 
nornicotine and N'-nitrosonornicotine. As used herein, the 
65 term "a reduced amount" or "a reduced level" is intended to 
refer to an amount of nornicotine and/or N'-nitrosonornico-
tine in a treated or transgenic plant of the genus Nicotiana 
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or a plant part or tobacco product thereof that is less than 
what would be found in a plant of the genus Nicotiana or a 
plant part or tobacco product from the same variety of 
tobacco, processed (i.e., cultured and harvested) in the same 
manner, that has not been treated or was not made transgenic 
for reduced nornicotine and/or N'-nitrosonornicotine. The 
amount of nornicotine may be reduced by about 10% to 
greater than about 90%, including greater than about 20%, 
about 30%, about 40%, about 50%, about 60%, about 70%, 
and about 80%. 
The term "tobacco products" as used herein include, but 
are not limited to, smoking materials ( e.g., cigarettes, cigars, 
pipe tobacco), snuff, chewing tobacco, gum, and lozenges. 
The present invention also encompasses a range of tobacco 
product blends that can be made by combining conventional 
tobacco with differing amounts of the low nornicotine and/or 
N'-nitrosonornicotine tobacco described herein. In further 
embodiments, the plant or plant part of the genus Nicotiana 
as described above is cured tobacco. 
In some embodiments of the present invention, the 
tobacco product reduces the carcinogenic potential of 
tobacco smoke that is inhaled directly with consumption of 
a tobacco product such as cigars, cigarettes, or pipe tobacco, 
or inhaled as secondary smoke (i.e., by an individual that 
inhales the tobacco smoke generated by an individual con-
suming a tobacco product such as cigars, cigarettes, or pipe 
tobacco). The cured tobacco described herein can be used to 
prepare a tobacco product, particularly one that undergoes 
chemical changes due to heat, comprising a reduced amount 
40 
All plants were maintained in growth chambers or green-
houses using standard potting soil and fertilizer. For the 
microarray studies, the metabolism of nicotine to nornico-
tine was accelerated by excising individual leaves and 
5 inserting their petioles into a solution of 0.1 % ethephon or 
1 % sodium bicarbonate. The leaves were then placed in a 
growth chamber (27° C.) for 5 to 7 hours to facilitate the 
entry of the ethephon or sodium bicarbonate solutions 
throughout the transpirational stream. The treated leaves 
10 were placed in small plastic storage bags after being lightly 
sprayed with water (to maintain high humidity) and cured 
for three days at 30° C. in the dark. To enhance the nicotine 
to nornicotine conversion in the transgenic plants generated 
in this study, detached leaves were dipped into a solution of 
15 0.2% ethephon, dried, and cured in plastic storage bags for 
seven days at room temperature in the dark. 
cDNA Libraries and Expressed Sequence Tags 
Total cellular RNA was isolated from senescing leaf tissue 
of Burley lines DH 91-1307-46 (NC) and DH 91-1307-46 
20 (Con) using the TRizol® reagent according to the manu-
facturer's protocol (Invitrogen). PolyA+ RNA was isolated 
from total RNA using the MessageMaker system (Invitro-
gen), and cDNA was subsequently synthesized and cloned 
into the lambda ZAP II phage vector using the ZAP-cDNA 
25 Synthesis and Gigapack III Gold Cloning Kit (Stratagene). 
Aliquots of the phage libraries were converted to pB!ue-
script-based plasmid libraries following the mass excision 
protocol outlined by Stratagene. 
Thousands of colonies from both the converter and non-
converter libraries were grown on selective solid media and 
picked into 384-well plates containing Luria broth (with 
ampicillin) in 10% glycerol to facilitate long term storage of 
the clones at -80° C. Over 11,000 clones from each library 
were transferred from the 384-well plates to 96-well growth 
of nornicotine and/or N'-nitrosonornicotine in the smoke 30 
stream that is inhaled directly or inhaled as secondary 
smoke. In the same manner, the tobacco products of the 
invention may be useful in the preparation of smokeless 
tobacco products such as chewing tobacco, snuff, and the 
like. 35 blocks and grown in selective media. Plasmids were isolated 
in 96-well format using the R.E.A.L. Preparation Kit (Qia-
gen) with the aid of a BioRobot 3000 Workstation (Qiagen). 
To generate the ESTs, the plasmid clones were sequenced 
using the T3 primer (Qiagen) and BigDye® Terminator 
The tobacco products obtained from the transgenic 
tobacco plants of the present invention thus find use in 
methods for reducing the carcinogenic potential of these 
tobacco products, and reducing the exposure of humans to 
the carcinogenic nitrosamine NNN, particularly for indi-
viduals that are users of these tobacco products. 
The following examples are offered by way of illustration 
and not by way of limitation. 
EXPERIMENTAL 
The following materials and protocols were utilized in the 
experiments described herein below. 
Plant Materials 
All plant materials utilized in these experiments were 
provided by Dr. Earl Wernsman, Department of Crop Sci-
ence, North Carolina State University. DH 91-1307-46 (NC) 
and DH91-1307-46 (Con) are near-isogenic doubled haploid 
Burley lines (nonconverter and converter, respectively) 
recovered from the same maternal haploid plant. Burley 
lines DH 98-326-3 (nonconverter) and DH 98-326-1 (con-
verter), and DH 98-325-5 (nonconverter) and DH 98-325-6 
(converter) represent two additional pairs of near-isogenic 
lines. SC58 is a flue-cured tobacco variety, nonconverter 
individuals of which are designated SC58 (crer)- SC58 
(CrCr) is a near-isogenic stable converter line that origi-
nated though the introgression of the single dominant con-
verter locus (Cr) found in the tobacco progenitor species N. 
tomentosiformis into SC58 (Mann et al. (1964) Crop Sci. 
4:349-353. After eight additional backcrosses to SC58, the 
near-isogenic SC58 (CrCr) line was created and subse-
quently maintained via self-fertilization. 
40 system (Applied Biosystems) according to the BigDye® 
cycle sequencing protocol. Performa® DTR 96-well plates 
(Edge Biosystems) were used to remove the unincorporated 
dye from the sequencing reactions prior to loading the 
samples onto a Perkin Elmer Prism 3700 96-Capillary 
45 Automated DNA Sequencer. 
Preparation of DNA Chips 
To obtain DNAs suitable for spotting onto glass slides, the 
M13 forward and reverse sequencing primers (Qiagen) were 
used as PCR primers to amplify cDNA inserts from the 
50 plasmids containing cDNAs represented in the EST data-
bases. Plasmid clones were subjected to PCR in 96-well 
format using an Applied Biosystems Gene Amp 9700 model 
thermocycler. The resulting PCR products were processed 
through Millipore Multiscreen™ PCR or Montage™ PCµ96 
55 purification systems. The resulting products were transferred 
into 384-well plates containing equal volumes of DSMO. 
The final DNA concentrations were estimated to be equal to 
or greater than 0.1 mg/ml. The DNAs were subsequently 
spotted onto amino silane-coated slides (Corning® GAPS 
60 II) using an Affymetrix GMS 417 array printer. DNAs were 
immobilized to the slide surface by UV crosslinking (-120 
mJ/m2 ), followed by baking at 75° C. for two hours. 
Microarray Hybridization and Analysis 
The amino ally! dUTP-based indirect method of dye 
65 incorporation described by "The Institute of Genome 
Research" (http://pga.tigr.org/protocols.html) was used to 
label nonconverter and converter RNAs with Cy3 and Cy3 
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fluorescent dyes (Amersham Biosciences). Briefly, 20 µg of 
total RNA was reverse transcribed in a 30 µI volume 
containing 400 units of SuperScript II RT (Invitrogen), 6 ng 
random hexamer primers, 0.5 mM each of dATP, dCTP, and 
dGTP, 0.3 mM dTTP, and 0.2 mM amino ally! dUTP 5 
(Sigma) in first strand synthesis buffer (Invitrogen). Reac-
tions were incubuted for 6 to 14 hours at 42° C., followed by 
hydrolysis of the RNA with NaOH. The resulting first strand 
cDNA molecules were colunm purified (Qiagen) and 
washed with phosphate buffer. Coupling reactions of the 10 
NHS-ester Cy3 or Cy5 fluorescent dyes to the cDNA 
occurred during incubation in 0.05 M sodium carbonate 
buffer (pH 9.0) and 25% DMSO at room temperature for 1.5 
hours. 
42 
seconds, annealing at 57° C. for 30 seconds, and extension 
at 72° C. for 90 seconds. A final extension step at 72° C. for 
10 minutes was included at the end of the 30 cycles. The 
amplicons were ligated into the pGEM Easy TIA vector 
(Promega), and 10 randomly selected clones from each 
amplification were subjected to DNA sequence analysis. 
Nucleic acid and predicted protein sequences of the various 
members of the 3D_C12 gene family were analyzed and 
compared using the BLAS TX (Altschul et al. (1997) Nucleic 
Acids Res. 25:3389-3402), Clusta!W (Higgins et al. (1994) 
Nucleic Acids Res. 22:4673-4680) and GAP (University of 
Wisconsin Genetic Computing Group software package) 
algorithms. 
The above described strategy was effective in identifying 
Microarray slides were prehybridized in a solution of 
5xSSC, 0.1 % SDS, and 1 % BSA at 42° C. for 45 minutes, 
rinsed gently with dH2O and isopropanol, and dried by low 
speed centrifugation. The Cy3- and Cy5-labeled cDNAs 
were colunm purified (Qiagen), combined, and hybridized to 
the DNA slides in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 µg/µl Poly A RNA, 0.45 µg/µl calf 
thymus DNA, and 50% formamide. The slides were incu-
bated with the hybridization solution for 14 to 16 hours at 
42° C. Post-hybridization washes consisted of sequential 
4-minute incubations with the following solutions: lxSSC, 
0.2% SDS; 0.lxSSC, 0.2% SDS; 0.lxSSC, and a final 10 
second rinse with 0.OlxSSC. 
15 full-length sequence information for 3D_C12 and 7D_A06. 
In addition, PCR amplifications using the PCR primer 
internal to the 3D_C12 coding region gave rise to partial-
sequence information for the unique 3D_Cl2-15 cDNA. In 
an attempt to obtain full-length sequence information for 
20 3D_Cl2-15, a gene-specific primer complementary to the 5' 
terminus of its coding region (5'-ATGGTTTTTCCCATA-
GAAGCC-3'; SEQ ID NO:21) was used in conjunction with 
a pB!uescript-specific reverse primer (5'-TCGAGGTC-
GACGGTATC-3'; SEQ ID NO:22). Although a full-length 
25 3D_Cl2-15 cDNA was not recovered, this amplification 
resulted in the isolation of 3D_Cl2-7, which proved to be 
another unique member of the 3D_C12 gene family. 
Transgenic Plant Analysis The microarrays were subsequently scanned using Sca-
nArray 2.1 (GSI Lumonics) or ScanArray Express (Perki-
nElmer). Sequential scanning for Cy5 and Cy3 fluorescence 
was performed at a maximal resolution of 10 gm/pixel, and 
laser power and PMT gain adjusted to provide reliable and 
equivalent signal strengths. The acquired array images were 
quantified for signal intensity with QuantArray™ analysis 
software (PerkinElmer), using the histogram-based method. 
Total intensities were used as quantification output fields, 
and the acquired data sets were saved as Unicode, tab-
delimited text files. Importation of the text files into Micro-
soft Excel enabled the subsequent calculation of Cy5/Cy3 
and Cy3/Cy5 ratios, the statistic we employed for the 40 
identification of candidate genes. 
The RNAi-based gene silencing constructs were 
30 assembled in a version of the pKYL80 cloning vector 
(Schardl et al. (1987) Gene 61:1-11) that was engineered to 
contain a 151-bp fragment of the soybean FAD3 gene intron 
between the Xhol and Sad restriction sites of the polylinker 
(pKYLX80I). To create a construct in which the FAD3 
35 intron was flanked by a sense and antisense fragment of 
3D_C12, a 99-bp region located immediately upstream of 
the stop codon of the 3D_C12 cDNA (FIGS. 3A-3G) was 
cloned between the HindIII-Xhol and Sacl-Xbal restriction 
Cloning Full-Length andAdditional Members of the 3D C12 
Gene Family 
To clone the entire coding region of3D_C12 and 7D_A06 
a modified 5'-RACE strategy was employed using a pB!ue- 45 
script II vector-specific forward primer (BlueSK; 
5'-CGCTCTAGAACTAGTGATC-3'; SEQ ID NO: 17) and a 
set of gene-specific reverse primers. Two 3D_Cl2-specific 
reverse primers were designed, one of which is complemen-
tary to the downstream portion of the 3' untranslated region 50 
(5'-TTTTTGGGACAATCAGTCAA-3'; SEQ ID NO:18) 
and the other complementary to a sequence within the 
coding region (5'-GTTAGATTTATCGTACTCGAATT-3'; 
SEQ ID NO:19). For the former primer, the first five Ts are 
complementary to the polyA tail of the transcript. A 55 
7D_A06-specific reverse primer (5'-TTCATTTCAAATT-
ATTTTATGCACCA-3'; SEQ ID NO:20) was also designed, 
and is complementary to a segment in the 3' untranslated 
region of this gene. PCR reactions contained 10 ng of 
converter tobacco leaf cDNA library (within the pB!uescript 60 
vector) as template, 2 µM concentration of each primer, 350 
µM of each dNTP, and 1.5 mM MgCl2 in a final reaction 
volume of 50 µL. Amplification was initiated by the addition 
of 2.5 units of UniPol enzyme mix using conditions 
described by the manufacturer (Roche). After an initial 65 
denaturation step at 94° C. for 4 minutes, the samples were 
subjected to 30 cycles of denaturation at 94° C. for 15 
sites of pKYLX80I in its sense and antisense orientation, 
respectively. The resulting HindIII-Xbal fragment contain-
ing the 3D_C12 sense arm, FAD3 intron, and 3D_C12 
antisense arm was subcloned into the pKYLX71 plant 
binary expression vector (Maiti et al. (1993) Proc. Natl. 
Acad. Sci. USA 90:6110-6114) between the 35S CaMV 
promoter and a rubisco small subunit terminator. 
Overexpression constructs were created by replacing the 
3-glucuronidase ORF of the plant binary expression vector 
pBI121 (Clontech) with the full-length coding regions of the 
3D_C12, 7D_A06, and 3D_Cl2-7 cDNAs. This placed the 
tobacco P450s under the transcriptional control of the 35S 
CaMV promoter. The pBI121- and pKYLX71-based con-
structs were transformed into Agrobacterium tumefaciens 
strain LBA 4404 and introduced into tobacco cul ti vars Petite 
Havana and DH98-325-6 (converter), respectively, using 
established protocols (Horsch et al. (1985) Science 227: 
1229-1231). 
Northern Blot Analysis 
Total cellular RNAs were isolated from tobacco leaves 
using the TRIZOL® method as described by the manufac-
turer (Invitrogen). Five to ten micrograms of RNA were size 
fractionated on a 1.2% agarose gel prepared in TBE buffer. 
RNA immobilization, probe labeling, and signal detection 
were carried out using the DIG nucleic acid labeling and 
detection kits according to the manufacturer's instructions 
(Roche). Alternatively, probes were synthesized using 32P-
dCTP according to protocols accompanying the Random 
Primed DNA Labeling kit (Roche). 
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Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
65° C. for 2 days. A 100 mg sample of crushed, dried leaf 
was added to 0.5 ml of 2 N NaOH in a 20 mL scintillation 
vial. The sample was mixed and allowed to incubate for 15 5 
minutes at room temperature. Alkaloids were extracted by 
the addition of 5 mL of extraction solution [0.04% quinoline 
(wt/vol) dissolved in methyl-t-butyl ether] and gently rotated 
on a linear shaker for 3 hours. Following phase separation, 
an aliquot of the organic phase was transferred to a sample 10 
vial. Samples were analyzed using a PerkinElmer Autosys-
tem XL gas chromatograph equipped with a flame ionization 
detector, a 4 mm split/splitless glass liner, and a 30 mx0.53 
mm ID DB-5 colunm. Chromatographic conditions were as 
15 
follows: detector temperature: 250° C.; injector temperature: 
250° C.; helium flow rate at 120° C.: 20 mL/min; injection 
volume: 2 µL; column conditions: 120° C., hold 1 minute, 
120-280° C. at 30° C./minute ramping rate, hold at 280° C. 
for 2 minutes. Alkaloid composition was determined by the 20 
TotalChrome Navigator software using a calibration curve. 
Example 1: Generation of EST Databases 
44 
nonconverter individuals (Fannin and Bush (1992) Med. Sci. 
Res. 20:867-868; Shi et al. (2003) J. Agric. Food Chem. 
51:7679-7683). 
To minimize the variability inherent with microarray 
experiments, reciprocal experiments were conducted simul-
taneously. In this manner, DH 98-325-5 RNA was labeled 
with Cy5 and DH 98-325-6 RNA was labeled with Cy3, and 
then in a reciprocal experiment DH 98-325-5 RNA was 
labeled with Cy3 and DH 98-325-6 RNA was labeled with 
Cy5 (collectively referred to as Exp. 2.1). Similarly, DH 
98-326-3 and DH 98-326-1 RNAs were labeled with Cy3 
and Cy5, respectively, in one experiment, and then the same 
RNAs were labeled with Cy5 and Cy3, respectively, in a 
reciprocal experiment (collectively referred to as Exp. 2.2). 
Even when conducted reciprocally, the results of any 
given microarray experiment are likely to include "false 
positives," representing genes that are differentially regu-
lated between a specific genotypic pair and/or uniquely in 
response to a specific treatment, as opposed to differences 
directly associated with the conversion phenomenon. To 
define the set of candidate genes that are most likely to be 
upregulated due to the conversion process, cDNAs were 
identified that met the following criteria: for any set of 
reciprocal experiments (i.e., Exp. 2.1, or Exp. 2.2), the 
25 hybridization intensity of a given cDNA had to be at least 
2-fold higher with the converter probe than nonconverter 
probe in at least one of the hybridizations, and not less than 
1.5-fold higher in the reciprocal experiment. 
RNAs isolated from senescing leaves of the converter 
genotype DH 91-1307-46(Con) and its near-isogenic non-
converter counterpart DH 91-1307-46(NC) were used to 
generate cDNA libraries. High-throughput automated DNA 
sequencers were initially used to generate single-run 
sequence information (ESTs) for 11,136 randomly chosen 30 
cDNAs from the converter library. The local alignment 
search tool BLASTX (Altschul et al. (1990) J. Mal. Biol. 
215:403-410) was used to compare the predicted protein 
sequence of each tobacco cDNA with the nonredundant 
protein database curated by the National Center for Biotech-
nology Information of the National Library of Medicine and 
National Institutes of Health. Subsequently, a similar anno-
tated EST database was generated by conducting sequencing 
runs on 11,904 cDNAs selected from the nonconverter 
library. 
Example 2: Microarray Analyses of Converter 
CDNA Library 
Methods 
Upon completion of the EST database generated from the 
converter cDNA library, the inserts from 4992 clones were 
amplified by PCR and spotted onto glass slides. Given the 
possibility that the nicotine demethylase enzyme may be 
catalyzed by an enzyme of the P450 class of oxidative 
enzymes, special attention was given to library entries that 
were predicted by BLASTX analysis to encode P450s. 
Experiment 2.1-
Leaves from near-isogenic lines DH 98-325-5 and DH 
98-325-6 were treated with ethephon and cured for 3 days at 
30° C. Alkaloid analysis revealed that virtually all of the 
nicotine had been metabolized to nornicotine in the DH 
98-325-6 leaf during this period while minimal nornicotine 
35 was observed in the DH 98-325-5 leaf. RNAs from the DH 
98-325-5 nonconverter plant were labeled with the Cy3 
fluorescent dye, and RNAs extracted from a DH 98-325-6 
(converter) leaf were labeled with Cy5. The Cy3- and 
Cy5-labeled cDNAs were incubated together on the same 
40 DNA chip and allowed to hybridize overnight. 
Experiment 2.2-
A microarray analysis similar to Exp. 2.1 was conducted 
using the DH 98-326-3 (nonconverter) and DH 98-326-1 
(converter) near-isogenic lines. In these experiments, leaves 
45 from each genotype were treated with 1 % sodium bicarbon-
ate and cured for 3 days at 30° C. At the end of the treatment 
period, nicotine was the predominant alkaloid in the DH 
98-326-3 leaf, while nearly all of the alkaloid in the DH 
98-326-1 leaf was nomicotine. As described for Exp. 2.1, 
50 these experiments were reciprocally conducted. 
Results 
From visual inspection of the BLASTX results, it was 
estimated that 31 unique P450 genes were represented in the 
database. When selecting specific 96-well plates to be 55 
included on the microarray, care was taken to ensure that all 
unique P450 genes would be included among the 4992 
cDNAs selected. 
In both Experiment 2.1 and Experiment 2.2, the great 
majority of the 4992 cDNAs spotted on the glass slides 
showed no substantial differences in their hybridization 
intensities to the competing Cy3- and Cy5-labeled probes. 
Of the 4992 cDNAs spotted on the glass slides, only five 
showed at least 2-fold higher expression in one hybridiza-
tion and not less than 1.5-fold in the reciprocal hybridization 
for both Exp. 2.1 and Exp. 2.2. These entries were desig-RNAs isolated from the near-isogenic Burley genotypes 
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), 
and DH 98-325-5 (nonconverter) and DH 98-325-6 (con-
verter) were used to generate Cy3- and Cy5-labeled cDNAs. 
To maximize the metabolic conversion of nicotine to nor-
nicotine in converter genotypes, detached leaves were 
treated with sodium bicarbonate or ethephon prior to curing, 
treatments that have been shown to accelerate nornicotine 
production in converter plants while having no effect in 
60 nated 3D_C12, 7D_A06, 27C_C12, 33A_D06, and 
34D_F06. BLASTX analysis of the partial sequence infor-
mation for 3D_C12 and 7D_A06 found in our EST database 
predicted that the cDNAs encode two closely related P450 
enzymes. 27C_C12 and 33A_D06 were predicted to encode 
65 glycine-rich cell wall proteins, displaying over 90% 
sequence identity to small tobacco glycine-rich proteins 
found in GenBank (e.g., Accession No. AAK57546). Clone 
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6963-member unigene chip that is representative of the 
closely-related P450 gene family that includes 3D_C12 and 
7D_A06 (3D_C12 and 7D_A06 themselves were not spot-
ted on the unigene slide). No other cDNAs on the array in 
34D_F06 was found to contain a double cDNA insert, one 
insert showing homology to serine/threonine protein 
kinases, and the other showing high sequence identity to the 
same glycine-rich cell wall proteins as the 27C_C12 and 
33A D06 cDNAs. 
Example 3: Microarray Analysis of CDNA 
Non-Converter Library 
Upon completion of the EST database from the noncon-
verter library (generated from senescing leaves of genotype 
DH 91-1307-46 (NC)), another set of microarray experi-
ments was initiated. For this next generation of microarrays, 
the goal was to produce glass slides containing the complete 
nonredundant set of genes represented in both libraries. 
5 Example 3, which included representatives of the contigs 
containing the glycine-rich protein-encoding 27C_C12 and 
33A_D06 and 34D_F06 cDNAs, scored positive by the 
defined criteria and also scored positive in Exp. 2.1 or Exp. 
2.2 of Example 2 above, regardless of whether the results 
10 were compared individually or collectively. 
To obtain an estimate of the number of unique genes that 
are represented in the database, clustering analysis was 
conducted to identify ESTs predicted to be represented 
multiple times in the database ( contigs) versus those pre-
dicted to be represented only once (singletons) (Huang and 
Madan (1999) Genome Res. 9:868-877). Due to the nature of 
the clustering algorithms, sequences showing high, but 
imperfect, sequence identities are clustered into the same 
contig. The total set of predicted unique genes, or uni genes, 
within a database is calculated as the sum of the contigs and 
singletons. Clustering analysis of the combined converter 
and nonconverter databases predicted 2246 contigs and 4 717 
singletons for a total of 6,963 unigenes. Inserts from all 
singletons and an individual from each contig were ampli-
fied by PCR and spotted onto glass slides, resulting in a gene 
chip containing the complete 6,963 unigene set. 
15 
20 
25 
30 
35 
TABLE 1 
Microarray results of members oftbe 3D_Cl2 gene family 
Experiment 2.1 
Cy3 Cy5 
cDNA reading reading 
3D_Cl2 15514.14 25928.95 
7D_A06 15238.23 37196.19 
Experiment 2.2 
Cy3 Cy5 
reading reading 
3D_Cl2 12756.43 28669.28 
7D_A06 7571.06 19180.94 
Example 3 
Cy3 Cy5 
reading reading 
131A_A02 11138.96 19638.82 
Cy5/ 
Cy3 
ratio 
1.67 
2.44 
Cy5/ 
Cy3 
ratio 
2.25 
2.53 
Cy5/ 
Cy3 
ratio 
1.76 
Experiment 2.1 
(reciprocal) 
Cy3 Cy5 
reading reading 
19355.85 9507.87 
13651.03 8121.04 
Experiment 2.2 
(reciprocal) 
Cy3 Cy5 
reading reading 
32198.81 16166.13 
42408.85 18440.17 
Example 3 
(reciprocal) 
Cy3 Cy5 
reading reading 
36963.45 10085.25 
Cy5/ 
Cy3 
ratio 
2.04 
1.68 
Cy5/ 
Cy3 
ratio 
1.99 
2.30 
Cy5/ 
Cy3 
ratio 
3.67 
In addition to creating a new DNA chip, the genetic 
materials used to generate hybridization probes also differed 
from those used in Example 2. SC58 is a flue-cured tobacco 
variety, nonconverter individuals of which are designated 
SC58(crer)- SC58(CrCr) is a near-isogenic stable converter 
line that originated though the introgression of the single 
dominant converter locus (Cr) found in the tobacco pro-
genitor species N. tomentosiformis into SC58 (Marni et al. 
(1964) Crop Sci. 4:349-353). After eight additional back-
crosses to SC58, the near-isogenic SC58(CrCr) line was 
created and subsequently maintained via self-fertilization. 
The conversion phenotype of SC58(CrCr) plants is unique 
with respect to standard converter tobacco lines in that the 
metabolism of nicotine to nomicotine in the leaf does not 45 
40 Combined Results 
require senescence or curing. Plants possessing the Cr 
converter locus from N. tomentosiformis contain nornicotine 
as the predominant alkaloid even in green leaf tissue (Wer-
nsman and Matzinger (1968) Tab. Sci. 12:226-228). 
The combined results of microarray experiments 
described above defined members of a closely related P450 
gene family, hereafter referred to as the 3D_C12 family, to 
be the best candidates for playing a direct role in the 
metabolic conversion of nicotine to nornicotine in converter 
tobacco plants. The hybridization results of the members of 
this P450 family in each of the three microarray experiments 
are shown in Table 1. The results of the microarrays were 
independently confirmed using Northern blotting assays. As 
RN As isolated from green leaf tissue of SC58( CrCr) and 
SC58(CrCr) were labeled with Cy3 and Cy5, respectively, 
and simultaneously hybridized to a DNA chip containing the 
entire 6,963 unigene set of cDNAs. The fluorescent dyes 
were reversed to produce the probes for a reciprocal experi-
ment as described in Exps. 2.1 and 2.2 of Example 2. 
Results 
50 shown in FIG. 2, an approximately 2-fold higher signal was 
observed in senescing, cured converter leaves compared to 
their nonconverter counterparts when RNA blots were incu-
bated with a radiolabeled 7D_A06 hybridization probe. 
55 
Results were evaluated using the same criteria as in 
Example 2, i.e., individual cDNAs were identified that 
showed at least 2-fold enhanced hybridization to the labeled 
SC58(CrCr) versus SC58(crer) cDNAs in one experiment 60 
and at least 1.5-fold enhancement in the reciprocal assay. 
Results were compared to those from Exp. 2.1 and Exp. 
2.2 in Example 2 above. Enhanced hybridization of con-
verter RNAs to cDNAs encoding members of the same 
closely related P450 family was the only result shared by all 65 
three microarray experiments using the defined criteria. 131 
A_A02 is the name of the cDNA that was spotted onto the 
Example 4: Sequence Analysis of the 3D_C12 
Gene Family 
Once microarray experiments defined 3D_C12 and 
7D_A06 as potentially being involved in the conversion 
process, obtaining complete DNA sequence information for 
these genes became the next step in their characterization. 
The original 3D_C12 and 7D_A06 clones that were 
sequenced when generating the EST database described 
elsewhere herein (and spotted onto the microarrays) were 
not full-length cDNAs. To obtain a full-length sequence, 
primers were generated corresponding to regions in the 3' 
flanking region and in the interior of the coding regions that 
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were sufficiently polymorphic to distinguish between 
7D_A06 and 3D_C12. These gene-specific primers were 
used in combination with primers specific to the cloning site 
of pB!uescript II to amplify cDNAs from the converter 
cDNA library in an attempt to obtain sequence that would 5 
include the complete 5' ends of the 3D_C12 and 7D_A06 
reading frames. 
This strategy led to the determination of the DNA 
sequence corresponding to the complete coding regions of 
3D_C12 (nt 1-1551 of SEQ ID NO:1; predicted amino acid 10 
sequence shown in SEQ ID NO:2) and 7D_A06 (nt 1-1554 
of SEQ ID NO:7; predicted amino acid sequence shown in 
SEQ ID NO:8) (FIGS. 3A-3G and 4). GAP analyses of the 
3D_C12 and 7D_A06 DNA and predicted protein sequences 
15 
showed that they share 93.4% DNA sequence identity and 
92.3% identity at the protein level (Tables 2 and 3). Initial 
BLASTX analysis against the nonredundant GenBank data-
base revealed that 3D_C12 and 7D_A06 share greatest 
sequence homology to CYP82El, a tobacco P450 gene of 20 
unknown function that is upregulated in response to fungal 
elicitors (Takemoto et al. (1999) Plant Cell Physiol. 
40:1232-1242). The CYP82El protein is 66.9% and 67.5% 
identical to the predicted amino acid sequences of 3D_C12 
(SEQ ID NO:2) and 7D_A06 (SEQ ID NO:8), respectively, 25 
and the CYP82El DNA sequence is 72.1 % and 73.5% 
identical to the respective coding sequences for 3D_C12 (nt 
1-1551 of SEQ ID NO:1) and 7D_A06 (nt 1-1554 of SEQ 
ID NO:7). 
30 
TABLE 2 
Nucleotide sequence identities between members of the 3D_Cl2 gene 
famil. 
3D_Cl2- 3D_Cl2- 3D_Cl2- 35 
3D_Cl2 7D_A06 7 10 15* 
7D_A06 93.4** 
3D_Cl2-7 93.7 94.0 
3D_Cl2-10 93.7 94.4 99.7 
3D_Cl2- 95.5 92.6 93.1 92.8 40 
15* 
131A_A02* 98.0 94.0 93.4 93.1 93.1 
*partial sequences 
**numbers indicate percentages 
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corresponding DNA sequence of 3D C12 and 92.6% iden-
tical to the same region of 7D_A06 (Table 2). 
Because the 3D_Cl2-15 fragment represented an addi-
tional, distinct member of the 3D_C12 gene family, an 
attempt was made to obtain a full-length cDNA sequence of 
this gene. A PCR primer specific to the first seven codons of 
the 3D_Cl2-15 reading frame was used in combination with 
a pB!uescript II-specific primer in an amplification reaction 
using our converter cDNA library as template. Sequence 
analysis of several independent amplification products failed 
to reveal a full-length 3D_Cl2-15 gene. Instead, a new 
member of this family was recovered, designated 3D_Cl2-7 
(FIGS. 3A-3G; coding sequence set forth as nt 1-1551 of 
SEQ ID NO:5). Across the full-length nucleotide sequence 
shown in SEQ ID NO:5, 3D_Cl2-7 shares 93.7% nucleotide 
sequence identity with 3D_C12 (across SEQ ID NO:1), 
94.0% nucleotide sequence identity with 7D_A06 (across 
SEQ ID NO:7), and 93.1% identity over the corresponding 
region of fragment 3D_Cl2-15 (SEQ ID NO:9) (Table 2). 
The predicted amino acid sequence of 3D_Cl2-7 (SEQ ID 
NO:6) is 92.8% identical to the 3D_C12 protein (SEQ ID 
NO:2), and 94.8% identical to the 7D_A06 protein (SEQ ID 
NO:8) (Table 3). 
Two additional members of the 3D_C12 family were also 
identified. A gene designated 3D_Cl2-10 (FIGS. 3A-3G; 
coding sequence set forth as nt 1-1551 of SEQ ID NO:3; 
predicted amino acid sequence set forth in SEQ ID NO:4) 
was recovered from an amplification reaction using a PCR 
primer complementary to a sequence in the 3' flanking 
region of 3D_C12 together with a Bluescript II-specific 
primer (and the converter library as template). 3D_Cl2-10 
differs at only five nucleotide positions from the 3D_Cl2-7 
nucleotide sequence (SEQ ID NO:5) (FIGS. 3A-3G), and at 
only two amino acids positions from the predicted 
3D_Cl2-7 protein product (SEQ ID NO:6) (FIG. 4). 
With the completion of the nonconverter EST database, 
another member of the 3D_C12 gene family was revealed. 
The partial DNA sequence of 131A_A02 (SEQ ID NO:11; 
predicted amino acid sequence set forth in SEQ ID NO:12) 
that is found in this database is 98.0% identical to the 
corresponding sequence of3D_C12, and 94.0% identical to 
the same region of7D_A06 (FIGS. 3A-3G and Table 2). As 
described in the previous section, 131A_A02 is a member of 
the 3D_C12 gene family that was represented on the com-
45 prehensive unigene chip used in microarray assays as 
described elsewhere herein. 
TABLE 3 
Predicted amino acid sequence identities between full-length members of 
the 3D C12 gene family. 
7D_A06 
3D_Cl2-7 
3D_Cl2-10 
3D_Cl2 
92.3* 
92.8 
92.5 
**numbers indicate percentages 
7D_A06 
94.8 
94.4 
3D_Cl2-7 
99.6 
In addition to enabling the acqms1t10n of full-length 
sequence information for the 3D_C12 and 7D_A06 cDNAs, 
the above described PCR amplifications yielded additional 
products that were closely related to, yet clearly distinct 
from, the 3D_C12 and 7D_A06 cDNA sequences. Using a 
primer directed against a sequence interior to the 3D_C12 
cDNA, in combination with a primer specific to pB!uescript 
II, a unique sequence designated 3D_Cl2-15 (FIGS. 3A-3G; 
SEQ ID NO:9; predicted amino acid sequence shown in 
SEQ ID NO:10) was amplified in addition to the expected 
3D_C12 product. 3D_Cl2-15 is 95.5% identical to the 
50 
Example 5: Transgenic Plant Analysis of Members 
of the 3D_C12 Gene Family 
To determine whether members of the 3D_C12 family of 
cytochrome P450 genes are involved in the metabolic con-
version of nicotine to nornicotine, transgenic plants were 
generated using constructs designed to either enhance or 
55 inhibit gene expression. To test the effects of down-regulat-
ing gene activity, an RNA interference (RNAi) strategy was 
employed. A 99-bp region of 3D_C12 located immediately 
upstream of the stop codon (FIGS. 3A-3G), was used to 
create a construct that would form a dsRNA hairpin within 
60 the plant cell. Such dsRNA structures are known to activate 
an RNAi silencing complex that leads to the degradation of 
both transgene RNAs and endogenous RNAs that are iden-
tical or highly homologous to the sequence found in the 
dsRNA (Wesley et al. (2001) Plant J. 27: 581-590; Water-
65 house & Helliwell (2002) Nat. Gen. Rev. 4: 29-38). 
Given that each member of the 3D_C12 characterized as 
described herein shares over 90% DNA sequence identity, an 
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RNAi construct synthesized against one member was 
expected to silence the entire gene family. Specifically, the 
RNAi construct generated against the 3D_C12 sequence 
shares sequence identities of 90/99 and 91/99 with the 
7D_A06 and 3D_Cl2-7 cDNAs, respectively, over this 
region (FIGS. 3A-3G). The 3D_C12/RNAi construct (also 
referred to in Example 7 as the 3D_C12Ri99 construct) was 
cloned downstream of the constitutive 35S promoter of 
cauliflower mosiac virus (CaMV) and introduced into the 
strong converter Burley tobacco line DH 98-325-6 using 
Agrobacterium-mediated transformation. 
A hallmark of RNAi-mediated silencing is the marked 
reduction in steady-state transcript accumulation of the gene 
whose activity has been down-regulated. To confirm that 
gene silencing of the 3D_C12 gene family had occurred in 
50 
conversion and would thus potentially complicate interpre-
tation of results ( e.g., assessing whether a novel phenotype 
was solely attributable to the transgene as opposed to being 
the result of the plant having undergone genetic conversion). 
5 Results 
Given the high degree of variability typically observed 
among independent transgenic plants transformed with the 
same trans gene construct, 10 independently transformed 
individuals were selected to assess the effects of the 
10 3D_C12/RNAi construct on the metabolic conversion of 
nicotine to nomicotine. Leaves from each of the 10 3D_C12/ 
RNAi individuals, in addition to two control plants trans-
formed with the pBI121 vector alone, were treated with 
ethephon and cured for seven days. Alkaloid analysis of 
these materials is shown in Table 4. 
TABLE 4 
Alkaloid analysis of DH 98-325-6 plants independently transformed with the 3D_Cl2/RNAi 
construct (and pBI121 vector control). Leaves were treated with ethephon and cured for 
seven da s. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
3D_Cl2 RNAi (1) 3.149 0.100 0.012 0.159 2.8 
3D_Cl2 RNAi (2) 2.569 0.193 0.009 0.110 7.0 
3D_Cl2 RNAi (3) 2.175 0.064 0.007 0.080 2.9 
3D_Cl2 RNAi (4) 3.517 0.125 0.012 0.139 3.4 
3D_Cl2 RNAi (5) 1.085 0.868 0.009 0.119 44.4 
3D_Cl2 RNAi (6) 0.025 2.260 0.011 0.122 98.9 
3D_Cl2 RNAi (7) 0.027 1.867 0.011 0.122 98.6 
3D_Cl2 RNAi (8) 2.268 0.128 0.009 0.102 5.3 
3D_Cl2 RNAi (9) 2.197 0.133 0.008 0.099 5.7 
3D_Cl2 RNAi 2.434 0.112 0.009 0.110 4.4 
(10) 
vector control (3) 1.811 1.1735 0.G18 0.170 48.9 
vector control (11) 0.290 2.090 0.013 0.143 87.8 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
the plants showing low nornicotine phenotypes, a Northern 
blot analysis was conducted using RNAs isolated from three 
of the transgenic plants possessing 3D_C12/RNAi con-
structs and displaying low nomicotine phenotypes, two 
individuals transformed with the 3D_C12/RNAi construct 
yet still showing high levels of nornicotine, and one of the 
vector-only control plants. 
To assess the affects of overexpression of gene activity, 
the cDNAs from the three members of the 3D_C12 gene 
family for which we first obtained full-length sequence 
information (3D_C12, 7D_A06, and 3D_Cl2-7) were 
cloned in their sense orientations downstream of the 35S 
CaMV promoter. These constructs were subsequently intro-
duced into N. tabacum cultivar Petite Havana using Agro-
bacterium-mediated transformation. The Petite Havana line 
is commonly used by researchers because of its shorter 
stature and abbreviated generation time in relation to com-
mercial tobacco cultivars. The converter/nonconverter status 
of the Petite Havana cultivar is unknown, but the alkaloid 
assays of the present application clearly showed that the 
plants in our possession were strong converters. 
Typical of line DH 98-325-6, ethephon treatment and 
40 curing resulted in substantial nomicotine production in the 
two control plants ( 48.9% and 87.8% conversion of nicotine 
to nomicotine ). In dramatic contrast, seven of the ten 
independent transgenic plants possessing the 3D_C12/RNAi 
construct displayed minimal nicotine to nomicotine conver-
45 sion, with conversion percentages ranging from 2.8 to 7.0 
percent. The other three 3D_C12/RNAi lines displayed 
alkaloid contents similar to the vector-only control plants. 
Concentrations of the minor alkaloids anabasine and anat-
abine did not appear to be significantly influenced by the 
50 presence or absence of the 3D_C12/RNAi transgene (Table 
4). 
Although the cDNA insert of the 3D_Cl2-7 gene was 
used as the specific hybridization probe, at the hybridization 
and wash conditions used in this experiment, cross-hybrid-
55 ization to the entire 3D_C12 gene family would be expected. 
As shown in FIG. 5, a strong hybridization signal was 
detected in each plant showing a high nomicotine pheno-
type, and minimal hybridization was detected in the plants 
Although the host plants in these experiments were con- 60 
verters, the present strategy was to conduct alkaloid assays 
transformed with the 3D_C12/RNAi construct that showed 
a low nomicotine phenotype. We thus conclude that the 
effective silencing of the 3D_C12 gene family inhibits the 
on green, non-cured tissue, where minimal nomicotine accu-
mulates in converter and nonconverter plants alike (and the 
35S CaMV promoter is very active). In fact, a nonconverter 
line was purposely chosen because tissue culturing, as 65 
required when conducting Agrobacterium-mediated trans-
formation, is known to enhance the frequency of genetic 
metabolic conversion of nicotine to nornicotine in tobacco. 
Alkaloid analysis of the Petite Havana transgenic plants is 
shown in Table 5. Four independently transformed plants 
containing the 35S:3D_C12 and 35S:3D_Cl2-7 constructs 
were tested along with seven independent 35S:7D_A06 
individuals and three plants independently transformed with 
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the pBI121 control vector. As expected, the green, non-cured 
leaves of the three vector-only control plants contained 
minimal amounts of nornicotine. Likewise, all plants trans-
formed with the 35S:3D_C12 and 35S:7D_A06 constructs 
showed minimal metabolic conversion of nicotine to norni-
cotine. A very different phenotype, however, was observed 
with plants transformed with 35S:3D_Cl2-7. All four plants 
independently transformed with this construct contained 
nornicotine as the predominant alkaloid in the green, non-
treated leaf; nicotine to nornicotine conversion percentages 
ranged from 94.6 to 98.6. 
TABLE 5 
52 
gene is expressed in its sense orientation (Fagard and 
Vaucheret (2000) Annu. Rev. Plant Physiol. Plant Mal. Biol. 
51: 167-194). 
If plant 35S:3D_C12 (1) was truly displaying a cosup-
5 pression phenotype, this phenotype would be expected to be 
maintained even upon ethephon treatment and curing of the 
leaves, similar to the low nornicotine phenotypes conferred 
by the 3D_C12/RNAi construct in the converter genotype 
DH 98-325-6 as described above. To test this prediction, 
10 alkaloid profiles were determined on ethephon treated, cured 
leaves of 35S:3D_C12 (1) and two vector-only control 
Alkaloid analysis of individual Petite Havana plants transformed with 3D_Cl2, 
3D_Cl2-7, 7D_A06 constructs or the pBI121 vector control. Green 
leaves were harvested and analyzed without treatment or curing. 
% % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* 
vector control (2) 0.673 0.018 0.006 0.G18 
vector control (8) 0.605 0.014 0.005 0.016 
vector control (10) 0.694 0.017 0.004 0.G18 
35S:3D_Cl2 (1) 0.706 0.005 0.006 0.020 
35S:3D_Cl2 (2) 0.814 0.022 0.007 0.017 
35S:3D_Cl2 (3) 0.630 0.010 0.003 0.012 
35S:3D_Cl2 (4) 0.647 0.010 0.004 0.011 
35S:3D_Cl2-7 (1) 0.005 0.347 0.002 0.012 
35S:3D_Cl2-7 (2) 0.006 0.255 0.002 0.009 
35S:3D_Cl2-7 (3) 0.017 0.300 0.002 0.010 
35S:3D_Cl2-7 (4) 0.010 0.384 0.002 0.G15 
35S:7D_A06 (1) 0.761 0.011 0.005 0.G18 
35S:7D_A06 (2) 0.507 0.009 0.003 0.007 
35S:7D_A06 (4) 0.653 0.015 0.006 0.G15 
35S:7D_A06 (5) 0.643 0.013 0.004 0.G18 
35S:7D_A06 (6) 0.521 0.007 0.004 0.014 
35S:7D_A06 (7) 0.716 0.015 0.005 0.020 
35S:7D_A06 (8) 0.701 0.027 0.004 0.G18 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
Example 6: Cosuppression of the 3D_C12 Gene 
Family 
In addition to the major conclusion that the 3D_Cl2-7 
gene was capable of mediating nicotine to nornicotine 
conversion, one additional observation stood out in the 
alkaloid analyses of the Petite Havana transgenic plants. The 
alkaloid results reported in Table 5 together with additional 
alkaloid assays conducted independently (data not shown) 
consistently showed one of the plants transformed with the 
35S:3D_C12 construct (35S:3D_C12(1)) as having less nor-
nicotine in the green, nontreated leaf than any other plant in 
% 
Conversion** 
2.6 
2.3 
2.4 
0.7 
2.6 
1.6 
1.5 
98.6 
97.4 
94.6 
97.5 
1.4 
1.7 
2.2 
2.0 
1.3 
2.1 
3.7 
plants. As shown in Table 6, ethephon treatment and curing 
40 
resulted in over 97% nicotine to nornicotine conversion in 
the two control plants whereas similarly treated 35S: 
3D_C12 (1) leaves displayed negligible conversion (0.6%). 
Leaves from five other plants expressing either 35S:3D_C12 
45 and 35S:7D_A06 transgenes were also subjected to ethep-
hon treatment and curing. In each case a high nornicotine 
phenotype was observed, similar to the vector-only control 
plants (data not shown). 
TABLE 6 
Alkaloid analysis of 35S:3D_Cl2 (1) and pBI121 vector controls plants. Leaves were 
treated with ethephon cured for seven days. 
% % 
Sample Nicotine* Nornicotine* 
vector control (8) 0.009 0.425 
vector control (10) 0.008 0.560 
35S:3D_Cl2 (1) 1.185 0.007 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
n.d., not detected 
% % % 
Anabasine* Anatabine* Conversion** 
n.d. 0.011 97.9 
n.d. 0.025 98.6 
n.d. 0.020 0.6 
this study. This may be the result of cosuppression of the 65 
3D_C12 gene family in this specific plant, a phenomenon 
frequently observed in transgenic plants even when a trans-
Finally, Northern blot assays were conducted on select 
plants representing each of the Petite Havana transgenic 
genotypes (FIG. 6). Using a 3D_Cl2-7 cDNA as a hybrid-
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ization probe, minimal signal was detected with RNAs 
isolated from green, nontreated leaves of the vector-only 
control plant. In contrast, hybridization was easily detected 
54 
in RNA samples from all four independent transgenic plants 
possessing the 35S:3D_Cl2-7 construct. A strong hybrid- 5 
ization signal was similarly observed using RNAs from all 
other transgenic plants tested that were transformed with the 
35S:3D_C12 and 35S:7D_A06 constructs, with the excep-
tion of the low nornicotine containing plant 35S:3D_C12 
A calibration curve was generated with a serial dilution of 
the 3D _ Cl 2-7 cDNA cloned into the pGEM®-T Easy vector 
(Promega Corporation, Madison, Wis.). The RT-PCR mix-
ture contained 2.5 mM MgC12 , 125 µMeach dNTP, 0.5 µM 
each primer, 0.5x SYBR® Green I, 0.5 µg cDNA (or 1 µl 
reference plasmid), and 1.25 U Platinum Taq polymerase 
(lnvitrogen Life Technologies). The sequences of the allele-
specific 3D_Cl2-7 primers (E4SyFwd and E4SyRev) were 
5'-ACGTGATCCTAAACTCTGGTCTG-3' (E4SyFwd 
(1 ). 10 (SEQ ID NO:29)) and 5'-GCCTGCACCTTCCTTCATG-3' 
(E4SyRev (SEQ ID NO:30)). RT-PCR was performed in a 
BioRad iCycler thermocycler (BioRad Laboratories, Hercu-
les, Calif.) set to the following protocol: 95° C. for 2 min; 
Overall results of the Northern blotting assays show that 
the 35S CaMV promoter was generally effective in mediat-
ing a high level of gene expression for each of the three 
members of the 3D_C12 gene family tested in this study. 
Failure to detect a hybridization signal in plant 35S:3D_C12 15 
(1) is consistent with the interpretation that the 3D_C12 
gene family has been silenced via cosuppression in this 
individual. 
35 cycles of 95° C. for 30 sec, 55° C. for 30 sec 72° C. for 
50 sec, followed by final extension at 72° C. for 5 min. A 
165-bp fragment of the a-tubulin gene was used as an 
internal standard. 3D_Cl2-7 cDNAconcentration was deter-
Example 7: Additional Characterization and 
Suppression of Additional 3D C12 Genes 
A second RNAi construct was prepared using polynucle-
otide sequences from the 3D_Cl2-7 sequence. The assem-
bly of the 3D_Cl2-7/RNAi expression cassette followed the 
same basic steps as those outlined for 3D_C12/RNAi above. 
Briefly, a 298-bp sense and antisense strand of the 
3D_Cl2-7 cDNA (SEQ ID NO:5) corresponding to the 
region between nucleotide positions 297 and 594 of the 
coding sequence (positions 1-1551 of SEQ ID NO:5) were 
ligated into the pKYLX801 vector downstream and 
upstream of the 151-bp soybean omega-6 fatty acid desatu-
rase intron (see GenBank Accession No. DQ672337), 
respectively. The primers (E4SFwd and E4SRev) used for 
the isolation of the 298-bp region by sense and antisense 
arms were 5'-AAGCTTTGACGCCATTTTTTCCAATCG-
3' (SEQ ID NO:27), and 5'-CTCGAGTTTTCCAGCGAT-
CATCTTCAC-3' (SEQ ID NO:28), respectively. The RNAi 
cassette was excised from pKYL801 and placed between a 
strong CaMV35S2 promoter and a rubisco small subunit 
terminator of the binary plant expression vector, pKYLX71 
(see FIG. 8). In the discussions below, this RNAi construct 
is referred to as the 3D_Cl2-7-Ri298 construct. 
Transgenic tobacco plants were generated via Agrobac-
terium-mediated transformation following the procedures 
provided above. Briefly, transformed burley tobacco plants 
were regenerated from calli on Murashige-Skoog (MS) 
medium supplemented with 100 mg/L kanamycin and plant 
hormones in a growth room maintained at 25° C. under a 16 
hr/8 hr light/dark cycle. Calli were transferred to fresh 
selection media every 2-3 weeks until shoots appeared. 
Small shoots were transferred to rooting media to allow root 
development for 2 weeks. Fully regenerated plants were 
transferred to a greenhouse and grown under standard con-
ditions. 
SYBR® Green I Chemistry 
mined from the transcript-specific calibration curve and 
20 normalized to the internal standard. Fold-induction was 
calculated by dividing the normalized fluorescence values of 
the converter by the nonconverter samples. Melting-curve 
analysis was used to confirm the purity of PCR products as 
described in Ririe et al. (1997) Anal. Biochem. 245:154-160. 
25 Two plants were sampled per treatment and amplifications 
were repeated three times. 
TaqMan® Chemistry 
Total RNA was isolated from tobacco lines using TRizol 
reagent. Purified RNA was treated with RNase-free DNase 
30 (TURBO DNA-Free™). First strand cDNA was synthesized 
using 10 µg of total RNA and the High Capacity cDNA 
Archive Kit (Applied Biosystems, Foster City, Calif.). The 
RT-PCR mixture contained lx TaqMan® Universal PCR 
Master Mix (Applied Biosystems, Foster City, Calif.), 400 
35 nM of each primer (E4TmFwd and E4TmRev), 250 nM 
TaqMan® minor groove binder (MGB) probe (E4MGB), 2 
ng of cDNA, and nuclease-free water (Afonina et al. (2002) 
Biotechniques 32:940-949). The primer and probe 
sequences were 5'-CGGTAATCGGCCATCTTTTC-3' 
40 (E4TmFwd (SEQ ID NO:31)), 5'-CCGAGTTTTC-
GAGCTAATGGA-3' (E4TmRev(SEQ ID NO:32)), and 
5'-CAATGACGAACGGCGACAG-3' (MGB probe(SEQ 
ID NO:33)). RT-PCR was performed in anABI 7500 Real-
Time System (Applied Biosystems, Foster City, Calif.) set to 
45 the following protocol: 50° C. for 2 min; 95° C. for 10 min; 
40 cycles of 95° C. for 15 sec, 60° C. for 1 min. Glyceral-
dehyde-3-phosphate dehydrogenase (G3PDH) was used as 
the endogenous control to normalize the amount of cDNA 
template in the reactions. Fold-change was determined by 
50 dividing the normalized fluorescence values of each sample 
by those obtained from a nonconverter or uncured control 
sample. For each treatment, RNA was isolated from three 
independent plants and amplifications were repeated 3 times 
per RNA sample. 
55 Northern and Southern Blot Analyses 
Total RNA was isolated from cured tobacco leaves using 
the TRizol reagent according to the manufacturer's instruc-
tions (Invitrogen, Life Technologies). Total RNA samples 
were separated on 1.2% TBE agarose gel, and transferred to 
60 positively charged nylon membranes by electroblotting with 
2xTBE buffer. Membranes were UV crosslinked and washed 
Total RNA was isolated from cured leaves of converter 
and nonconverter burley tobacco plants using the TRizol® 
reagent (Invitrogen, Life Technologies, Carlsbad, Calif.). 
Purified RNA was treated with RNase-free DNase (TURBO 
DNA-Free™, Ambion, Austin, Tex.). First strand cDNA was 
synthesized using 5 µg of total RNA and the StrataScript® 
First-Strand Synthesis System (Stratagene, Cedar Creek, 
Tex.). Relative quantitative RT-PCR was employed for 
determining the abundance of the 3D_Cl2-7 cDNA using 65 
SYBR® Green I fluorescence chemistry Morrison et al. 
(1998) Biotechniques 24:954-962. 
in 2xSSC for 5 min. Northern blot hybridization, washing, 
and detection were carried out using the digoxigenin (DIG) 
System as described by the manufacturer (Roche Diagnos-
tics Corp., Indianapolis, Ind.). The 1.8 kb full-length ORF of 
the 3D_Cl2-7 cDNA was labeled with DIG and used as a 
probe. 
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described above. Plants were fertilized with Peter's Profes-
sional All Purpose Plant Food (20-20-20; Spectrum Brands 
Inc., Madison, Wis.) once a week. 
RT-PCR Analysis of3D _ Cl2-7 Expression in Converter and 
Nonconverter Tobacco 
To further characterize the role of3D_Cl2-7 in nicotine 
N-demethylation, experiments were performed to demon-
strate that the regulation of3D_Cl2-7 expression is consis-
tent with the levels of nicotine N-demethylation activity 
observed in converter versus nonconverter tobacco. 
To determine the rate of3D_Cl2-7 mRNA accumulation 
in converter and nonconverter tobacco, an allele-specific 
real-time RT-PCR strategy was employed. Because RT-PCR 
involves the detection and measurement of the amplification 
products of a PCR template, the use of allele-specific 
primers allows the quantification of a single isoform among 
a group of highly homologous sequences. For accurate 
Genomic DNA was extracted with DNAzol® (Invitrogen, 
Life Technologies) from green tobacco leaves according to 
manufacturer's protocol. After incubation with FcoRl or 
Neal restriction enzymes overnight, 15 µg of the digested 
DNA was separated on 0.7% TBE agarose gel, depurinated 5 
with 0.25 M HCl for 10 min, and denaturated with 0.5 N 
NaOH for 30 minutes. DNA was blotted overnight by 
capillary transfer onto positively charged nylon membranes 
(Roche Diagnostics Corp.) and hybridized at 65° C. over-
night with a 515-bp DIG-labeled fragment of the neomycin 10 
phosphotransferase II (NPT II) gene. Hybridization, wash-
ing, and detection were performed according to the proto-
cols supplied with the DIG System. The primers used for the 
amplifications of the Northern and Southern hybridization 
probes were E4FIFwsd (5'-ATGGTTTTTCCCATA- 15 
GAAGCC-3' (SEQ ID NO:34)), E4FIRev (5'-ATG-
GTTTTTCCCATAGAAGCC-3' (SEQ ID NO:35)), Kan-
Fwd (5'-TGAATGAACTGCAGGACGAG-3' (SEQ ID 
NO:36)), and KanRev (5'-AATATCACGGGTAGC-
CAACG-3' (SEQ ID NO:37)). 20 quantification of the 3D_Cl2-7 transcript, two different 
segments of the 3D_Cl2-7 coding region were amplified 
and both SYBR® Green and TaqMan® chemistries were 
used to generate fluorescence signals. RT-PCR analysis 
using the SYBR® Green I chemistry revealed an 80-fold 
Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
50° C. for 2 days. A 100 mg sample of crushed, dried leaf 
is added to 0.5 ml of 2 N Na OH in a 20 ml scintillation vial. 
The sample was mixed and allowed to incubate for 15 
minutes at room temperature. Alkaloids were extracted by 
the addition of 5 ml of extraction solution [0.04% quinoline 
(wt/vol) dissolved in methyl-t-butyl ether] and gently rotated 
25 increase in the levels of the 3D_Cl2-7 transcript in the cured 
leaves of converter versus nonconverter tobacco. A single 
peak melting curve and gel electrophoretic analyses of the 
amplicons confirmed the homogeneity of the PCR products. 
on a linear shaker for 3 hours. Following phase separation, 
In the TaqMan® chemistry-based RT-PCR experiment, 
3D_Cl2-7 transcript levels were quantified in untreated and 
ethephon-treated converter and nonconverter tobacco leaves 
that were cured for 0, 1 or 5 days. Low levels of3D_Cl2-7 
transcripts were detected in the uncured leaves or following 
an aliquot of the organic phase was transferred to a sample 30 
vial. Samples were analyzed using a PerkinElmer Autosys-
tem XL (PerkinElmer, Boston, Mass.) gas chromatograph 
equipped with a flame ionization detector, a 4 mm split/ 
splitless glass liner and a 30 mx0.53 mm ID DB-5 colunm. 
Chromatographic conditions were as follows: detector tem-
perature: 250° C.; injector temperature: 250° C.; helium flow 
35 a 1-day curing period regardless of conversion type or 
ethephon treatment. Similarly, base line levels of3D_Cl2-7 
at 120° C.: 20 ml/min; injection volume: 2 µl; column 
conditions: 120°, hold 1 min, 20-280° C. at 30° C./min 
ramping rate, hold at 280° C. for 2 min. Alkaloid compo-
sition was determined by the TotalChrome Navigator soft-
ware using a calibration curve. Means of the alkaloid 
measurements were separated according to Fisher's Pro-
tected LSD (PROC MIXED). 
transcription were observed in converter or nonconverter 
leaves that were cured for 5 days without ethephon treat-
40 ment. In contrast, a 7.5-fold increase in 3D_Cl2-7 transcript 
Plants 
Double haploid burley tobacco lines DH 98-325-5 (325-5; 45 
nonconverter) and DH98-325-6 (325-6; converter) 
described above were used in all experiments, except for the 
fluorogenic 5' nuclease (TaqMan®) chemistry-based RT-
PCR assays where the isogenic DH 91-1307-46 (noncon-
verter) and DH 91-1307-46 (converter) lines were used. All 
plants were grown in a controlled environment greenhouse 
equipped with supplemental lighting providing, a 14 hr/10 
50 
hr light/dark cycle. 
For curing, tobacco leaves were collected from converter 
and nonconverter plants about 1 month before flowering and 55 
treated by dipping each leaf twice for 10 sec, into 2% 
ethephon and dried for 2 hours. Leaves were cured for up to 
two weeks in plastic bags, under dark conditions, until they 
turned yellow. Cured leaves were used for the Northern and 
alkaloid analyses. Samples of cured leaves subjected to GC 60 
analysis were dried at 50° C. for 2 days. For Southern 
analysis, green tobacco leaves of adult plants were used. To 
produce T 1 generation transgenic plants, primary transfor-
mants (T 0 ) were self-pollinated, and the harvested T 1 seed 
was screened by germinating seedlings on MS-agar plates 65 
containing 100 mg/L kanamycin for 6 weeks. Survivors 
were transplanted to soil and grown in a greenhouse as 
accumulation was detected in the cured leaves of converter 
versus nonconverter tobacco, and a 70-fold increase was 
observed in the uncured versus cured leaves of a converter 
tobacco variety when ethephon treatment preceded the 5-day 
curing period. While not intending to be limited by any 
particular theory, these results suggest that 3D_Cl2-7 is a 
major contributor to nicotine N-demethylation and is 
strongly inducible by ethylene in senescing tobacco leaves. 
Suppression of Nicotine to Nornicotine Conversion by the 
3D_Cl2-Ri99 and 3D_Cl2-7-Ri298 Constructs 
To compare the extent to which 3D_C12 and 3D_Cl2-7 
mediate the suppression of nomicotine production, con-
verter and nonconverter burley tobacco plants were trans-
formed with the two gene silencing vectors. Ten (10) trans-
genic plants were regenerated per RNAi construct. About 
80% of tobacco plants overexpressing either the 99-bp or 
298-bp inverted repeat showed reduced nornicotine levels 
compared to the empty vector controls (Tables 7 and 8). In 
the nonconverter genotype, 3D_Cl2-Ri99 and 3D_Cl2-7-
Ri298 expression reduced nicotine to nomicotine conver-
sion by about 1.8-fold (2.0%) and 3.0-fold (1.2%), respec-
tively, in comparison to the rate of conversion detected in the 
vector controls (3.6%) (Table 7). Among the silenced non-
converter plants, the lowest conversion level of 0.9% was 
achieved using the 3D_Cl2-7-Ri298 construct (Table 7). 
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TABLE 7 
Alkaloid analysis of nonconvertor burley tobacco plants 
transformed witb the 3D C12-Ri99 or 3D C12-7-Ri298 construct. 
% Nicotined % Nornicotined % Conversione 
3D-C12-Ri99 
1.693 0.034 2.0 
2 1.435 0.031 2.1 
3 2.095 0.043 2.0 
4 2.868 0.053 1.8 
5 0.947 0.025 2.6 
6 2.357 0.043 1.8 
7 2.599 0.043 1.6 
8 0.796 0.020 2.4 
9 2.178 0.039 1.8 
10 3.162 0.061 1.9 
MEAN 2.013 0.039 2.oa 
STE 0.748 0.012 0.3 
3D_Cl2-7-Ri298 
3 1.806 0.020 1.1 
4 1.948 0.207 1.4 
5 2.061 0.020 1.0 
6 2.704 0.040 1.5 
8 2.652 0.023 0.9 
9 1.074 0.G15 1.3 
MEAN 2.041 0.024 1.2b 
STE 0.550 0.008 0.2 
Vector ControW 
1.206 0.052 4.2 
2 1.265 0.038 2.9 
3 1.752 0.058 3.2 
4 1.230 0.072 5.6 
5 1.777 0.060 3.3 
6 1.536 0.044 2.8 
MEAN 1.461 0.054 3.6c 
STE 0.240 0.011 1.0 
10 
15 
20 
25 
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TABLE 8-continued 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
Linec % Nicotined % Nornicotined % Conversione 
3 2.175 0.064 2.9 
4 3.517 0.125 3.4 
8 2.268 0.128 5.3 
9 2.197 0.133 5.7 
10 2.434 0.112 4.4 
MEAN 2.654 0.122 4.5a 
STF 0.573 0.039 1.6 
3D_Cl2-7-Ri298b 
2.043 0.020 1.0 
2 3.427 0.026 0.8 
3 2.603 0.020 0.8 
5 2.427 0.030 1.2 
6 2.106 0.021 1.0 
7 1.412 0.G15 1.1 
8 3.328 0.028 0.8 
9 1.493 0.G15 1.0 
10 2.065 0.G18 0.8 
MEAN 2.323 0.021 0.9b 
STE 0.669 0.005 0.1 
Vector Controt,i 
0.126 1.550 92.5 
2 0.330 2.604 88.8 
3 0.060 1.419 95.9 
4 0.114 1.267 91.7 
5 0.119 1.303 91.6 
MEAN 0.150 1.628 92.lc 
STE 0.093 0.498 2.3 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
35 
bOf the plants transformed with an RN Ai construct, only silenced individuals are shown. 
Alkaloid data represent the means of 2 measurements. 
bOf the plants transformed with an RN Ai construct, only silenced individuals are shown. 
'Numbers represent independently transformed individuals. 
'Numbers represent independently transformed individuals. 
"Percentage of leaf dry weight. 
e[% nornicotine/(% nicotine + % nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.05). 
fsTE, standard error 
gTobacco plants transformed with only pKYLX71 vector were used as controls. 
"Percentage of leaf dry weight. 
e[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.05). 
fsTE, standard error 
40 gTobacco plants transformed with only pKYLX71 vector were used as controls. 
Relative to nonconverter tobacco, nomicotine accumula-
tion was suppressed even more dramatically in the silenced 
individuals of the strong converter plants (Table 8). Using 
3D_Cl2-Ri99 constructs, nicotine conversion was reduced 45 
to levels as low as 4.5% in 3D_Cl2-Ri 99-transformed 
To test the heritability of nomicotine suppression in the 
3D_Cl2-7-Ri298-transformed plants, a set of 3D_Cl2-7-
Ri298-transformed converter and nonconverter lines that 
displayed the lowest levels of nicotine conversion were 
advanced to the T 1 generation (Table 9). Because segrega-
tion of the transgene(s) occurs in the T 1 progeny, transgenic 
individuals were identified by selecting seedlings capable of 
growing on kanamycin-containing media. Nine kanamycin-
325-6 tobacco plants in sharp contrast to the 325-6 control 
plants exhibiting about 98% conversion rates; Table 8). 
However, using the 3D_Cl2-7-Ri298 construct even greater 
reductions in nicotine conversion were obtained (Table 8). 
Four 3D_Cl2-7-Ri298-transformed individuals converted 
as low as 0.8% of their nicotine to nomicotine, and the 
arithmetic mean across the 9 silenced transformants was 
0.9% conversion. All silenced plants were morphologically 
indistinguishable from both the empty vector and wild-type 
controls (data not shown). 
TABLE 8 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
3D_Cl2-Ri99 
2 
% Nicotined 
3.419 
2.569 
% Nornicotined 
0.100 
0.193 
% Conversione 
2.8 
7.0 
50 resistant progenies of each selected T0 -generation 3D_Cl2-
7-Ri298 transformant and four kanamycin-resistant indi-
viduals from each selected vector control line were analyzed 
for alkaloid content. The rate of nicotine conversion did not 
differ significantly between the primary 3D_Cl2-7-Ri298 
55 transformants and their T 1 progeny, indicating high herita-
bility of the nomicotine suppression trait (see Tables 7, 8, 
and 9). However, advancing the "nonconverter" vector con-
trol line by a single generation increased the nicotine to 
60 nornicotine conversion rate from 4.2% to an average value 
of 11.6%, illustrating the high degree of instability of the 
conversion locus in transgenic plants lacking the 3D_Cl2-
7-Ri298-specific RNAi construct (Tables 7 and 9). Overall, 
these results show that RNAi-mediated silencing of the 
65 3D_C12 gene subfamily is a highly effective means of 
lowering nomicotine production in both nonconverter and 
strong converter tobacco plants. 
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TABLE 9 
Alkaloid analysis ofT 1-generation 3D C12-7-Ri298 transformants. 
Line % Nicotinec % Nornicotinec % Conversiond 
3D_Cl2-7-Ri298#3 
Mean 
STE 
3D_Cl2-7-Ri298#5 
Mean 
STE 
3D_Cl2-7-Ri298#8 
Mean 
STE 
Vector Control#! e 
Mean 
STE 
3D C12-7-Ri298#2 
Mean 
STE 
3D_Cl2-7-Ri298#8 
Mean 
STE 
3D_Cl2-7-
Ri298#10 
Mean 
STE 
Vector Control#2e 
Mean 
STE 
DH98-325-5 (nonconverter) 
1.764 0.024 
0.456 0.004 
1.500 0.020 
0.306 0.006 
1.772 0.020 
0.409 0.003 
1.466 0.203 
0.713 0.161 
DH98-325-6 (converter) 
1.970 0.019 
0.536 0.004 
1.623 0.022 
0.300 0.002 
1.419 0.017 
0.515 0.004 
0.028 1.170 
0.006 0.234 
).4a 
0.3 
1.3a 
0.3 
1.2a 
0.3 
)).6b 
9.7 
1.oa 
0.3 
1.3a 
0.2 
1.3a 
0.3 
97.6c 
0.5 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
~eans and standard errors (STE) represent 9 and 4 T1 progenies of the 3D_C12-7-Ri298 
construct and empty vector-transformed (vector control) lines, respectively. 
"Percentage of leaf dry weight. 
d[% nornicotine/(% nicotine+% nornicotine)] x 100; values followed by different letters 
are significantly different according to Fisher's Protected LSD (0.015). 
eTobacco plants transformed with only pKYLX71 vector were used as controls. 
Furthermore, transforming tobacco with the 3D_Cl2-7-
298 construct conferred a 3.6-fold reduction in nicotine 
conversion relative to typical nonconverter control plants 
without affecting plant growth and development. 
To demonstrate that the down-regulation of nornicotine 
production in 3D _Cl2-7-298-transformed tobacco was con-
comitant with a reduction of the 3D_C12 gene subfamily 
transcripts, a 3D_Cl2-7 cDNAprobe was hybridized to the 
total RNA isolated from cured leaves of nonconverter and 
converter plants. A weak hybridization signal was generated 
by the RNA isolated from 3D_Cl2-7-Ri298 transformants 
displaying low nornicotine content in contrast to the strong 
signal produced by the RNA extracted from plasmid control 
60 
6) of the 3D_Cl2-7-Ri298 construct using Southern blot 
analysis of genomic DNA digested with the EcoRI restric-
tion enzyme. Transgene copy number was confirmed using 
Neal digested DNA ( data not shown). These results indicate 
5 that the integration of a single 3D_Cl2-7-Ri298 construct 
into the genome of a strong converter tobacco is sufficient 
for suppressing nornicotine production to very low levels. 
10 
GENERAL CONCLUSIONS 
The analyses outlined in Examples 1-6 above resulted in 
the discovery of a closely related P450 gene family, desig-
nated the 3D_C12 family, whose collective steady-state 
15 
transcript levels were significantly elevated in converter 
tobacco plants that were actively metabolizing nicotine to 
nornicotine in comparison to their nonconverter counter-
parts. Transgenic plant analysis demonstrated that the sup-
pression of gene expression of this P450 family in converter 
20 
25 
30 
35 
tobacco lines inhibited the metabolism of nicotine to norni-
cotine to levels similar to that observed in nonconverter 
plants. Furthermore, sense expression of several individuals 
of this closely related gene family identified one member, 
designated 3D_Cl2-7, as playing a direct role in the meta-
bolic conversion of nicotine to nornicotine. Overexpression 
of3D_Cl2-7 using a strong constitutive promoter caused a 
dramatic increase in nornicotine production and accumula-
tion in non-cured green leaves of transgenic tobacco plants, 
a tissue where nicotine is normally the predominant alkaloid 
in converter and nonconverter plants alike. Given that the 
cytochrome P450 family member designated 3D_Cl2-10 
differs from 3D_Cl2-7 at only two amino acid residues 
immediately following the start methionine and within the 
N-terminal signal sequence, it is predicted that these 
encoded products function identically. 
The contrast in alkaloid phenotypes between the 35S: 
3D_C12 (1) plant and vector-only control plants was most 
dramatic in leaves that had been ethephon treated and cured 
(0.6% conversion versus >97% conversion; Table 6). How-
40 ever, it is noteworthy that the nornicotine content of the 
co-suppressed 35S:3D_C12 (1) plant was reduced even in 
green, nontreated leaves where the high nornicotine pheno-
type is typically not manifest in converter or nonconverter 
tobacco lines. The green, nontreated leaves of line 35S: 
45 3D_C12 (1) showed only 0.7% nicotine to nornicotine 
conversion, whereas every other plant in this experiment 
showed conversion percentages ranging from 1.3 to 3.7 
(Table 5). This result suggests that the inhibition of gene 
expression of the 3D_C12 family may prove to be effective 
50 in the further lowering of nornicotine levels even in tobacco 
lines where genetic conversion isn't typically a major prob-
lem (such as flue-cured tobaccos) or in the nonconverter 
individuals in lines that are prone to genetic conversion 
(such as Burley tobaccos). 
or wild-type plants. These results indicate that the down- 55 
regulation of nicotine conversion was a result of RNAi-
mediated gene silencing of the nicotine N-demethylase 
gene(s). 
Southern blotting assays using members of the 3D_C12 
gene family as hybridization probes gives very complex 
banding patterns, suggesting that more members of this gene 
family may exist even beyond those that have been identi-
fied and characterized herein ( data not shown). The hypoth-Determination of Transgene Copy Number 
To determine whether the integration of multiple 
3D_Cl2-7-Ri298 copies were required for producing trans-
plants displaying very low nicotine N-demethylase activity, 
Southern analysis was performed on selected individuals 
exhibiting <1.5% nornicotine accumulation. The number of 
transgenes varied widely among these plants including indi-
viduals containing 1 copy (325-5, lines 5 & 8; 325-6, lines 
2 & 8), 5 copies (325-6, line 10), and 6 copies (325-5, line 
60 esis that the 3D_C12 gene family is comprised of additional 
members is further supported by the recent publication of75 
full-length tobacco P450 cDNAs of unknown function (U.S. 
Patent Application Publication 20040162420). Within this 
list of P450s are additional cDNAs that would, based on the 
65 work described herein, be placed within the 3D_C12 family 
in view of their display of over 90% amino acid sequence 
identity to the protein sequences shown in FIG. 4. 
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With respect to the specific molecular function of the 
3D_Cl2-7 gene or the nearly identical family member 
3D_Cl2-10, it is possible that it encodes the actual nicotine 
demethylase enzyme which catalyzes the oxidative N-dem-
ethylation of nicotine to nornicotine (FIG. 1). Alternatively, 
the 3D_Cl2-7 encoded enzyme or nearly identical 3D_Cl2-
10 encoded enzyme may produce a product that leads to the 
up-regulation of the nicotine demethylase activity of the 
leaf, as opposed to directly catalyzing the N-demethylation 
reaction. 
In addition, an allele-specific RT-PCR was employed to 
compare 3D-Cl2-7 expression between converter and non-
converter plants (Example 7). An approximately 80-fold 
increase in 3D-Cl2-7 expression in converter versus non-
converter plants was identified using the SYBR® Green-
chemistry RT-PCR assay. A 7.5-fold up-regulation was iden-
tified by the TaqMan® chemistry-based RT-PCR 
experiment. While the DH 91-1307-46 tobacco variety used 
in the TaqMan® chemistry-based RT-PCR experiment 
exhibits low to moderate levels of nicotine conversion, the 
DH98-325-5 nonconverter plants used in the SYBR® 
Green-based RT-PCR assay consistently convert a very low 
percentage of their nicotine to nornicotine. Expression of the 
3D-Cl2-7 gene was induced at least 7-fold by ethylene in 
senescing leaves of converter tobacco plants. 
62 
pin RNA in which the stem region was engineered from this 
298-bp fragment of the 3D_Cl2-7 cDNA inserted as an 
inverted repeat. The loop of the hairpin was created by 
placing a 151-bp intron of the FAD gene between the two 
5 sides of the palindromic sequences. An arm length of298-bp 
was used for the inverted repeats. 
3D_Cl2-7-Ri298-transformed plants accumulated less 
nornicotine than those harboring the 3D_Cl2-Ri99 con-
struct (Tables 7 and 8). No correlation was found between 
10 the number of copies of the 3D_Cl2-7-Ri298 construct and 
nornicotine production (Tables 7 and 8). The 3D_Cl2-7-
Ri298 expression cassette enabled the production of tobacco 
with a conversion rate as low as 0.8%, which is below the 
3-5% rate detected in burley lines used by seed producers. 
15 Such dramatic reduction in nornicotine production by tar-
geting this particular region of the 3D_Cl2-7 polynucleotide 
is an unexpected result. Also, suppression of nornicotine 
production showed a high degree of heritability in the T 1 
progeny of the primary transformants (Table 9). Suppression 
20 of nornicotine production in these transgenic plants yielded 
no obvious differences in growth and development when 
compared to wild-type plants. 
All publications and patent applications mentioned in the 
specification are indicative of the level of those skilled in the 
25 art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to 
the same extent as if each individual publication or patent 
application was specifically and individually indicated to be 
An additional RNAi construct, 3D_Cl2-7-Ri298, was 
prepared based on a region of the 3D_Cl2-7 polynucleotide 
that corresponds to nucleotide positions 297 through 594 of 
SEQ ID NO:5. Expression of this RNAi construct allows for 30 
the suppression of nornicotine production in a strong con-
verter tobacco line below the levels normally found in 
nonconverter plants. The expression cassette of the 
3D_Cl2-7-Ri298 construct encoded an intron-spliced hair-
incorporated by reference. 
Although the foregoing invention has been described in 
some detail by way of illustration and example for purposes 
of clarity of understanding, it will be obvious that certain 
changes and modifications may be practiced within the 
scope of the appended claims. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 37 
<210> SEQ ID NO 1 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 1 
atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
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-continued 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc tct 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act cga att aat gga aat tcg agt acg 528 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
ata aat eta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt tta tea atg 672 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
gaa ttt gta tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggt cat att aag gca atg aaa agg aca ttt aag gat ata 768 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aac tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt ggt gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa ttg agt aaa gaa tat ctt gat gaa ggt tac tct cgt 912 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca aca gtt ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg aca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
aat caa aat gee ttg atg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gat aga tgg gta gaa gag agt gat att aag gat tta gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa aag gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cat gaa aat gta aag gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa gag act aga tta ttc gca aac gtc atg aaa ctg cag 1248 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
us 10,383,299 B2 
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-continued 
405 410 415 
cgc gat cct aaa etc ttg tea aat cct gat aag ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
ttc ate get ggt gat att gac ttc cgt ggt cac cac tat gag ttt ate 1344 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
cca ttt ggt tct gga aga cga tct tgt ccg ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac eta aca atg gca cat tta ate cag ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aaa act cca aat gac gag gee ttg gat atg aag gaa ggt gca ggc ata 1488 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
ace ata cgt aag gta aat cca gtg gaa ttg ata ata acg cct cgc ttg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
gca cct gag ctt tac taaaacctaa gatctttcat cttggttgat cattgtttaa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaga tgggtattca tttacctttt ttcaattaat tgcatgtacg agctttttta 1651 
atttggtata tttgtaacaa taagtaaaga atgattgtgc taatatataa agatttgcag 1711 
aagataattg actgattgtc cc 1733 
<210> SEQ ID NO 2 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 2 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
US 10,383,299 B2 
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Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 3 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 3 
atg ctt tct CCC ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
us 10,383,299 B2 
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etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 912 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
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aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 1248 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 1344 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag CCC ttg gat atg aag gaa ggt gca ggc ata 1488 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 1651 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 1711 
aagataattg actgattgtc cc 1733 
<210> SEQ ID NO 4 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 4 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
US 10,383,299 B2 
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85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
74 
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Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 5 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 5 
atg gtt ttt CCC ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg cga aaa aat cga aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act cga att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
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gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 912 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aag gca acg gtg ttt agt ttg gtc ttg gat gca gca 960 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 1008 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 1056 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 1104 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta cga tta tat cca cca gga cct 1152 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 1200 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 1248 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 1296 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 1344 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga cga tct tgt cca ggg atg act tat gca ttg 1392 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 1440 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag CCC ttg gac atg aag gaa ggt gca ggc ata 1488 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 1536 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 1591 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 1651 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 1711 
aagatgattg actgattgtc cc 1733 
<210> SEQ ID NO 6 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
US 10,383,299 B2 
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<400> SEQUENCE, 6 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
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405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 7 
<211> LENGTH, 1727 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1554) 
<400> SEQUENCE, 7 
atg gtt ttt ccg gta gaa gee att gta ggg eta gtg ace ttc aca ttt 48 
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc tac ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa CCC 96 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccg gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
tac ttc gat gac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac gga CCC gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg tta gtt gta age agt tac gaa get ata aaa gat tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aaa aat gee atg eta ttt ttg gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
tct tac tgg cga aaa aat cgt aaa tta att att cag gaa gtt etc tct 432 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttc gee aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act cga att gat gga aat tcg agt acg 528 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
us 10,383,299 B2 
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Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aag aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
aaa ata atg gag gtt ggt aca gaa ggg aat gaa caa gat ttt ata gat 864 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
gtg gtg ctt tea aaa atg agt aat gaa tat ctt ggc gaa ggt tac tct 912 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
cgc gat act gtc ata aaa gca aca gta ttt agt ttg gtc ttg gat gca 960 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
gca gac aca gtt get ctt cac ata aat tgc gga atg gca tta ttg ata 1008 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
aac aat caa aat gee ttg aag aaa gca caa gaa gag ata gac aca aaa 1056 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
gtt ggt aag gat aga tgg gta gaa gag agt gat att aag gat ttg gta 1104 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
tac etc caa get att gtt aaa gaa gtg tta cga tta tat cca ccg gga 1152 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
cct ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga 1200 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
tat cac att cct aaa gga act aga eta ttc gca aat gta atg aaa eta 1248 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
caa cgt gat cct aaa etc tgg tea aat cct gat aag ttc aat cca gag 1296 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
aga ttc ate get cgt gat att gac ttt cat ggt cag cac tat gag tat 1344 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
ate ccg ttt ggt tct gga aga cgc tct tgt ccg ggg atg act tat gca 1392 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
ttg caa gtg gaa cac eta aca atg gca cat ttg ate cag ggt ttc aat 1440 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
tac aga act cca act gat gag CCC ttg gat atg aaa gaa ggt gca ggc 1488 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
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ata act ata cgt aag gta aat cct gtg aaa gtg ata att acg cct cgc 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
ttg gca cct gag ctt tat taaaatctaa gatgtttcat cttggttgat 
Leu Ala Pro Glu Leu Tyr 
515 
cattgtttaa tactcctaga tgggtattca tctacctttt ttcaattagt tgtcggtacg 
tattttttta atttggtaag tttgtaataa taagtaaaga aggattgtgc taatatataa 
tggtgcataa aataattgaa 
<210> SEQ ID NO 8 
<211> LENGTH, 518 
<212> TYPE, PRT 
atg 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 8 
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
1536 
1584 
1644 
1704 
1727 
86 
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Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
Leu Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 9 
<211> LENGTH, 539 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (539) 
<400> SEQUENCE, 9 
atg gtt ttt CCC ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa CCC 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get cga aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gat gee att ttc tee aat cgt cca get ttt ctt tat ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
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100 105 110 
gaa tac ctt ggc tac agt aat gee atg eta ttt tga caa aat acg gac 384 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe * Gln Asn Thr Asp 
115 120 125 
ctt act ggc gaa aaa ata gaa aat tag tea ttc agg aag ttc tct gtg 432 
Leu Thr Gly Glu Lys Ile Glu Asn * Ser Phe Arg Lys Phe Ser Val 
130 135 140 
eta gtc gtc tcg aaa aat tga age acg tga gat ttg gtg aaa ttc aga 480 
Leu Val Val Ser Lys Asn * Ser Thr * Asp Leu Val Lys Phe Arg 
145 150 155 
cga gca tta aga att tat aca etc gaa ttg atg gaa att cga gta cga 528 
Arg Ala Leu Arg Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg 
160 165 170 
taa ate taa ca 539 
* Ile * 
<210> SEQ ID NO 10 
<211> LENGTH, 173 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 10 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp Leu 
115 120 125 
Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val Leu Val 
130 135 140 
Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg Arg Ala Leu Arg 
145 150 155 160 
Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg Ile 
165 170 
<210> SEQ ID NO 11 
<211> LENGTH, 666 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... ( 666) 
<400> SEQUENCE, 11 
atg gtt ttt CCC ata gaa gee att gta gga gca gta ace eta att aca 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr 
1 5 10 15 
ttt etc tta tac ttc eta tgt aca aaa aaa tct caa aaa cat tea aag 96 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys 
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20 25 30 
CCC tta cca acg aaa ate CCC gga gga tgg ccg gta ate ggc cat ctt 144 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
ttc cac ttc aat aac gac ggc gac gac cgt cca ttt get cga aaa etc 192 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
gga gac tta get gat aaa tac ggc CCC gtt ttc act ttt egg eta ggt 240 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
ctt CCC ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc 288 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
ttc tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac 336 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
ggc gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac 384 
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
gga cct tac tgg cga aaa aat cgt aaa tta gtc att cag gaa gtt etc 432 
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
tct get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att 480 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
caa acg age att aag aat tta tac act cga att aat gga aat tcg agt 528 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser 
165 170 175 
acg ata aat eta agt gat tgg tta gaa gaa ttg aat ttt ggt ctg ate 576 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
180 185 190 
gtg aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa 624 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu 
195 200 205 
caa gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt 666 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 12 
<211> LENGTH, 222 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 12 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr 
1 5 10 15 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys 
20 25 30 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
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Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser 
165 170 175 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
180 185 190 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu 
195 200 205 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 13 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
NO,1 
<400> SEQUENCE, 13 
gacgaggcct tggatatgaa ggaaggtgca ggcataacca tacgtaaggt aaatccagtg 60 
gaattgataa taacgcctcg cttggcacct gagctttac 99 
<210> SEQ ID NO 14 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
NO,3 
<400> SEQUENCE, 14 
gacgagccct tggatatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 15 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
NO,5 
<400> SEQUENCE, 15 
gacgagccct tggacatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 16 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from SEQ ID 
NO,7 
<400> SEQUENCE, 16 
gatgagccct tggatatgaa agaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
94 
95 
aaagtgataa ttacgcctcg cttggcacct gagctttat 
<210> SEQ ID NO 17 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 17 
cgctctagaa ctagtgatc 
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 18 
tttttgggac aatcagtcaa 
<210> SEQ ID NO 19 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 19 
gttagattta tcgtactcga att 
<210> SEQ ID NO 20 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 20 
ttcatttcaa attattttat gcacca 
<210> SEQ ID NO 21 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 21 
atggtttttc ccatagaagc c 
<210> SEQ ID NO 22 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 22 
tcgaggtcga cggtatc 
<210> SEQ ID NO 23 
<211> LENGTH, 1118 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
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99 
19 
20 
23 
26 
21 
17 
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<400> SEQUENCE, 23 
ctgtcattaa agcaacggtg tttgtaagtt catctgtcat ttttcattta ttcactttta 60 
ttttgaggag cagacatgtt aataataatt tggagcaact gtaaagttat ctatgtgtac 120 
aggttcgagc ctcaggtgca accactaatg cttgtattag attatgttgt ctgcatcata 180 
cccctaattg gagtgtggct cttcccgaac cctgcaatgc tggatgctgg atgctttatg 240 
tatcagactg acctttttgt taaactatct aaatactaag gatgatttaa taaaaatata 300 
gaatggtaaa cagaaaaaga tgagattatt tttggggcta tatggattcg cccgggcttt 360 
gggaggtaaa acggtatcta ccagttgaga ctttactcca gaactttatc tcgagagctc 420 
tgaataaaaa tgaaatagta tttaccactc caaaatcttt gatggtaaaa agatgagata 480 
taacctctta taattgattg aaccacgttg atagaataaa acttctttac tcccattcag 540 
cataagaaaa atgaaaccaa acggaattct tctctttttt agggggaaat tccttaattg 600 
cttgttgaat atagattcat gtcgttattc tatttttaat aatgatgaaa atcaatatag 660 
tcaaagttaa tacttatgtc atttggtttg cggacaagtt atattggaac tatataatac 720 
gtctattata gaatagtgat tatttagagg atatacattt tttttggata aatatttgat 780 
ttattggatt aaaaatagaa tatacaggta aggtctaaaa cgtgtgtttg cttttacact 840 
aaataaactt gacctcgtac aattctaaga aaatatttga aataaatgaa ttattttatt 900 
gttaatcaat taaaaaaatc atagtataga tgagatgtgt gcatacttgg caataactat 960 
actaactaaa acaaggtatg tgaataattg atattccttt tttaattatt cttttttcca 1020 
gagtttggtc ttggatgcag cagacacagt tgctcttcac ataaattggg gaatggcatt 1080 
attgataaac aatcaaaagg ccttgacgaa agcacaag 1118 
<210> SEQ ID NO 24 
<211> LENGTH, 998 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 24 
gtaagttcat ctgtcatttt tcatttattc acttttattt tgaggagcag acatgttaat 60 
aataatttgg agcaactgta aagttatcta tgtgtacagg ttcgagcctc aggtgcaacc 120 
actaatgctt gtattagatt atgttgtctg catcataccc ctaattggag tgtggctctt 180 
cccgaaccct gcaatgctgg atgctggatg ctttatgtat cagactgacc tttttgttaa 240 
actatctaaa tactaaggat gatttaataa aaatatagaa tggtaaacag aaaaagatga 300 
gattattttt ggggctatat ggattcgccc gggctttggg aggtaaaacg gtatctacca 360 
gttgagactt tactccagaa ctttatctcg agagctctga ataaaaatga aatagtattt 420 
accactccaa aatctttgat ggtaaaaaga tgagatataa cctcttataa ttgattgaac 480 
cacgttgata gaataaaact tctttactcc cattcagcat aagaaaaatg aaaccaaacg 540 
gaattcttct cttttttagg gggaaattcc ttaattgctt gttgaatata gattcatgtc 600 
gttattctat ttttaataat gatgaaaatc aatatagtca aagttaatac ttatgtcatt 660 
tggtttgcgg acaagttata ttggaactat ataatacgtc tattatagaa tagtgattat 720 
ttagaggata tacatttttt ttggataaat atttgattta ttggattaaa aatagaatat 780 
acaggtaagg tctaaaacgt gtgtttgctt ttacactaaa taaacttgac ctcgtacaat 840 
tctaagaaaa tatttgaaat aaatgaatta ttttattgtt aatcaattaa aaaaatcata 900 
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gtatagatga gatgtgtgca tacttggcaa taactatact aactaaaaca aggtatgtga 960 
ataattgata ttcctttttt aattattctt ttttccag 998 
<210> SEQ ID NO 25 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR Primer 
<400> SEQUENCE, 25 
ctgtcattaa agcaacggtg 
<210> SEQ ID NO 26 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR Primer 
<400> SEQUENCE, 26 
ggccttgacg aaagcacaag 
<210> SEQ ID NO 27 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 27 
aagctttgac gccatttttt ccaatcg 
<210> SEQ ID NO 28 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 28 
ctcgagtttt ccagcgatca tcttcac 
<210> SEQ ID NO 29 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 29 
acgtgatcct aaactctggt ctg 
<210> SEQ ID NO 30 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 30 
gcctgcacct tccttcatg 
<210> SEQ ID NO 31 
<211> LENGTH, 20 
20 
20 
27 
27 
23 
19 
100 
101 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 31 
cggtaatcgg ccatcttttc 
<210> SEQ ID NO 32 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 32 
ccgagttttc gagctaatgg a 
<210> SEQ ID NO 33 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 33 
caatgacgaa cggcgacag 
<210> SEQ ID NO 34 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 34 
atggtttttc ccatagaagc c 
<210> SEQ ID NO 35 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 35 
tttttgggac aatcagtcaa t 
<210> SEQ ID NO 36 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 36 
tgaatgaact gcaggacgag 
<210> SEQ ID NO 37 
<211> LENGTH, 20 
<212> TYPE, DNA 
102 
20 
21 
19 
21 
21 
20 
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<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 37 
aatatcacgg gtagccaacg 
What is claimed is: 
1. A tobacco seed or a tobacco plant grown therefrom, 
wherein said tobacco seed or tobacco plant comprises a 
stable mutation in a wild type allele of a nicotine demeth-
ylase comprising a coding sequence having at least 98% 
identity to SEQ ID NO: 3, wherein said mutation reduces or 
eliminates the expression or activity of said nicotine dem-
ethylase, wherein the amount of nornicotine or N'-nitroso-
nomicotine in said tobacco plant is reduced by greater than 
about 10% compared to a control tobacco plant comprising 
said wild type allele, and wherein said tobacco plant is a 
Nicotiana tabacum plant. 
2. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said tobacco seed or tobacco 
plant grown therefrom is homozygous for said mutation. 
3. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said tobacco plant has a 
non-converter phenotype and reduced nicotine demethylase 
activity from said nicotine demethylase. 
10 
20 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 20% compared to a control tobacco plant 
comprising said wild type allele. 
12. The tobacco seed or tobacco plant grown therefrom 
15 according to claim 1, wherein the amount of nomicotine or 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 60% compared to a control tobacco plant 
comprising said wild type allele. 
13. The tobacco seed or tobacco plant grown therefrom 
20 according to claim 1, wherein the amount of nomicotine or 
N'-nitrosonomicotine in said tobacco plant is reduced by 
greater than about 90% compared to a control tobacco plant 
comprising said wild type allele. 
14. A method comprising preparing a tobacco product 
25 using a cured tobacco leaf from the tobacco plant of claim 
1. 
15. The method of claim 14, wherein said tobacco product 
is selected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
4. The tobacco seed or tobacco plant grown therefrom 30 
according to claim 1, wherein said tobacco plant has a 
non-converter phenotype and comprises less than 5% nico-
tine demethylation. 
16. A tobacco product comprising cured tobacco from the 
tobacco plant of claim 1, wherein said tobacco product is 
selected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
17. A method comprising: 5. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said tobacco seed or tobacco 35 
plant grown therefrom is selected from the group consisting 
a. detecting in a tobacco plant or plant part thereof a 
mutation in a polynucleotide having at least 96% 
sequence identity to SEQ ID NO: 3, and wherein said 
mutation is in a sequence encoding the tryptophan 
residue at position 329 of SEQ ID NO: 4; and 
of _a Burley type, a dark type, a flue-cured type, and an 
Onental type. 
6. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said mutation is selected from 40 
the group consisting of a point mutation, a deletion, and an 
insertion. 
b. producing a tobacco product from said tobacco plant or 
plant part thereof comprising said mutation detected in 
step a. 
18. The method of claim 17, wherein said tobacco plant 
is a Nicotiana tabacum plant. 
7. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said wild type allele encodes 
SEQ ID NO: 3. 
8. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said stable mutation in a wild 
type allele is a mutation in any nucleotide corresponding to 
nucleotides 265 to 625 of SEQ ID NO: 3. 
9. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said stable mutation in a wild 
type allele is a mutation in any nucleotide corresponding to 
nucleotides 700 to 1250 of SEQ ID NO: 3. 
10. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein said stable mutation in a wild 
type allele is a mutation in any nucleotide corresponding to 
nucleotides 1420 to 1551 of SEQ ID NO: 3. 
11. The tobacco seed or tobacco plant grown therefrom 
according to claim 1, wherein the amount of nornicotine or 
45 . 19. The method of claim 17, wherein said tobacco plant 
1s selected from the group consisting of a Burley type, a dark 
type, a flue-cured type, and an Oriental type. 
20. The method of claim 17, wherein said plant part is 
selected from the group consisting of a cell, a protoplast, a 
50 cell tissue culture from which a whole plant can be regen-
erated, a callus, an embryo, pollen, an anther, an ovule, a 
seed, a leaf, a flower, a stem, a branch, a fruit, a root, and a 
root tip. 
21. The method of claim 17, wherein said tobacco product 
55 is_ selected from the group consisting of a cigarette, a cigar, 
pipe tobacco, snuff, chewing tobacco, gum, and a lozenge. 
22. The method of claim 17, wherein said mutation 
reduces or eliminates the expression of said polynucleotide. 
* * * * * 
